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1.

REVIEW OF THE RELATED LITERATURE
1.1

1.1.1

Pain Mechanisms
Historical Account

Pain is one of the most common experiences of man and the explanations of its nature probably one of his oldest preoccupations.
Throughout the years, several theories have been proposed to explain
the phenomenon of pain; as research evidence began to accumulate all
these theories have been shown to be inadequate.
One of the earlier writers on pain, Aristotle, considered pain
to be a manifestation of the soul, an emotion, and the epitome of unpleasantness (Aristotle

[330

B.C.?] cited by Hardy et al., 1952).

Man was thought to continuously fluctuate between two emotional states
of pleasure and pain; thus, pain was equated with the unpleasantness
one experiences throughout his/her life (Aristotle [330 B.C.?] cited
by Hardy et al., 1952).
The view of pain as an emotional state was championed until the
end of the eighteenth century when Darwin proposed the Intensive Theory of pain (Darwin, 1794, cited by Hardy et al., 1952).

The Inten-

sive Theory considered pain to occur whenever any of the "sensorial
emotions" namely heat, touch, sight, taste, or smell were stronger
than usual (Darwin, 1794, cited by Hardy et al., 1952).

Although the

Intensive Theory was popular for a long time, evidence now demon1
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strates that in some cases pain is in itself a particular form of
sensation (Sweet, 1959; Dash and Deshpande, 1976).
The twentieth century saw the Intensive Theory of pain replaced
by the Specificity Theory which until recently was the theory taught
in medical schools (DeSousa and Wallace, 1977).

The Specificity The-

ory implies a straight-through transmission system from somatic pain
receptors via specialized pain fibers and a pain pathway to a "pain
center" in the brain (Sweet, 1959).

Evidence today, however, suggests

that the perception of pain cannot be directly related to the neural
activity in any particular anatomical structure (Melzack and Wall,
1965).

Furthermore, pain is influenced by many psychological vari-

ables such as attention, anxiety, suggestion, and prior conditioning;
thus, the perception of pain includes a very pervasive psychological
component (Melzack and Wall, 1965).
Recently, research concerning pain has moved in the direction of
investigating the plasticity and modifiability of events in the central nervous system (CNS) through various physiological and psychological techniques; these techniques will be reviewed briefly; pertinent physiological and anatomical descriptions also will be presented.
In addition, the involvement of the cholinergic, serotonergic, and
endogenous opioid systems in the rhenomenon of pain will be reviewed.
However, before proceeding any further, it is necessary to define some
relevant terms which will be employed throughout this dissertation.
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1.1.2

Definitions

Just as there have been many theories proposed to explain the
phenomenon of pain, many definitions have been proposed.

Analysis of

the current literature suggests that the term "pain" must be defined
in terms of psychology rather than physiology, and therefore is only
applicable for use when describing the human experience.

Merskey

( 1978) has proposed the following definition of pain: "pain is an unpleasant experience which we primarily associate with tissue damage
or describe in terms of tissue damage or both".
Next, the term "nociception" is defined as potentially tissuedamaging thermal, mechanical, or chemical energy impinging upon specialized

nerve endings called nociceptors (Fordyce, 1978).

In this

scheme, the pain experience must be perceived in order for it to be
said to have occurred.

However, nociceptive input for pain needs not

occur since man may perceive pain even in the absence of noxious
stimuli such as in phantom limb pain.
ious

Similarly, the presence of nox-

stimuli does not insure the experience of pain since various

neurological defects, the administration of drugs, or other factors
make it possible for noxious stimuli to exist without being perceived.
Thus, the terms pain and nociception although related to one another
clearly are not interchangeable.
Finally, the terms "analgesia" and "antinociception" are defined
as the failure of an organism to exhibit pain- and nociceptive-induced
behaviors, respectively; behavior is defined as observable, measurable,
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overt, verbal and non-verbal actions of an organism (Fordyce, 1978).
In regards to pain and. nociception, the essence of the problem is that
there are pain- and nociceptive-induced behaviors.

It is these part-

icular behaviors such as the various autonomic responses and voluntary
or reflex muscular movements in laboratory animals as well as the
verbal and non-verbal descriptions by humans which are observed and
quantitated in the study of nociception and pain.
1.1.3

Psychological Factors Influencing Pain

Presently, there exists a large and increasing body of evidence
which suggests that pain is influenced by a variety of psychological
factors (Sternbach, 1978).

To understand pain first one must take

into account its interaction with the overall total personality.
Since an individual's personality is shaped from birth, a developmental analysis might prove useful in demonstrating the importance of
early childhood events in shaping the pain experience.

Pozanski

(1976) demonstrated that children (age 5 to 16 years) who exhibit
recurrent pain syndromes, for which there is no evident organic causation, such as chronic abdominal pain, headache, and limb pain come
from families

in which the parents themselves were more prone to

exhibit pain behaviors.

Pozanski (1976) suggests that the models

presented by parents influenced pain associated behaviors in their
children.
Second, pain also has a very important

cultur~l

dimension.

People respond to pain not only as individuals but also as members of
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their cultural heritage.

While differences in pain behavior among

cultural and ethnic groups are not well understood, consistencies
within a particular group suggest that members of the group model
normative standards for both the degree and way in which suffering
is perceived and exhibited (Craig, 1978). Cultural specific attitudes
towards pain can be summarized as follows:

Yankees are apathetic,

matter of fact, doctor-help oriented; Jews are concerned about implications of pain and distrust pain relief procedures; Italians
readily express desire for pain relief; Irish block both expressions
of suffering and concern for the implications of pain (Craig, 1978).
Third, some reinforcing, environmentally situated events may be
pain contingent; that is, certain reinforcing events will not occur
unless preceded

by pain behaviors.

Pain medications prescribed on

a "take only as needed" basis may be effective reinforcers or positive consequences of pain-related behavior or pain percetion if the
patient feels better when sedated or analgetic (Fordyce, 1978).

Sim-

ilarly, accident victims or wounded war heroes who are in pain may
receive love,· attention, and .affection as rewards for pain behavior
(DeSousa and Wallace, 1977).

Finally, pain behavior is often rewarded

financially; monetary compensation after successful litigation is an
excellent reinforcement causing people to remain in pain (DeSousa and
Wallace, 1977).
Indirect reinfo=cement of pain behavior may occur when pain behavior leads to avoidance of some aversive or unpleasant consequence
such as avoiding an unpleasant job, a threatening social encounter,
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or an aversive set of duties and responsibilities (Fordyce, 1978).
Paraphrased, "when I am in pain, bad things don't happen which otherwise would (Fordyce, 1978)".
Fourth, in order for any stimulus to produce pain it must affect
either the arousal or selective aspects of the patient's attention.
Since an individual possesses a finite attention capacity, it follows
that involvement of attention in one area will be accompanied by removal of attention from another area.

In fact, almost any situation

that attracts intensive maintained attention will diminish or abolish
pain perception (Melzack, 1961).
Strong relationships between pain and mood have been demonstrated.
Anxiety is generally recognized

as inceasing pain; thus, anything

which diminishes anxiety may be expected to diminish pain (Merskey,
1978) .

Even the mere presence of the word pain during instructions

in an experimental situation decreased the level of electroshock pain
in patients as compared to a group of patients in which the mention of
pain was not made during the instructional process (Hall and Stride,
1954).

On the other hand, excitement or aggression may leave subjects

totally oblivious.even to serious trauma.

Most notable examples are

(i) football players and other sportsmen who suffer traumatic blows

during competition but do not notice any pain until the contest is
completed and (ii) severely wounded soldiers performing heroic tasks
in spite of apparently incapacitating injuries (Merskey, 1978).
Overall, a most important psychological component of pain has
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been amply demonstrated.

The next section reviews the many pertinent

physiological and anatomical aspects of pain.
1.1.4

Physiological and Anatomical Correlates
1.1.4.1

Nociceptors

Specific somatic receptors, called nociceptors, which convey
neural impulses arising from a noxious stimuli have been identified
and characterized as follows:

(i) nociceptors are much more resistant

to damage from noxious input than the low threshold mechanical and
thermal receptors (ii) nociceptors have higher thresholds with respect
to all stimuli in comparison to other sensory receptors of the same
tissue and (iii) unlike other receptors, nociceptors undergo the
process of sensitization; that is, repeated stimulation reduces the
threshold for activation and increases the £requency of discharge per
unit of stimulus (Perl, 1976).
Nociceptors can be classified by measuring the discharge f:::-equency of isolated peripheral nerves in response to a variety of nox·
ious and innocuous stimuli applied to the skin (Besson and Perl, 1969).
Briefly, (i) "mechanical nociceptors" respond to strong mechanical
stimuli but are not at all excited by noxious thermal stimuli, (ii)
"mechanical and thermal nociceptors" respond to both strong mechanical
and noxious cold, and (iii) "polymodal nociceptors" respond to noxious
mechanical, cold, and heat stimuli (Angel, 1977).

In addition, a

fourth group of nociceptors called "chemosensitive nociceptors" has
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been identified in the anesthetized skin of leprosy patients; the
application of several algesic substances to blistered skin produced
pain as measured by the patients verbal reports; noxious thermal and
mechanical stimuli were ineffective (Dash and Deshpande, 1976) ..
The morphological structure of nociceptors
tified unequivocally.

has not been iden-

Attempts to describe the morphological substrate

for nociceptors have been based upon delineation of the receptor
function of a spot of skin with subsequent fixation, excision, and
histological examination, or by the functional isolation of a known
structure and accurate determination of its adequate stimulus (Angel,
1977) .

Research in this area has been concentrated on the receptor

structure in the human tooth since most authorities believe that only
the sensation of pain is felt when any form of stimulation is applied
to the dental pulp (Scott and Maziarz, 1976).
For many years, free nerve endings were considered to be nociceptors.
type

However, most receptors in mammalian hairy skin are of this

indica~ing

that such endings probably subserve sensations other

than pain (Weddell et al., 1955).

In addition, the cornea

lS

inner-

vated exclusively by free nerve endings but mediates sensations of
touch, pressure, and temperature as well as pain (Lele and Weddell,
1956).

Although no morphological

differe~ces

are seen among free

nerve endings, the possibility of physiological specificity remains.
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1.1.4.2

Primary Afferent Nerve Fibers

Nerve impulses generated by stimulation of nociceptors in the
body tissues are transmitted along primary afferent nerve fibers to
various destinations in both the spinal cord and brain (Melzack,
1973).

The peripheral nerve contains a heterogeneous mixture of

primary afferent fiber types which can· be classified by utilizing a
knowledge of nerve fiber diameter and impulse conduction velocity.
A simple classification scheme is summarized as follows: the "A"
fiber group consists of five subgroups of myelinated fibers designated
in order of diminishing fiber diameter (20 to 1

~m)

from alpha (a)

through epsilon (s); the conduction rate of nerve impulses (120 to
4 m/s) varies directly with the diameter of the axon (Angel, 1977).
"C" fibers are unmyelinated, have diameters of 0.3 to 1.5

~m,

and

conduction rates of 0.4 to 2.0 m/s (Angel, 1977).
Clark et al. (1935) demonstrated that for the cat C fibers conducted to the CNS neural impulses which elicited autonomic responses
similar to those produced by noxious stinulation; A fibers were ineffective.
In humans, electrical stimulation of A a fibers has been correlated with pricking pain sensations whereas stimulation of A-delta (o)
and C fibers produced prolonged, chronic, dull, sometimes burning pain
sensations (Torebjork, 1974; Torebjork and Hallin, 1974; Willer et
al., 1978).
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Clinical observations do not completely support the role played
by these small diameter primary afferent fibers in pain perception;
for instance, two peripheral neuropathies, namely

Fabry's Disease

and a hereditary sensory disease both result in a decrease of the
number of small diameter primary afferent fibers found in the peripheral nerve, but are associated with increased and decreased pain
sensations, respectively (Wall, 1978).

However, since pain perception

involves numerous higher brain centers as well as primary afferent
fibers it would be difficult to speculate about the changed state of
pain perception in neuropathies on the basis solely of the state of
the primary afferent nerve fiber.
Finally, Applebaum et al. (1976) demonstrated that 50% of the
small unmyelinated fibers in the ventral roots arise from dorsal root
ganglion and are sensory fibers.

Furthermore, many of these fibers

are selectively responsive to noxious cutaneous mechanical and thermal stimuli (Clifton et al., 1976).

Thus, these fibers may also par-

ticipate in the transmission of neural impulses arising from noxious
stimulation.
1.1.4.3

Spinal Cord Involvement

The cytoarchitectonic

investi~ations

of Rexed (1952) established

that neurons of the dorsal horn of the spinal cord are arranged in a
series of six clearly defined laminae.

The surface of each lamina is

roughly parallel to the dorsal and ventral surfaces of the cord;
laminae are numbered consecutively I through VI from the extreme
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dorsal aspect to the center of the spinal cord.
Christensen and Perl (1970) demonstrated that lamina I neurons
are excited by intense thermal and mechanical cutaneous stimulation.
This finding
ing

has been confirmed in several laboratory animals includ-

the rat (Giesler et al., 1976).

Although experiments involving

recording from lamina II cells have not been performed extensively,
Perl (1976) has shown that some lamina II cells were excited by high
intensity thermal and mechanical stimuli.
Neurons in lamina V can be excited by noxious thermal and mechanical

stimuli

(Price and Mayer, 1975).

These neurons in contrast to

lamina I neurons also respond to innocuous thermal and mechanical
stimuli; their firing rates increase as the stimulus increases throughout a range of innocuous to noxious intensities; these neurons have
been called "wide dynamic range neurons" (Price and Mayer, 1975;
Giesler et al., 1976).
Neurons located in laminae III and IV show excitatory responses
to innocuous touch and pressure movements and pressure stimulation;
however, these neurons were not excited by noxious pressure stimulation(Giesler et al., 1976).
In summary, it appears that there are two populations of neurons
in the dorsal horn which are responsive to noxious stimulation: (i)
lamina I, marginal, neurons and (ii) lamina V, wide dynamic range
neurons.

12
1.1.4.4

Ascending Transmission Systems

Three anatomically distinct pathways convey sensory information
from the periphery to the cerebral cortex; they include

(i) the

dorsal column-lemniscothalarnic system, (ii) the spinocervical-lemniscothalarnic system, and (iii) the spinothalamic system which consists of spinoreticular, paleospinothalarnic, and neospinothalamic
components (Angel, 1977).

It appears that all three ascending trans-

mission systems participate in the transmission of neural impulses
arising from noxious input (Dennis and Melzack, 1977).
For years the dorsal columns has been viewed as carriers only
of innocuous touch and proprioceptive information.

While this still

appears to be the case for primary afferent fibers ascending in the
dorsal columns it can no longer be said of the secondary afferent
fibers.

Petit (1972) determined that 9.3% of fibers examined in the

dorsal columns originated from spinal neurons.

The frequency of

evoked tonic discharge in these secondary afferent fibers increased
accordingly to the strength of applied heat and mechanical stimulus
even when the stimulus was brought well into the noxious range (Petit,
1972).

Thus, the dorsal column-lemniscothalamic system has the cap-

acity to transmit nociceptive information.
Neurons which demonstrate increased discharge frequencies in
response to noxious mechanical and thermal stimuli have been shown
to be present in the spinocervical tracts of the cat (Price and Brown,
1975) and monkey (Bryan et al., 1974).

In addition, some of these
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cells respond exclusively to noxious mechanical stimulation (Bryan
et al., 1974) .
The spinothalamic system is believed to be the principal pathway for conveying nociceptive information in man and primates
(Willis, 1976).

Trevino et al. (1974) demonstrated that many spino-

thalamic neurons have their origins in spinal cord laminae known to
be associated with the transmission of nociceptive information such
as laminae I, IV, and V (see section 1.1.4.3).
Price and Mayer (1975) demonstrated that 50% (41 out of 82)
of the cells studied in the anterolateral quadrant of the spinal
cord responded to both innocuous and noxious mechanical stimuli
while 12% (10 out of 82) of the cells studied responded only to
noxious mechanical stimuli.

Similar results in studies of the

projections to various midline and intra-laminar thalamic nuclei
(Willis, 1976) via the spinothalamic tract as well as to the medullary reticular formation (Fields et al., 1975) via the spinoreticular tract also have been obtained.
Finally, it should be pointed out that specific central structures (such as the nuclei of the lateral diencephalon) which receive
neural input via the rapidly conducting dorsal column, spinocervical, and

~eospinothalamic

tracts are activated prior to other

central sites (such as midline and intralaminal thalamic nuclei
and brain stem reticular formation) to which the slowly conducting
paleospinothalamic and spinoreticular tracts ascend, respectively
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(Bowsher, 1976).

Dennis and Melzack (1977) suggest that the rapidly

conducting systems convey phasic information about pain whereas the
slowly conducting systems carry tonic information.
Overall, it appears that all of the ascending tracts discussed
above participate in the transmission of nociceptive information to
various higher centers in the CNS.

The heterogeneity of the ascending

systems in terms of termination sites as well as the rate at which
neural impulses are transmitted suggest that specific ascending
systems may selectively activate not only anatomically specific brain
sites but also physiologically specific mechanisms.
1.1.4.5

Supraspinal Associated Structures

Various supraspinal structures such as the reticular formation,
thalamus, and cortex have been implicated in processing information
concerning noxious stimulation (Kerr and Wilson, 1978).
Casey et al. (1974) have demonstrated that 57% (59 out of 104)
of the units studied in the medullary nucleus reticularis gigantocellularis responded to innocuous and noxious mechanical stimuli; in
addition, 25% of these units responded exclusively to noxious mechanical stimuli.

Investigations of the nucleus ventralis of the medulla

have also demonstrated that a majority of cells (70%) respond to noxious heat and mechanical stimulation; some of these cells respond exclusively to noxious stimulation (Benjamin, 1970).
Imprecisely defined regions in the pontine reticular formation
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(Eickhoff et al., 1978), mesencephalic reticular formation (Young and
Gottschaldt,l976;Eickhoff et al., 1978), and mesencephalic central
grey region (Eickhoff et al., 1978) also contain cells which respond
to noxious stimulation.

Again, the majority (>70%) of the units test-

ed in each study responded to innocuous as well as noxious heat and
mechanical stimuli; some (>16%) of the units tested respond

exclu~

sively to noxious stimulation.
The thalamic posterior group of nuclei (PO) contain neurons which
resp?nd to noxious stimulation of the skin; 30% of 258 neurons studied
were determined to be nociceptive; 16% responded exclusively to noxious mechanical stimuli while 14% of the cells responded differentially
to both noxious and innocuous mechanical stimulation (Dong and Wagman,
1976).
Similarly, neurons in the medial thalamus particularly the nucleus parafasicularis, respond to noxious mechanical stimuli; however,
more than half of the nociceptive neurons in the medial thalamus,
unlike the nociceptive cells in the PO, did not respond to innocuous
mechanical stimulation (Dong et al., 1978).
ipates

Thus, the thalamus partic-

in the nociceptive phenomenon.

Cerebral cortical involvement in the appreciation of nociceptive
input has been suggested by the following experiments. First, ablation
of the secondary somatosensory cortex, the anterior ectosylvian gyrus,
and its bordering sulci increased the escape threshold to noxious electric

shock in cats; ablation of the primary somatosensory cortex was
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ineffective (Berkely and Parmer, 1974).
Second, specific evoked potentials (EPs) have been demonstrated
to arise from noxious tooth pulp stimulation in man;

tooth pulp-

evoked potentials were not present when devitalized teeth of normal
patients were stimulated or when an individual congenitally insensitive to pain was used as the subject (Chatrian et al., 1975).

Re-

cently, Chen et al. (1979) demonstrated that the amplitudes of specific components of the EP waveform were directly related to the stimulus intensity and subjective pain response as measured by the subject's verbal reports.
1.1.4.6

Descending Systems

Anatomically, the brain stem reticular formation receives input
fibers from a number of higher centers.

Axon degeneration studies

have demonstrated that fibers originating in all parts of the cerebral cortex, especially the motor cortex, descend to terminate in the
brain stem reticular formation; the majority of these fibers end in
two fairly well defined areas, the pontine nucleus pontis oralis, and
the medullary nucleus reticularis gigantocellularis (Rossi and Brodal,
1956) .

Electrical stimulation of intralaminar and midline thalamic

nuclei has been shown by intracellular recording techniques to depolarize cells located in pontine and medullary reticular formation
(Mancia et al., 1974a).

The existence of intrareticular connections

within the brainstem itself

wh~ch

produce primarily ascending inhibi-

tory effects also have been demonstrated by intracellular recording
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techniques (Mancia et al., 1974b).
Neuron degeneration studies show that reticulospinal fibers
from the medial portions of the pontine and medullary reticular formation descend to terminate in cervical and thoracic spinal cord;
more than half of the cells in specific reticular nuclei namely pontis
caudalis, oralis, gigantocellularis, ventralis, and lateralis project
to the spinal cord (Torvik and Brodal, 1957).
Recently, descending reticulospinal projections from medullary
reticular nuclei were studied with autoradiographic methods; the nucleus reticularis gigantocellularis projects primarily to motor related areas such as laminae VII and VIII; the nuclei raphe magnus and
reticularis magnocellularis project primarily to laminae with known
nociceptive input such as laminae I, II, III, and V (Basbaum et al.,
1978; see section 1.1.4.3).
Overall, the brain exhibits the anatomical capacity to influence
sensory input at several levels of the CNS.

An analysis of how these

descending systems affect nociception will be discussed in sections
l. 3 • 4 and 1. 4 . 4 .

1.1.5

Gate Control Theory

The Gate Control Theory of pain developed by Melzack and Wall in
1965 has attracted its share of criticism; nevertheless, it remains
the most readily accepted theory of pain today.

The basic proposals

of this theory as set forth by Melzack and \vall (1965) will be pre-
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sented as follows.

First, the transmission of nerve impulses by primary afferent
nerve fibers to spinal cord transmission cells (T cells) is modulated
by a spinal gating

mech~nism

in the dorsal horn.

The substantia gel-

atinosa, laminae II and III, is considered to be the site of the spinal gating mechanism.
Second, the spinal gating mechanism is influenced by the relative
amounts of activity in large, Aa fibers and small diameter Ao and C
fibers; activity of large fibers tend to inhibit transmission (close
the gate) while activity in the small fibers tend to facilitate transmission (open the gate) .

The

mechanism of this effect is that large

Aa fibers have a brief excitatory effect on spinal T cells but then
close the gate by inhibiting transmission from Aa, Ao, and C fibers
through activation of interneurons in the substantia gelatinosa.

On

the other hand, Ao and C fibers prevent this inhibitory effect by inhibiting the inhibitory interneurons, thus opening the synaptic gate
and increasing excitatory input to the T cells.

However, clinical

observations do not completely support this hypothesis (see section
1.1.4.2).
Third, the spinal gating mechanism is influenced by nerve impulses

that descend from the brain.

As described previously, various

cognitive factors such as attention, anxiety, etc. influence pain
responses.

The brain stem reticular formation as well as reticula-

spinal projections inhibit transmission from the spinal T cells. Since
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fibers from the cortex project to the reticular formation as well as
directly to the spinal cord by means of corticospinal fibers this
provides a system by means of which cognitive processes are able to
influence spinal T cell activity.
Fourth, a specialized system of large diameter, rapidly conducting fibers (the central control trigger) activates selective cognitive processes which then influence, by way of descending fibers, the
modulatory properties of the spinal gating mechanism.

The dorsal

column medial lemniscal and dorsolateral systems could fulfill the
function of the central control trigger (Melzack and Dennis, 1978).
The fifth proposal is that when the output of the spinal cord T
cells exceeds a critical level, it activates those neuronal areas
which subserve the complex, sequential pattern of pain related behavior.
A final aspect of the Gate Control Theory is referred to as the
central biasing mechanism (Melzack and Dennis, 1978).

Here, brain-

stem areas which are known to exert an inhibitory control over transmission in the pain signalling system receive inputs from widespread
parts of the body and in turn project to widespread parts of the spinal cord and brain.

Stimulation of the small diameter afferents can

increase input to this central biasing mechanism resulting in the
closing of the gates to noxious inputs from selected body areas.
cells of the midbrain reticular formation are known to have large
receptive fields and electrical stimulation of reticular formation

The
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can produce analgesia in discrete areas of the body.

It is possible

then, that particular body areas may project especially to some reticular areas, and these in turn would close the gate to input from
particular parts of the body.

This model could be used to explain

aspects of hyperstimulation analgesia of

which acupuncture and trans-

cutaneous electrical stimulation are but two examples.
1.1.6

Brain Mechanisms

It is obvious that the phenomenon of pain cannot be viewed solely
in terms of sensory perception without r3garding motivational affective and cognitive processes.

Melzack and Casey (1968) proposed a

three dimensional psychological scheme to include (i) sensory-discriminative, (ii) motivation-affective, and (iii) cognitive-evaluative
components of pain.

A brief summary of their proposal follows.

First, the neospinothalamic tract, the spinocervical tract, and
postsynaptic elements in the dorsal column-medial lemniscal system all
project at least in part to the ventral basal thalamus which shows a
discrete somatotopic organization.

Since all of these ascending sys-

tems appear to be involved in the transmission of nociceptive information, these rapidly conducting tracts have the capacity to process
information concerning the spatial, temporal, and magnitude properties of the nociceptive input.

Therefore, this system may subserve the

sensory-discriminative dimension of pain.
Second, the spinoreticular and paleospinothalamic tracts project
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to the brainstem reticular formation and limbic system.

Since the

reticular formation and limbic system have been shown to participate
in the pain process, the powerful motivational drive and unpleasant
affective

characte~istics

of pain may be influenced by activities in

those particular brain regions which are affected primarily by the
slowly conducting spinal systems.
Third, various cognitive activities such as cultural values,
attention, and anxiety all have a profound effect on the pain experience.

These cognitive functions must be able to act selectively on

the sensory and motivation systems in order to influence the pain response.

The dorsal column-medial lemniscal system and dorsolateral

projection pathways rapidly carry impulses directly and indirectly to
the cerebral cortex.

Influences that descend from the cortex are known

to act at the level of the ventrobasal thalamus as well as dorsal horn
cells.

Therefore, these rapidly conducting ascending and descending

systems appear to have the capacity to influence pain related information being transmitted over the more slowly conducting pathways and
thus account for the fact that psychological processes play an important role in determining the quality and intensity of pain.
Melzack and Casey (1968) suggest that these three psychological
processes interact with one another to provide perceptional information regarding the location, magnitude, and spatiotemporal properties of the noxious stimulus; motivational tendency toward escape; and
cognitive information based upon past experience and probability of
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outcome of the various response.

All three components then influence

the appropriate motor mechanisms which produce the overt behaviors
characterizing the pain response.
1.1.7

Importance of Pain

Pain is of crucial biological importance; true value of this can
be seen in congenitally insensitive individuals who suffer excessive
tissue damage such as burning a hand or arm on a heated stove, chewing
off the end of their tongues, or chopping a knee with an axe all because of the inability to experience pain which would have protected
them from these various occurrences (Swanson et al., 1965).

Although

pain does serve as a warning of injury to the individual and is of

great diagnostic value to the physician it may also be an unnecessary
evil at times when its warning effect is useless such as in terminal
cancer or phantom limb pain.
1.1.8
1.1.8.1

Treatment of Pain

Pharmacological Intervention

The ideal analgesic agent should be effe9tive when given orally,
rapidly active after ingestion, and sufficiently strong to produce an
appropriate level of analgesia; it should not produce tolerance, addiction, or respiratory depression; its actions should be specific and
associated with few side effects; finally, an antidote should be available.

In other words the ideal analgesic should control pain without

producing any undesirable side effects and dependence (Villaverde and
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MacMillan, 1977).
The narcotic analgesics are the group of drugs which, among analgesics available today, fulfill the above criteria most closely, even
though they are far from being ideal; most of them are opium derivatives while others are synthetic or semisynthetic products; morphine and
meperidine are the principal members of these two groups, respectively.
Besides producing analgesia the narcotics also produce, even when
used in therapeutic doses,undesirable side effects such as sleepiness,
nausea, vomiting, and respiratory depression.

Among serious problems

associated with the narcotics is that of the tolerance which develops
to the analgesic effects upon repeated administrations; that is, continually increasing doses of narcotic must be administered to produce
a sufficient analgesia.

Unfortunately, in the chronic pain patient the

doses of narcotic required are often extremely high increasing the
frequency and severity of the associated side effects.

In addition,

as tolerance further develops there is no dose of narcotic which will
produce analgesia short of

~ausing

death.

In addition to tolerance, physical dependence, i.e. addiction,
develops with repeated use of narcotics; the abuse liability and possibility

of developing psychological dependence on the effects of these

compounds is one of the major limitations for their clinical use. However, in patients with painful terminal illnesses, this factor should
not prevent the physician from alleviating the patient's pain and discomfort.
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The principal use of the narcotics is for the treatment of severe
pain which cannot be alleviated by other analgesics, such as in cancer, traumatic accidents, burns, fractures, and severe visceral
lesions.
The salicylates, most notably acetylsalicylic acid (aspirin),
constitute a second major group of analgesics.

The overall analgesic

effect of the salicylates is inferior to that achieved by the narcotics; salicylates do appear to be more effective against integumental
than visceral pain.
While used in therapeutic doses, the salicylates do not produce
respiratory depression or sleepiness, prolonged salicylate use may
cause hyperventilation, tinnitus, and mental confusion.

Gastro-

intestinal distress, nausea, and vomiting, are the most common side
effects.

Salicylates are recommended for treatment of headache,

arthritis, dysmenorrhea, and neuralgia.
Para-aminophenol derivatives such as phenacetin and acetaminophen and pyrazalon derivatives such as antipyrine and aminopyrine
and their modern congeners such as indomethacin all produce an equivalent level of analgesia as do the salicylates and consequently these
compounds are employed in the treatment of similar types of pain as
are the salicylate drugs.

It should be emphasized that with many of

these drugs their analgesic effect may depend on their peripheral
antiinflammatory action.
gout.

Thus, they may be useful in arthiritis and
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In addition, high doses of phenacetin produce methemoglobinemia,
nephropathy and hepatic necrosis while high doses of acetaminophen
may cause thrombocytopenia and nephrotoxicity.

However, in recommen-

ded therapeutic doses, phenacetin and acetaminophen are well tolerated.

Aminopyrine and possibly antipyrine produce severe blood dyscrasias such as thrombocytopenia and agranulocytosis; consequently, these
compounds are reserved for use in cases that do not respond to salicylates or

para-~~nophenol

derivatives.

Antimalarials, most notably quinine, whose main use is for the
treatment of malaria also produce analgesia.

As analgesics, however,

their effects are weaker than those of the salicylates.

Quinine is

used only with considerable caution due to the potential nephrotoxic
and hemolytic idiosyncratic reactions.
Finally, certain groups of drugs are used for specific types of
pain as follows:

(a) local anesthetics such as procaine, lidocaine,

and dibucaine are used primarily to produce surface and infiltration
anesthesia in localized parts of the body; (b) vasodilators such as
nitroglycerine and amyl nitrate are used for the treatment of angina
pectoris, both as a preventive and for relief of the acute attack;
(c) corticoids such as cortisone, hydrocortisone, and prednisone are
employed in the treatment of pain associated with inflammation, arthritis and bursitis; and (d) muscle relaxants such as meprobamate are
used to treat pain associated with muscle spasms in rheumatic disease
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or following trauma.
While numerous analgesic agents are employed for the relief of
pain, the narcotic analgesic compounds constitute the most effective
and most potent analgesics available today.

In view, however,·of

their side actions and addictive liability, improvements in the pharmacological manipulation of pain, particularly chronic pain, are required.
1.1.8.2

Neurosurgical Ablative Techniques

Various neurosurgical ablative procedures such as dorsal rhizotomy, chemical sympathectomy, percutaneous chordotomy, and chemical
hypophysectomy have been employed, without a great deal of success,
in the management of chronic pain.
Dorsal rhizotomy, sectioning of the dorsal roots, failed to produce long term (6 month} analgesia in the majority of cases (Loeser,
1974}.

Aside from imperfect surgical procedures, several other

explanations may account for this lack of success.

First, the source

of pain may not lie in the periphery, therefore, deafferentation would
not isolate the brain from the pathology (Melzack and Loeser, 1978}.
Second, deafferentation may itself generate abnormal firing patterns
which the patient senses as painful (Loeser, 1974}.

Finally, primary

afferent sensory nerve fibers associated with nociceptors are known
to exist in the ventral roots (Applebaum et al., 1976}; the presence
of these fibers also may account for the failure of dorsal rhizotomy
to relieve pain (Clifton et al., 1976}.

Overall the

best prognosis
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for the patient offered dorsal rhizotomy for the relief of chronic
pain is poor.
Similarly, the localized injection of phenol (6.7% in water) into
the sympathetic chain, chemical

sympathectomy

is useful only when

the disease is confined within the visceral cavity; it therefore is
rarely successful in pain of malignant disease in which the cells at
any early stage invade neighboring structures innervated by the somatic nerves of the body wall (White, 1974).

Furthermore, chemical

sympathectomy suffers from a high incidence of associated complications such as pneumothorax, kidney puncture, and intravascular injec·tions as well as a postoperative neuritis in the groin area and thigh
regions of a large number of patients (14.6%; Reid et al., 1970).

Radiofrequency currents are used to produce lesions in the anterolateral quadrant of the spinal cord for the relief of chronic pain.
Initially pain relief is excellent for 90% of the patients (n=l,279);
however, an abrupt decrease in efficacy occurs three months after the
operation and continues to decrease thereafter so that only 40% of
the patients continue to report adequate pain relief one year after
the operation (Rosonoff, 1974).

In addition, complications such as

muscle weakness, sphincter paralysis, and localized burning sensations
have also been reported (Mullan et al., 1963).

One explanation which

may account for this procedural failure is that ascending tracts convey impulses arising from noxious stimuli are not restricted to the
anterolateral quadrant of the spinal cord (see section 1.1.4.4).
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Chemical hypophysectomy, neuroadenolysis, is achieved by the localized injection of absolute ethanol into the pituitary gland (Morrica,
1974).

This procedure was initiated in cancer patients with diffuse

bone and/or visceral matastesis arising from hormone-dependent tumors
(Morrica, 1974).

Miles and Lipton (1976) reported that cancer pain

arising from other nonhormone-dependent tumors was also relieved by
chemical hypophysectomy.

However, since ethanol injected into the

pituitary has been shown to spread to the hypothalamus, it may act
there to interfere with pain perception (Miles and Lipton, 1976;
Yanagida et al., 1979).

Finally, the severe complications

associ~ted

with chemical hypophysectomy such as diabetes insipidus, hypoadrenalism, hypothyroidism, decreased libido, hyperthermic crisis, hyperphagia, and anhydrosis suggest that this procedure be used only after
other treatment procedures have failed to relieve pain (Morrica, 1976).

Overall, the neurosurgical ablative techniques have the disadvantages of being restricted to a specific part of the body, gradual return of pain with time, or more seriously, various permanent neurological complications.

Thus, these methods for pain relief are grad-

ually being replaced by other related methods namely nerve stimulation
techniques.

1.1.8.3

Stimulation Produced Analgesia (SPA)

Reynolds (1969)

first employed electrical stimulation of the mid-

brain periaqueductal grey matter (PAG) to render rats sufficiently
antinociceptive to pe:form abdominal surgery.

Since then, PAG stimu-

29

lation-induced analgesia (SPA) in laboratory animals has been reported
to block behavioral responses such as extreme pinch (Reynolds, 1969),
tissue damaging heat (Mayer and Liebeskind, 1974), electric tooth pulp
stimulation (Oliveras et al., 1974), and the application of various
algesic substances (Melzack and Melinkoff, 1974).

Electrical stimu-

lation of other central sites such as the septal nuclei, dorsolateral
thalamic nuclei were effective with regard to only certain types of
noxious stimuli (Mayer and Liebeskind, 1974); stimulation of the ventrobasal complex of the thalamus and lateral hypothalamus was completely ineffective (Mayer and Liebeskind, 1974).
In humans, electrical stimulation of various areas in the CNS
such as the dorsal columns (Shealy et al., 1967), internal capsule
(Adams et al., 1974), and PAG (Richardson and Akil, 1977a, b) produced analgesia.

However, the occurrence of undesirable side effects

such as nystagmus, nausea, vertigo, reports of enhanced pain sensations as well as the lack of prolonged effectiveness of treatment has
limited the clinically effective target site to an area between the
nucleus parafasicularis and third ventricle at the level of the posterior commisure (Richardson and Akil, 1977a, b).

SPA can be measured after only a few seconds of central stimulation (Mayer et al., 1971) and the post stimulation duration of effectiveness in the rat lasts for minutes to hours (Mayer and Liebeskind,
1974).

Similarly, 30

minut~s

of stimulation afforded 3 to 4 hours of

pain relief in humans (Hosobuchi et al., 1977).

Thus, SPA provides

an alternative approach for the control of chronic intractable pain.
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Evidence suggests that SPA, morphine-induced antinociception, and
the endogenous opioid system all may be interrelated.

The mechanism

involved in SPA as well as the role played by the endogenous opioid
system in antinociception and analgesia will be reviewed subsequently
(see sections 1.3.4 and 1.4.4).

1.1.8.4

Psychological Manipulations

The first nonphysical method employed in the treatment of chronic
pain utilizes placebos, pharmacologically inert agents.

Placebo-in-

duced analgesia reduced pain by about half of its original intensity
in a variety of clinical situations for about 30% of the patients studied (Evans, 1974).

On the other hand, placebos reduced experimentally-

induced pain in only 3 to 16% of the experimental populations (Evans,
1974).

Thus, placebos relieve pathological pain more effectively than

they relieve experimental pain.

It should be pointed out here that

the placebo was at least half as effective as the assumed strength of
the analgesic drug being administered under double blind conditions
regardless of what analgesic was administered (Evans, 1974).

This

finding holds true for aspirin (Evans, 1974), morphine (Evans, 1974),
and transcutaneous electrical stimulation (Thorsteinsson et al., 1978).
Overall, the judicious use of placebo-induced analgesia for a
specific group of patients appears to be useful and in some cases may
be more clinically effective than specific drugs.

In addition, cer-

tain variables within the doctor patient relationship such as trust,
belief, and the drug giving ritual appear to produce powerful curative

31
effects and therefore should be emphasized as a foundation on which
all other therapeutic procedures concerning the treatment of chronic
pain be built.
A second nonphysical method used for the treatment of chronic
pain is called hypnosis-induced analgesia.

The usefulness of hypnosis

in the relief of pain was demonstrated early in the 19th century when
limb amputations and other major operations were performed apparently
painlessly with hypnosis as the only analgesic-anesthetic agent
(Esdaile, 1957 cited by Hilgard, 1978).

Since hypnotizability is seen

as a personality trait which an individual possesses rather than a
skill which may be improved with time (Perry, 1977), the range of
patients in which hypnosis-induced analgesia would likely be effective
is severely restricted.
Since naloxone fails to antagonize hypnosis-induced

analgesia

(Goldstein and Hilgard, 1975), it does not appear that the endogenous
opioid system is involved in mediating this effect.

Hilgard (1978)

suggests that hypnosis-induced analgesia occurs primarily at higher
cognitive levels which include cortical involvement.
The final nonphysical technique used in the treatment of chronic
pain employs operant conditioning methods.

Pain behavior, like other

ope=ants, while initially elicited by an antecedent stimulus may come
under the control of consequences (Fordyce et al., 1973).

When an

operant is followed by a positive consequence such as praise, attention, money, or food that behavior is likely to occur in the future.
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Alternatively, when an operant is followed by a negative consequence
such as criticism or loss of valued rewards that behavior is likely
to occur less in the future.

Thus, in a specific group of patients,

pain behavior may occur only because it is followed by positive consequences.

Fordyce et al. (1973) successfully employed the operant

conditioning technique in a study utilizing a selected group of patients who suffered from chronic pain which was thought to occur from
factors other than tissue pathology.

The results of this study demon-

strated (i) a significant decrease in medication required and (ii)
significant increases in walking and nonreclining activities.

1.2

Cholinergic System in Antinociception and Analgesia

1.2.1

Central Cholinergic System

Central actions of cholinergic agonists and antagonists, anticholinesterases, and acetylcholine (ACh) itself must be considered
in terms of the presence and distribution of cholinergic synapses

o~

cholinoceptive neurons or both, as well as in terms of cholinergic
pathways.

A variety of histochemical and biochemical techniques and binding studies have been utilized to investigate brain neuronal mechanisms in which ACh is

t~:ought

to be the neurotransmitter.

Acetyl-

cholinesterase (AChE) has been investigated utilizing histochemical
procedures (Shute and Lewis, 1967; Lewis and Shute, 1967) while ACh
(Cheney et al., 1975), choline acetyltransferase (CAT; Kobayashi et
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al., 1975), and high affinity choline uptake (Kuhar et al., 1973a,
1975) have been investigated by various biochemical tests.

More

recently, binding studies as well as studies of muscarinic and nicotinic cholinoceptivity have been used to determine the distribution
of muscarinic (Kobayashi et al., 1978a; Krnjevic, 1974) and nicotinic
(Hunt and Schmidt, 1978)

binding sites.

Since all of the afore-

mentioned parameters are considered to be functionally components of
cholinergic neurons and synapses, indirect evidence from these studies
concerning the distribution of cholinergic synapses and pathways can
be obtained.
Shute and Lewis (1967) demonstrated that AChE accumulated at the
proximal end of sectioned nerves whereas it disappeared distal to the
division.

Utilizing histochemical procedures, Shute and Lewis (1967)

and Lewis and Shute (1967) mapped the cell bodies and axons of cholinergic neurons in the CNS.
from these studies.

Two principal cholinergic pathways emerged

First, the ascending reticular system arises from

reticular and tegmental nuclei of the brainstem and projects via dorsal and ventral tegmental pathways to virtually all cortical and subcortical structures.

Second, the cholinergic limbic system consisted

of septa-hippocampal connections as well as hippocampal afferent
projections to the medial sortex, nuclei connecting with the ascending
cholinergic reticular system, and subfornical and supraoptic crest.

Electrolytic lesions of the medial septal area decreased ACh
levels, CAT activity, and high affinity choline uptake in the hippocampus (Kuhar et al., 1973a).

Identical effects were observed in the
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interpeduncular nucleus area when the medial habenular areas was lesioned (Kuhar et al., 1975).

This provides additional evidence for

cholinergic septa-hippocampal and habenular-interpeduncular tracts.

Utilizing mass fragmentography and gas chromatography, Cheney et
al.

(1975) demonstrated that a high ACh/CAT ratio which is indicative

of cholinergic terminals was found in (i) olfactory structures, (ii)
preoptic nuclei, (iii) several hypothalamic and thalamic nuclei, (iv)
habenular and mammalary nuclei, (v) various midbrain nuclei, (vi)
locus coeruleus 7

and (vii) nucleus interpositus of the cerebellum.

In addition, high content of CAT has been demonstrated in certain cranial nerve nuclei including III, IV, VII, and XII as well as nuclei
salvitorius, tractus solitarius and caudate putamen of the rat brain
stem (Kobayashi et al., 1975).

Utilizing a binding assay, Kobayashi et al.

(1978a) found a

high density of cholinergic muscarinic binding sites in the hippocampus, caudate-putamen, nucleus accumbens and cerebral cortex; septal
areas, interpeduncular nuclei, habenular nuclei, and medial thalamus
exhibited a less dense population of binding sites; least dense binding site distribution was observed in the spinal cord and cerebellum.

The distribution of cholinergic nicotinic binding sites has also
been investigated utilizing binding assays (Hunt and Schmidt, 1978).
Binding sites were predominantly found with central areas of the brain
associated with direct sensory input such as olfactory bulbs, superior
colliculus, cochlear nuclei, the substantia gelatinosa, and the prin-
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cipal trigeminal sensory nucleus (Hunt and Schmidt, 1978).

Certain

limbic areas such as the hippocampus, amygdala, mammallary bodies,
and dorsal tegmental nucleus also contain nicotinic binding sites
(Hunt and Schmidt, 1978).

Presynaptic localization of a neurotransmitter substance must be
considered in terms of the concept of the synaptic vesicle.

Accord-

ingly, ACh has· been shown to be contained in synaptic vesicles obtained from the synpatosomal fraction of cerebral cortical tissue
(Whittaker and Sheridan, 1965) and of other brain tissues.

Altogether,

localization of ACh-containing 'resicles agrees with that of other markers

of the cholinergic system.

It must be added in this context

that ACh-containing vesicles are morphologically specific and differ
from those containing GABA or catecholamine(Karczmar, 1976).

Localized injections of ACh and subsequent recordings from various
cholinoceptive neurons have provided additional information concerning the central cholinergic system.

Most cholinoceptive cells in the

CNS were excited and depolarized; occasionally inhibitory, hyperpolarizing responses were observed (Krnje-vic, 1974) .
atory

The :nost common excit-

action of ACh in the CNS has muscarinic characteristics;_ it is

relatively slow in onset and very prolonged and is readily blocked by
atropine; the ionic mechanism of depolarization is probably a reduction in potassium conductance(Krnjevic, 1974).

Other excitatory ef-

fects occur at nicotinic sites: ACh has a very quick and rapidly reversible effect on some CNS neurons such as the Renshaw cell; dihydrobeta-erthroidine and mecamylamil".e blocked this effect (Krnjevic, 1974) .
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Finally, inhibition of some CNS neurons caused by a specific increase
in potassium permeability is mediated by muscarinic receptors
(Krnjevic, 1974).
It should be pointed out that the presence of cholinoceptive
neurons, ACh and AChE by themselves do not insure proof of cholinergic transmission.

For instance, the cerebellum contains AChE con-

taining cells and fibers but no specific pathway in the cerebellum has
been shown to act by release of ACh

(Krnje~ric,

1974).

Finally, ACh was the first neurotransmitter substance collected
following stimulation of different CNS preparations (Pepeu, 1973) .
The original method of Mitchell (1963) for studying ACh release from
the cerebral cortex utilized the cortical cup; ACh content was determined by bioassay on the dorsal muscle of the leech.

Investigations

of ACh release from subcortical structures were made possible by the
push-pull cannula described by Gaddum (1961).

In either case, ACh re-

lease studies were only possible if 95% of the AChE present had been
previously inhibited (Lancaster, 1971). ACh release has been demonstrated in such brain areas as sensory motor, auditory, parietal, and
visual cortex; caudate nucleus; ventrobasal complex of the thalamus;
thalamic nuclei ventralis, lateralis, and posterior; hypothalamus;
medulla; and spinal cord (Pepeu, 1973).

In addition, ACh release from

central brain sites depends upon the presence of calcium ions (Randic
and Padjen, 1967).

Overall, the release studies provide additional

evidence and information concerning the distribution of the central
cholinergic system.
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In summary, what emerges is the concept that cholinergic synapses
and pathways are present in many CNS structures;the major central
cholinergic system comprises a diffuse ascending tegmental-mesencephalic-cortical system; the most notable pathways included here are
the ventral and dorsal tegmental pathways, habenulo-interpeduncular
tract, septohippocampal tract, and thalamocortical tract.

1.2.2

Interactions with Other Neurotransmitter Systems

Next, the interaction between the cholinergic, catecholaminergic,
and serotonergic neurotransmitter systems throughout the CNS has been
demonstrated (Karczmar, 1975).

Cholinergic agonists and antagonists

affect levels and/or turnover rates of brain catecholamines and serotonin (5-HT) ; the effect on the 5-HT system is most pronounced
(Karczmar, 1976).

Diisopropyl phosphofluoridate (DFP) increased 5-HT

levels in the rabbit midbrain, thalamus, hippocampus, and medulla
(Barnes et al., 1974); effects were reversed by atropine (Barnes et
al., 1975).

DFP recently has been shown to increase both 5-HT levels

and turnover in several rat brain regions; effects were reversed by
atropine (Barnes et al., 1978).

Furthermore, DFP increased levels of dopamine (DA) in several
rabbit brain parts including the thalamus, hypothalamus, midbrain, and
hippocampus (Glisson et al., 1972, 1974).

Alternatively, DFP decreased

norepinephrine (NE) levels in the same four rabbit brain regions discussed above (Glisson et al., 1972, 1974).

The effect of DFP on NE

arises from central actions while the DFP effect on DA depends in part
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on peripheral actions; atropine methyl nitrate, the quaternary analogue which does not readily penetrate the blood brain barrier (BBB)
blocked the DFP effect on DA but was ineffective against NE (Glisson
et al., 1974).
Concerning reciprocal relationships, ACh-5-HT interactions may be
bidirectional.

5-hydroxytryptophan (5-HTP), the metabolic precursor

for 5-HT, significantly increased the level of ACh following pretreatment with the serotonergic neurotoxin 5,6-dihydroxytryptamine in mice
(Barnes et al., 1973a, b).

On

~~e

other hand, ACh brain levels were

not affected by the catecholamine neurotoxin, 6-hydroxydopamine or by
the metabolic precursor for catecholamines, 1-dopa (Barnes et al.,
1973c) .
The pharmacological evidence described above
the interaction between various
is widespread.

neurotransmi~ter

demonstra~es

that

systems in the CNS

The exact mechanism of these effects, in terms of

neurotransmitter turnover rates and pertinent circuitry remains to be
established.

In addition, the results discussed above suggest that

it may be difficult to obtain a predictable cholinergic effect that
would depend solely on cholinergic synapses and pathways and/or cholinoceptive neurons.

However, specific effects of cholinergic drugs

on behavior are obtained as discussed in the following sections.
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1.2.3

1.2.3.1

Antinociception and Analgesia

Compounds Which Affect the Cholinergic System

Several cholinomimetic compounds such as dibromopyruvic acid
(Martinet al., 1958), tremorine (Chen, 1958), arecoline (Herz,
1961), oxotremorine (Harris et al., 1968), carbachol (Metys et al.,
1969), and pilocarpine (Houser and Van Hart, 1973); various anticholinesterase agents such as physostigmine (Harris et al., 1968)
and DFP (Koehn and Karczmar, 1978); and ACh itself (Pedigo et al.,
1975) produce antinociception when administered to mice and rats.

Recently, physostigmine (Sitaram et al., 1977) and arecoline
(Sitaram, 1979, personal communication) have caused an analgetic
action in normal human volunteers.

Scopolamine, an anticholinergic agent, produced antinociception
when administered to monkeys (Pert, 1975).

The discrepancy between

findings in the monkey and all other species including man concerning the involvement of the cholinergic system in nociception cannot
be explained at present.

The antinociceptive and analgesic states produced by the compounds mentioned above will henceforth be referred to as cholinergicinduced antinociception and analgesia, respectively.
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Prostigmine (Slaughter and Munsell, 1940), pilocarpine (Saxena
and Gupta, 1958), DFP (Bhargava and Way, 1972), and ACh (Pedigo et
al., 1975) potentiate narcotic-induced antinociception in laboratory
animals.

In addition, some partial agonists of narcotics such as

cyclazocine, cyclorphan, nalorphan, and pentazocine are converted from
inactive to active antinociceptive agents in the mouse in the presence
of physostigmine (Harris et al., 1967).
Some of these various agents which affect the central cholinergic
system proved to be more potent on a milligram basis than morphine;
for instance, oxotremorine was 3000 times more potent than morphine
in the mouse (Leslie, 1969).

Finally, oxotremorine but not morphine

could produce antinociception when administered to frogs (Nistri et
al., 1974).
Several anticholinesterase agents such as pyridostigmine
(Slaughter, 1950)

physostigmine (Floodmark and Wrammer,

1945)

and neostigmine (Hand and Audin, 1944; Christensen and Gross, 1948)
potentiate narcotic-induced analgesia in humans.

In fact, the com-

bination of neostigmine with a narcotic analgesic was considered to be
more effective than the narcotic analgesic used alone as the dose of
the narcotic employed to produce analgesia could be reduced, hence
lessening the severity of associated side effects, most notably nausea
and somnolence (Hand and Audin, 1944).

1.2.3.2

Central Muscarinic Nature

Cholinergic-induced antinociception and analgesia result from
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actions involving central cholinoceptive sites of the muscarinic type
as suggested by the following.

First, tertiary anticholinergic-anti-

muscarinic agents such as atropine sulfate and scopolamine which cross
the BBB antagonize cholinergic-induced antinociception and analgesia;
quaternary anticholinergics such as atropine methyl nitrate and methylscopolamine which do not cross the BBB are ineffective (Herz, 1961;
Handley and Spencer, 1969; Pedigo et al., 1975; Sitaram et al., 1977;
Koehn and Karczmar, 1978).

On the other hand, various anticholinergic

drugs which block central cholinoceptive sites of the nicotinic type
such as dihydro-13-erythroidine(Herz, 1961), various alpha substituted
acetylcholine derivatives (Dewey et al., 1975), nicotine and hexamethonium (Pert, 1975), and·mecamylamine (Pedigo et al., 1975) do not
affect cholinergic-induced antinociception.

It may be added that in

monkeys, only those anticholinergic agents such as scopolamine which
cross the BBB are effective antinociceptive agents when administered
systemically; methylscopolamine was ineffective (Pert, 1975).
Second, muscarinics, but generally not nicotinics (see however,
below), do exert antinociceP.tion.

For instance, carbachol, a quater-

nary cholinomimetic which also possesses some activity at nicotinic
receptors, produces antinociception when administered intracerebroventricularly (Icvt); effects were reversed by atropine (Metys et al.,
1969).
Drug interactions with muscarinic receptors in peripheral tissues
appear to be stereospecific; (+) isomers of beta-substituted methylcholine mimick the action of muscarine; (-) isomers were inactive
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(Ellenbroek and Van Rossurn, 1960).

Chemical derivatives of beta-

substituted methylcholine which exhibit muscarinic action stereospecifically antagonized ACh-induced antinociception in mice; (+) isomers
were active while the (-) isomers were inactive (Dewey et al., 1975).
Thus, cholinergic-induced antinociception appears to be stereospecifically

mediated by muscarinic receptors in the CNS.

It must be added that while most laboratories have failed to
demonstrate antinociceptive activity for compounds which interact with
nicotinic cholinergic receptors (Herz, 1961; Metys et al., 1969; Pert,
1975; Pedigo et al., 1975),

Phan et al. (1973) showed that nicotine

produced antinociception when administered to rodents; the effect was
blocked by mecamylamine but atropine was ineffective.

However, more re-

search concerning this effect is required before two independent cholinergic systems can be implicated in the production of antinociception
and analgesia.
Pharmacological evidence concerning specific central sites for
cholinergic modulation of the antinociceptive state comes from many
sources.

Intraventricular (Ivt) administration of carbachol (Metys

et al., 1969), oxotremorine (Handley and Spencer, 1969), ACh (Pedigo
et al., 1975), and scopolamine (Pert and Maxey, 1975) suggest the involvement of structures immediately around the ventricular system
since the time course of the antinociceptive state and diffusion properties of these drugs limit their potential sites of action to those
particular areas.

In addition, Ivt administrations of oxotremorine

and arecoline into the septal area, mesencephalic reticular formation,
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hypothalamus, and medial thalamic nuclei produce significant antinociception; applications into the striate or hippocampus were ineffective;
effects were reversed by atropine (Metys et al., 1969).
The close anatomical proximity of the ascending cholinergic reticular formation and the paleospinothalamic and spinoreticular tracts
which carry nociceptive information (see section 1.1.4.4), as well as
the fact that Ivt applications of cholinomimetic agents into these
areas produced antinociception led Sitaram et al. (1977) to postulate
that physostigmine produced analgesia by virtue of its action mediated
by the ascending reticular activating system.
In any case, the specific sites and pathways involved in mediating and modifying cholinergic-induced antinociception and analgesia
remain to be further identified.
1.2.3.3

Mechanisms

The mechanisms of effects concerning cholinergic-induced antinociception are not known.

The following evidence suggests as well as

refutes various possible explanations.·
First, the production of antinociception and elevation of ACh
levels may be correlated for some centrally acting cholinomimetics
such as oxotremorine (Harris et al., 1969).

Morphine which produces

a potent level of antinociception also increases brain ACh levels
(Hano et al., 1964).

However, various partial narcotic agonists and

antagonists such as nalorphine, naloxone, pentazocine, and cyclazocine
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(Howes et al., 1969) as well as several CNS depressants such as methylparafynol, hydroxydione, pentobarbital, and reserpine (Giarman and
Pepeu, 1962) do not produce antinociception but increase brain ACh
levels.

Therefore, no correlation exists between the ability of a

compound to produce antinociception and increase brain ACh levels.
Thus, cholinergic-induced antinociception needs not be directly attributable to enhancement of brain ACh levels.
Alternatively, oxotremorine and morphine decrease the turnover
rate of brain ACh (Norberg and Sundwall, 1977); this

action of mor-

phine appears to be due to its antirelease effect (Domino et al.,
1976).

However, pentobarbital also decreases brain ACh turnover

(Norberg and Sundwall, 1977).

Again, no correlation exists between

the ability of a compound to produce

antinoci~eption

and decrease ACh

turnover.

It should be pointed out that correlations between the antinociceptive state and whole brain or brain region neurochemistry may be
misleading.
ated

It may be that the pertinent neurochemical changes associ-

with antinociception are restricted to nondetectable brain sites.

Alternatively, the compounds which affect the cholinergic system may
interact with other neurotransmitter systems to produce antinociception.

Since the various agents which affect the central cholinergic

system influence the levels and turnover rates of other neurotransmitters in the CNS, nociception and pain are probably mediated by a
complex interplay of neurotransmitters (see section 1.2.2).

To
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identify the neurotransmitter or neurotransmitters involved, various
pharmacological manipulations were attempted as follows.
Pretreatment with reserpine which decreases brain DA, NE and
5-HT levels, antagonized the antinociceptive states produced by physostigmine (Pleuvry and Tobias, 1971) and tremorine (Sethy et al.,l971).
Since reserpine decreases both catecholamines and indoleamines (Shore
and Brodie, 1957), the following procedures were utilized to differentiate the involvement of the various neurotransmitters.
Concerning the involvement of DA and NE, diethyldithiocarbamate,
which reduces brain NE levels by inhibiting dopamine-beta-hydroxylase
(DBH), antagonized the antinociceptive state produced by tremorine
(Sethy et al., 1971), physostigmine and oxotremorine (Pleuvry and
Tobias, 1971), while alpha-methylparatyrosine (AMPT), a tyrosine hydroxylase inhibitor, 1-dopa, the metabolic precursor for DA and NE,
and pimozide, aDA receptor blocker, were ineffective (Paalzow and
Paalzow, 1975).

These data suggest that NE may play a role in cholin-

ergic-induced antinociception but that DA probably does not.
Various manipulations which affect the serotonergic system exert,
on the whole, inconsistent effects on cholinergic antinociception.
For instance, precursor loading with 5-HTP enhances physostigmineinduced antinociception in mice (Pleuvry and Tobias, 1971) but not in
rats (Paalzow and Paalzow, 1975).

Para-chlorophenylalanine (PCPA)

which decreases brain 5-HT levels by inhibiting tryptophan hydroxylation, antagonizes physostigmine-induced antinociception in mice
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(Pleuvry and Tobias, 1971) and rats (Bhattacharya and Nayak, 1978);
however, PCPA had no effect on oxotremorine (Pleuvry and Tobias, 1971;
Paalzow and Paalzow, 1975) or DFP-induced antinociception (Koehn and
Karczmar, 1978) in rats.

Overall, reports from various authors con-

cerning the involvement of the serotonergic system in cholinergicinduced antinociception are contradictory and inconclusive.

The in-

volvement of the serotonergic system in antinociception and analgesia
will be discussed in more detail in section 1.3.
Endogenous opicid system may constitute another system that could
be involved in cholinergic-induced antinociception (see also section
1.4).

Naloxone, a pure narcotic antagonist, antagonized the anti-

nociceptive state produced by physostigmine and oxotremorine (Harris
et al., 1969), ACh (Pedigo et al., 1975) and DFP (Koehn and Karczmar,
1978).

Furthermore, antagonism of DFP-induced antinociception by

stereoisomers of some narcotic antagonists was shown to be stereospecific (Koehn et al., 1979).

On the other hand, Pedigo et al.(l975)

demonstrated that inactive (+) isomers of partial narcotic agonists
antagonized ACh-induced antinociception; (-) active isomers were ineffective.
Since one of the major characteristics of morphine-induced antinociception is the tolerance which arises on chronic treatment, studies utilizing a cross tolerance design were performed to discern a

possible common mechanism of cholinergic- and morphine-induced
nociception.

a~ti

Invariably, cross tolerance did not develop between mor-
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phine-induced antinociception and antinociceptive state produced by
oxotremorine (Howes et al., 1969), physostigmine (Pleuvry and Tobias,
1971), scopolamine (Pert and Maxey, 1975), or DFP (Koehn et al.,l979).
The results do not nullify the idea that morphine and the various
compounds which affect the cholinergic system may be acting on opiate
sensitive systems to produce their antinociceptive states since tolerance may not develop at sites at which the cholinomimetics and anticholinesterases act to produce antinociception.

Overall, the data

suggest the possible involvement of an endogenous opioid system in
cholinergic-induced antinociception.

The involvement of the endoge-

nous opioid system in antinociception and analgesia will be discussed
in greater detail in section 1.4.
In summary, the exact neurochemical mechanisms involved in mediating or modifying cholinergic-induced antinociception remain only
poorly understood at this time.
1.2.4

Locomotion and Exploration

Cholinergic agonists and antagonists induce or affect a number
of animal locomotor and related overt behaviors including a state
referred to as "alert non-mobile behavior" (ANMB; Karczmar ,· 1977) .
Concerning the spontaneous locomotor activity in rats, ACh
(Herman et al., 1972), arecoline (Costall et al., 1972), and physostigmine (Adams, 1973) decrease spontaneous
this effect was reversed by atropine.

locomotor activity;

Alternatively, atropine sul-

fate and scopolamine increase spontaneous locomotion; the corre-
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spending quaternary compounds were ineffective(Adams, 1973).

Thus,

stimulation of central cholinergic muscarinic receptors attenuate
while blocking those receptors enhances locomotion.

· The locomotor depression produced by cholinomimetics and anticholinesterases appears to be primarily related to the relative activity

of the dopaminergic and cholinergic systems in the nigrostriatal

and extrapyramidal pathways; locomotion is mediated by cholinergic
projections to the striatum which are behaviorally inhibitory; this
system may be modulated via dopaminergic inhibition (Karczmar, 1977).
However, locomotion may also depend upon a cholinergic inhibitory
mechanism in the septa-hippocampal system. Atropine or scopolamine
applied to dorsal or ventral hippocampal sites increased locomotor
activity in the rat (Leaton and Rech, 1972) and mouse (Abeelen et al.,
1972).

ANMB combines with what appears to be mental alertness;

again,

hippocampus may be the site involved as ANMB correlates with theta
waves or hippocampal slow activity electroencephalographic (EEG) patterns(Karczmar, 1977).

However, hippocampal slow theta wave may not

be always concomitant with immobility or ANMB.

In rats, the presence

of hippocampal theta wave activity was correlated with attentional or
investigational responses occurring during exposure to a novel environment (exploratory activity; Komisaruk, 1970).

In addition, intra-

hippocampal administrations of m2thylscopolamine increased exploratory
activity, in two strains of mice; neostigmine was ineffective (Abeelen
et al., 1972).

Thus, exploration appears to be blocked by a cholin-
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ergic inhibitory mechanism residing probably in septal-hippocam?al
pathways.
1.2.5

Thermoregulation

Meyers (1974) described a scheme for the role of the cholinergic
system in thermoregulation of that cat and monkey.

According to this

scheme, the anterior hypothalamic preoptic area contains neurons which
are thermosensitive as well as a comparator mechanism which contrasts
the set point with local temperature; 5-HT and NE are released within
this area to activate and inhibit, respectively, a cholinergic heat
production system which then passes through the posterior hypothalamus.
The posterior hypothalamus contains a set point mechanism which de/++
.
.of.
pen d s upon t h e Na +Ca
rat1o,
an a b errat1on
wh1ch.
w1ll .
act1vate an
independent cholinergic heat dissipating system.
Evidence from pharmacological studies support this scheme.
First, intracerebral administrations of carbachol (Avery, 1970) or
ACh (Rudy and Wolf, 1972) into anterior hypothalamic sites produced
hyperthermia.

Alternatively, pilocarpine or ACh produced hypothermia

when administered into posterior hypothalamic sites; effects were reversed by atropine (Kirkpatrick and Lomax, 1970).
~,ticholinesterases

Cholinomimetics and

administered systemically produce hypothermia in

the rat (Lomax and Jenden, 1966; Kirkpatrick and Lomax, 1970; Meeter
and Wolthius, 1968); however, whether sites and/or mechanisms other
than the hypothalamic thermoregulatory center are involved is undetermined at this time.
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1.3

Serotonergic System in Antinociception and Analgesia
1.3.1

Central Serotonergic System

Just as the central actions of drugs which affect the cholinergic system must be considered in terms of the associated central
cholinergic structures, so too must drugs which affect the central
serotonergic system be viewed in terms of corresponding serotonin
(5-HT) receptors, synapses, and pathways.
Unlike the cholinergic cell bodies which exist in a very diffuse
pattern throughout the CNS, cell bodies of 5-HT neurons are mainly
localized in midline raphe nuclei of the lower brainstem.

Utilizing

fluorescent histochemical techniques, Dahlstrom and Euxe (1964)
identified nine distinct brainstem regions associated with 5-HT neurons; these regions were consecutively labelled Bl through B9 from
the caudal medulla to the rostral pons.
Bl, B2, and B3, namely raphe nuclei pallidus, obscurus, and
magnus (NRM), respectively, are located in the ventromedial medulla
and send axons down the spinal cord via anterior and lateral funiculi
to terminate with 5-HT containing terminals in the spinal dorsal,
ventral grey matter, and sympathetic chain (Dahlstrom and Fuxe, 1965;
Basbaum et al., 1978).

These nuclei and associated projection path-

ways constitute the descending 5-HT system.
5-HT neurons located in the central dorsomedial midbrain, namely
raphe nuclei dorsalis (B7) and medianus (B8) project to the telenceph-
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alan and diencephalon.

The greatest number of ascending 5-HT fibers

originate in the dorsal raphe (B7) ; striatal and hippocampal 5-HT
projections arise chiefly in the dorsal and median raphe nuclei,
respectively (Dahlstrom and Fuxe, 1964; Lorens and Guldberg, 1974).
5-HT cells in the region of the formatio reticularis (B9) located
just ventral to B7 and B8 in the midbrain also project rostrally to
the diencephalon (Dahlstrom and Fuxe, 1964).
Two groups of 5-HT cells are found in the pons; the raphe nucleus
po~tis

(BS) lies at the level of the nucleus motorius and the B6 cell

group is found on the midline just below the fourth ventricle; both
BS and B6 send fibers to the hypothalamus (Dahlstrom and Fuxe, 1964;
Fuxe and Jonsson, 1974).

The final group of 5-HT cells is located

in the vicinity of the area postrema in the medulla; projection sys'tems from this group remain to be identified (Dahlstrom and Fuxe,l964).
Altogether, the B4 through B9 cell groups and projection systems

com~

prise the ascending 5-HT system.
The metabolic pathways involved in the synthesis and catabolism
of brain 5-HT are outlined briefly as follows (Messing and Lytle,l977).
First, the amino acid, tryptophan, is taken up into the neuron and
5-hydroxylated by tryptophan hydroxylase (TH) to form the intermediate
metabolite, l-5-hydroxytr1ptophan (5-HTP); the intracerebral hydroxylation of tryptophan is the primary factor and rate limiting reaction
controlling cerebral 5-HT formation (Moir and Eccleston, 1968).

5-HTP

is then decarboxylated by the enzyme aromatic l-amina acid decarboxyl-
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ase to form 5-hydroxytryptamine (5-HT; serotonin).

Following release

from the neuron, 5-HT is actively taken up by presynaptic nerve terminals where it is deaminated and oxidized by the enzymes monoamine
oxidase and aldehyde dehydrogenase, respectively, to form the major
metabolite, 5-hydroxyindoleacetic acid (5-HIAA).

1.3.2

Role of 5-HT in Antinociception and Analgesia

Various experimental procedures have been utilized to investigate
a possible role of 5-HT in the production of antinociception and analgesia; included here are pharmacological studies, dietary manipulations,

and electrical lesions experiments; electrical stimulation

studies will be discussed in section 1.3.4.

Para-chlorophenylalanine (PCPA) decreases 5-HT and 5-HIAA levels
by inhibiting TH, the rate limiting enzyme in 5-HT synthesis (Koe and
Weissman, 1966).

PCPA decreased jump response thresholds to electric

shocks in rats; this effect was reversed by the administration of the
metabolic precursor, 5-HTP (Tenen, 1967).

5-HTP produced antinoci-

ception when administered by itself to rats (Contreras and Tamayo,
1967; Radouco-Thomas et al., 1967).

However, administration of 5-HTP

increases 5-HT formation within 5-HT neurons but also leads to the
formation of 5-HT within dopamine neurons (Fuxe et al., 1971).

In

contrast, 1-tryptophan administrations increase 5-HT formation only
in 5-HT neurons due to the relatively specific localization of the
enzyme tryptophan hydroxylase (Moir and Eccleston, 1968).

L-trypto-

phan administrations do not affect sensitivity to electric shocks in
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rats (Hole and Marsden, 1975).

Fluoxetine hydrochloride (Lilly

110140), a specific inhibitor of 5-HT uptake into synaptosome (Wong
et al., 1974), increased jump response thresholds in rats (Messing
et al., 1975).

Quipazine, which mimicks the effects of 5-HT on var-

ious smooth muscle preparations (Hong et al., 1969), also produced
antinociception when administered to rats; effects were antagonized
by methysergide (Samanin et al., 1976). The major factor which prevents researchers from determining whether 5-HT participates in antinociception and analgesia is the lack of a specific 5-HT receptor
blocker.

Five drugs (cinanserin, cyproheptadine, methysergide,

methergoline, and methiothepin) have been suggested to block 5-HT
receptors in the

b~ain

based on their ability to block the effects

of 5-HT on smooth muscle and invertebrate neurons; unfortunately,
their 5-HT antagonism is not entirely specific (Haigler and Aghajanian,
1977).

Rats fed a tryptophan deficient diet exhibited low tryptophan
and 5-HT levels and decreased flinch-jump thresholds; PCPA augmented
the hypernociceptive state; administrations of tryptophan or fluoxetine restored flinch-jump thresholds to control levels (Lytle et al.,
1975; Messing et al., 1976).
Electrolytic lesions in the median forebrain bundle,
ventrolateral tegmentum, and dorsomedial tegmentum

s~ptum,

dec~eased

telen-

cephalic 5-HT content and increased sensitivity to electric foot-shock
in rats (Lints and Harvey, 1969; Harvey and Lints, 1971); these two
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effects were reversed by the administration of 5-HTP; administrations
of 1-dopa were ineffective (Harvey et al., 1975).
While electrolytic lesions of specific CNS structures such as the
median forebrain bundle decrease brain 5-HT content and produce hypernociception, the electrolytic lesioning process itself probably destroys non-serotonergic neurons as well.

In addition, when 5-HT neu-

rons in the dorsal (B7) or median raphe (B8) are destroyed by electrolytic lesions no alteration in nociceptive responses in rats were
observed (Harvey et al., 1974; Lorens and Yunger, 1974).

In summary, while some evidence suggests that 5-HT participates
in antinociception and analgesia, no conclusive evidence for the relationship exists.
l. 3. 3

Serotonin (5-HT) and !-lorphine-Induced Antinociception

Many of the various pharmacological and physiological manipulations

which are known to affect the central serotonergic system and

the nociceptive state also affect morphine-induced antinociception.
Several compounds which affect the serotonergic system have been
shown by a variety of testing procedures to potentiate narcotic-induced antinociception; included here are 5-HTP (Contreras and Tamayo,
1967; Radouco-Thomas et al., 1967), fluoxetine (Messing et al., 1975),
as well as 5-HT itself administered intraventricularly (Ivt; Sewell
and Spencer, 1974).

Pretreatment with PCPA antagonized morphine-in-

duced antinociception; this effect was reversed by 5-HTP (Garlitz
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and Frey, 1972).

Methysergide, cinanserin, and cyproheptadine also

antagonized morphine-induced antinociception (Garlitz and Frey, 1972;
Yaksh et al., 1976a).
Electrolytic lesion studies have produced varying effects on
morphine-induced antinociception depending upon the lesion placement.
Lesions that destroy specific ascending serotonergic fiber systems,
as demonstrated by the resultant decrease in telencephalic 5-HT
content, fail to alter the antinociceptive action of morphine in the
rat: sites included here are (i) nucleus raphe medianus (B8; Lorens
and Yunger, 1974; Hole and Marsden, 1975), nucleus raphe dorsalis
(B7; Lorens and Yunger, 1974; Hole and Marsden, 1975), dorsal and ventral tegmental nuclei of Gudden (Lorens et al., 1975), and median forebrain bundle (Harvey et al., 1975).
On the other hand, electrolytic lesions of the nucleus raphe
magnus (B3) antagonized morphine-induced antinociception in the rat
(Proudfit and Anderson,l975).

Since the nucleus raphe magnus (B3) is

known to contain 5-HT neurons which descend to terminate on spinal
cord structures known to respond to noxious stimuli (Proudfit and
Anderson, 1975; Basbaum et al., 1978), the descending serotonergic system may participate in the expression of morphine-induced antinociception.
1.3.4

Serotonin(5-HT) and Stimulation Produced Analgesia (SPA)

Drugs which affect the serotonergic system have been shown to
alter stimulation produced analgesia (SPA) similarly to their effect
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on morphine-induced antinociception (see section 1.3.3).

Thus, PCPA

antagonized the antinocieptive state produced by morphine (Gorlitz
and Frey, 1972) as well as by electrical stimulation (SPA) of the
nucleus raphe dorsalis (B7) in the rat (Akil and Mayer, 1972).

Similarly, electrical stimulation of the nucleus raphe magnus
(B3) also produced antinociception in the rat (Proudfit and Anderson,
1975) .

Related studies have shown that selective lesions of the

spinal cord dorsolateral funiculus (DLF) prevents the antinociceptive
actions of SPA applied to periaqueductal grey
morphine (Basbaum et al., 1977).

~ites

(PAG) or of

Similarly, DLF lesions prevent the

inhibitory effect of nucleus raphe magnus (B3) on spinal cord neurons
in laminae I, II, and v which are considered to be involved in pain
modulation (Fields et al., 1976; see section 1.1.4.3).

Recently,

serotonin-containing fibers which descend from the nucleus raphe magnus (B3) and terminate in lamina I, II, IV, and v have been shown to
descend through the DLF (Basbaum et al., 1978).

These particular

studies along with those described in section 1.4.4 illustrate the
importance of the descending serotonergic system underlying the antinociceptive actions of SPA and morphine administrations.
While the serotonergic system appears to participate, at least
in part, in mediating SPA and morphine-induced antinociception, it
is also apparent that other neurotransmitter systems also mediate
these effects.

Pharmacological manipulations of catecholamine sys-

tems alter SPA; pimozide, a dopamine receptor blocker, decreased while
apomorphine, a dopamine receptor stimulator increased SPA; disulfiram,
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which depletes NE by inhibiting the enzyme dopamine-beta-hydroxylase
(DBH), increased SPA (Akil and Liebeskind, 1975).

NE specifically

reduced the firing rate of dorsal horn interneurons in response to
noxious stimuli but did not alter the firing rate in cells excited by
innocuous stimuli (Belcher et al., 1978).

Recently, Yaksh (1979)

reported that the antinociceptive action of morphine applied to PAG
sites could be antagonized only by the combined intrathecal administrations of phentolamine, a NE receptor blocker, and methysergide;
administrations of either antagonist alone significantly although
incompletely antagonized this morphine effect.

Clearly, non-seroton-

ergic systems exist which participate in the expression of SPA and
morphine-induced antinociception.
1.4

Endogenous Opioid System in Antinociception and Analgesia
1.4.1

Endogenous Opioid System

One of the more interesting findings in neuroscience research has
been the discovery of stereospecific opiate binding sites in the CNS
(Goldstein et al., 1971) and subsequent isolation and identification
of several endogenous opioid peptides (Hughes et al., 1975a; Guillemin
et al., 1976; Li and Chung,l976).

The endogenous opioid peptides sub-

sequently have demonstrated opiate-like activities, particularly the
ability to produce antinociception, when administered to laboratory
animals (see section 1.4.2).
The first endogenous opioids found in the brain and sequenced by
Hughes et al.

(1975a) were the pentapeptides, methionine- and leucine-
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enkephalin, which differed from each other only in the terminal amino
acid.

Subsequently, other larger peptides found in the brain and pi-

tuitary exhibited similar opiate action; included here are beta (B)endorphin (Li and Chung, 1976) and alpha (a)- and gamma (y}-endorphin
(Guillemin et al., 1976}.

The endorphins each share a common amino acid sequence with the
terminal residues of S-lipotropin

(LPH), a 91 amino acid pituitary

peptide discovered by Li et al. (1965}; residues 61 to 91, 61 to 76,
and 61 to 77 of S-LPH are identical with
respectively.

s-,

a-, andy-endorphin,

Finally, the structure of methionine-enkephalin occu-

pies position 61 to 65 of B-LPH.

Goldstein (1976) suggested that S-LPH might be enzymatically
cleaved in the pituitary to form a-,
methionine-enkephalin.

B-, andy-endorphin and, in turn,

However, it has recently been shown that

hypophysectomy failed to alter the quantity and distribution of the
endorphins (Cheung and Goldstein, 1976) or enkephalins (Kobayashi et
al., 1978b) in the brain suggesting that the pituitary and brain
constitute separate compartments with respect to these peptides.
Presently, research aimed at identifying possible prohormones and/or
precursors for the various opioid peptides is being conducted (Yang
et al., 1979).
The enkephalin content of various CNS structures has been shown
to be unevenly distributed by a variety of assay procedures including
bioassay (Hughes et al., 1977), radioimmunoassay (Yang et al., 1977;
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Kobayashi et al., 1978b), and receptor binding studies (Simantov et
al., 1976a).

In general, the striatum, central grey region, nucleus

accumbens, and hypothalamus contained the highest content of methionine-

and leucine-enkephalin; the thalamus, amygdala, pons, medulla,

and caudate-putamen contained lesser amounts of the enkephalins; the
midbrain, hippocampus, cerebellum, and cortex exhibited the lowest
enkephalin content (Hughes et al., 1977; Yang et al., 1977; Kobayashi
et al., 1978b; Simantov et al., 1976a).

In every brain region stud-

ied, the methionine-enkephalin content was found to be 2 to 7 times
greater than the corresponding leucine-enkephalin content (Kobayashi
et al., 1978h).

In addition, immunohistochemical studies have also

demonstrated the presence of methionine- and leucine-enkephalin positive fibers in laminae I, II, III, V, and VII of the spinal cord
(Watson et al., 1977; Simantov et al., 1977).
On the other hand, S-endorphin-like immunoreactivity is seen
predominantly in the h7pothalamus, septum, midbrain, and pons-medulla
while no material attributable to B-endorphin could be found in the
striatum, hippocampus, cortex, or cerebellum (Rossier et al., 1977b;
Watson et al., 1978).

Overall, the distribution of a B-endorphin

reactive system and a methionine-enkephalin reactive system in the
CNS appear to be quite different suggesting the existence of two
separate opioid peptide systems.
Opiate binding_sites and opioid peptide containing cell bodies
and/or terminals have been found for the most part to be distributed
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in close proximity to each other.

For example, in accordance with the

relative distributions of opioid peptides, the periaqueductal grey
region, several hypothalamic nuclei, and spinal cord laminae I, II,
and III exhibited high density of opiate binding sites; the cortex and
cerebellum contained the least dense opiate binding sites (Kuhar et
al., 1973b; Atweh and Kuhar, 1977a, b).

On the other hand, the nu-

cleus raphe magnus (NRM) contains a high level of methionine-enkephalin positive cells (Hokfelt et al., 1977) but exhibits a low level
of opiate binding sites (Atweh and Kuhar, 1977a).

Subcellular fractionation experiments demonstrated that enkephalin-like-activity was predominantly localized to the synaptosomal
fraction, the region known to contain several neurotransmitters
(Simantov et al., 1976b).

Finally, methionine- and leucine-enkephalin are released from
synaptosomes and isolated striatal slices by potassium-induced neuron
depolarization or veratridine (Henderson et al., 1978); 8-endorphin
is released from pituitary as well as hypothalamic sites by potassiumevoked cellular depolarization (Przewlocki et al., 1978; Osborne et
al., 1979).
Overall, the enkephalins and endorphins fulfill two criteria
required for identity as a neurotransmitter substance.

First, these

peptides exhibit the differential distribution expected of a neuronal
system in the CNS.

Second, pharmacological antagonism establishes

whether the neurotransmitter is released and characterizes the
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receptor mediating the various responses (see sections 1.4.2 and 1.4.3),
However, several other criteria such as physiologically-induced release, vesicular location, transmitter synthesizing system, and identity of action must be met before their role as neurotransmitter substances is established.
1.4.2

Antinociception, Analgesia, Enkephalins, and Endorphins

The enkephalins and 6-endorphin have been shown to produce a dose
dependent, naloxone reversible, antinociceptive state following intracerebroventricular (Icvt) administrations in the rat (Belluzzi et al.,
1976; Bloom et al., 1976), mouse (Buscher et al., 1976; Loh et al.,
1976), and cat (Meglio et al., 1977).

Enkephalin-induced antinociception develops after a 2 to 3
minute latency and lasts for 5 to 10 minutes (Buscher et al., 1976);
antinociception produced by 6-endorphin lasts up to 90 minutes after
administration (Loh et al., 1976).

It appears that the short duration

of enkephalin-induced antinociception and, in fact, the failure of
some investigators to demonstrate any antinociceptive action (Bloom
et al., 1976) is attributable to the fact that the enkephalins, unlike
$-endorphin, are rapidly destroyed enzymatically in the brain (Dupont
et al., 1977) .

Structurally

methionine-enkephalin, which are resistant to enzymatic degradation
are active antinoci.:::eptive agents when administered systemically or
orally (Roemer et al., 1977).

2

altered enkephalins, most notably D-ala -
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The enkephalins and S-endorphin also produce antinociception in
the rat when administered directly into the midbrain periaqueductal
grey region (Chang and Fang, 1976; Malick and Goldstein, 1977) or
intrathecally (Yaksh and Henry, 1978; Yaksh et al., 1978).
Finally, methionine-enkephalin reduced the firing rate of dorsal
horn neurons activated by noxious stimuli but did not affect the firing rate of neurons activated by innocuous stimuli; inhibitory effects
were

reve~sed

by naloxone (Randic and Miletic, 1978).

1.4.3

Antinociception, Analgesia,

Jacob et al.

~,d

Naloxone

(1974) first demonstrated that naloxone administered

by itself produced hypernociceptive responses in rats; subsequently,
some laboratories have confirmed this hypernociceptive action of naloxone in rodents (Grevert and Goldstein, 1977; Carmody et al., 1979).
Goldstein et al. (1976) failed to observe the hypernociceptive
naloxone effect.

Frederickson

et. al.

(1977)

later reported

that the hypernociceptive response produced by naloxone followed a
diurnal rhythm.
In humans, Grevert and Goldstein (1978) showed that naloxone
failed to alter responses in experimentally-induced pain situations
namely cold water imMersion and ischemia. Alternatively, Buschbaum
et al., (1977) reported that naloxone produced hypoalgesia and hyperalgesia in individuals determined to be pain sensitive and pain insensitive, respectively.

The diurnal variation in nociceptive respon-
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siveness produced by naloxone in laboratory animals has also been
demonstrated in humans (Davis et al., 1978).

Finally, naloxone en-

hanced the post-operative pain arising from the removal of impacted
molars (Levine et al., 1978).

Naloxone also restored pain sensi-

tivity, measured as an increase in flexor reflex, in an individual
who was congenitally insensitive to pain (Dehen et al., 1978).
Overall, it appears that naloxone produces hypernociception
and hyperalgesia only in special cases which may be associated with
increased activity in the endogenous opioid system such as stress
(Madden et al., 1977; Rossier et al., 1977a).

Several other pharmacologically- and physiologically-induced
antinociceptive states can be antagonized by naloxone: included here
are acupuncture (Mayer et al., 1976); transcutaneous electrical stimulation (Chapman and Benedetti, 1977); stimulation produced analgesia
(SPA; Akil et al., 1976; see section 1.4.4 for further discussion);
stress induced by cold water (Bodnar et al., 1977), footshock(Chesher
and Chan, 1977), and immobilization (Amir and Amit, 1978); phenoxybenzamine (Elliot et al., 1976); nitrous oxide (Berkowitz et al.,
1977); physostigmine and oxotremorine (Harris et al., 1969); acetylcholine (Pedigo et al., 1975); and diisopropyl phosphofluoridate
(DFP; Koehn and Karczmar, 1978).

It must be pointed out that naloxone

antagonism of antinociception and analgesia is necessary but not sufficient evidence to conclude the involvement of the endogenous opioid
system as mediating these effects.

Since non-specific actions of
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naloxone could contribute to its antagonism of antinociception and
analgesia it is necessary to determine whether this antagonism is
stereospecific.
1.4.4

Stimulation Produced Analgesia (SPA)

Reynolds (1969) first demonstrated that focal electrical stimulation applied to the midbrain periaqueductal gray matter (PAG) rendered rats sufficiently antinociceptive to permit abdominal surgery.
Since then, numerous studies have demonstrated that focal electrical
stimulation of discrete brain regions produced a profound, long lasting level of antinociception (SPA) in laboratory animals as well as
in humans (see section 1.1.8.3).
The most significant factor, however, concerning SPA is the fact
that SPA and opioid-peptide-induced antinociception appear to share
both common sites and mechanisms of action.

A number of studies have

mapped the b'rain for effective antinociceptive sites with SPA and
opioid microinjections.
Electrical stimulation of the mesencephalic gray matter and periaqueductal grey matter produced antinociception as measured by a va=ietv of noxious stimuli in the rat (Mayer and Liebeskind, 1974); loci
in the central gray surrounding the aqueduct and caudal portions of
the third ventricle were particularly effective (Rhodes and Liebeskind,
1978).
tion

Similarly, the most sensitive sites to intracerebral applicaof morphine in the rat lie in the ventrolateral sections of the
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caudal PAG region (Yaksh et al., l976b).
Electrical stimulation of other brain areas such as the septum,
medial thalamus, ventral tegmentum, and pretectal area produced test

specific antinocicpetive states; ventrobasal thalamic and lateral
hypothalamic sites were ineffective (Mayer and Liebeskind, 1974;
Rhodes and Liebeskind, 1978).

On the other hand, morphine injected

into the posterior, anterior, and ventromedial hypothalamus, medial
thalamus, and caudate increased flinch-jump thresholds in rats (Jacquet
and Lajtha, 1973).

Inejcted into the septum, morphine was ineffective

(Jacquet and Lajtha, 1973) .
The nucleus raphe magnus (NRM) of the medulla yields a

profo~md

level of antinociception following electrical stimulation in the rat
and cat (Proudfit and Anderson, 1975; Oliveras et al., 1978; see section 1.3.4).

Alternatively, the nucleus reticularis gigantocellularis

of the medulla is extremely sensitive to local injections of morphine;
applications into other medullary nuclei including NRM were ineffective (Takagi et al., 1977).
In summary, the degree of overlap for common effective brain
sites of SPA and morphine, while not perfect, is impressive as it
concerns the medial portions of the brain stem extending from the rostral medulla to the diencephalon.

In fact, concurrent mapping studies

performed in the same animal demonstrate that PAG sites are particularly sensitive to both procedures (Yeung et al., 1977).
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The tail flick response in rats is considered to be a spinal
reflex since both spinally intact animals as well as animals with
spinal transections (T4-T5) respond to noxious heat stimulus applied
to the rat's tail (Irwin et al., 1951).

Since both morphine and SPA

have been reported to block the tail flick response in rats (Mayer
et al., 1975), the spinal cord appears to participate, at least in
part, in mediating antinociception produced by these two methods.
In addition, recent electrophysiological investigations demonstrate that morphine injections as well as electrical stimulation of
PAG sites specifically inhibited the responses of spinal cord wide
dynamic range interneurons to noxious heat but not to innocuous mechanical stimuli.

Neither the narcotics nor electrical stimulation

affected neurons which responded exclusively to innocuous stimuli;
thus, both procedures appear to specifically inhibit input at the
spinal cord level (Bennett and Mayer, 1979).

Cross tolerance studies were performed to identify common neural
substrates activated by SPA and morphine.

Tolerance to SPA develops

upon repeated stimulation in both the rat (Mayer and Hayes, 1975) and
human (Hosobuchi et al., 1977); this tolerance exhibits cross tolerance to the antinociceptive and analgesic actions of morphine; tolerance to morphine reduced the effectiveness of SPA in the rat (Mayer,
and Hayes, 1975) whereas tolerance to SPA increased the dose of morphine required to produce analgesia in humans (Hosobuchi et al.,
1977) .

Tolerance to SPA and cross tolerance with morphine decreased

after periods of nonstimulation in both species (Mayer and Hayes,
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1975; Hosobuchi et al., 1977).
As stated earlier (see section 1.4.3), Akil et al. (1976)
demonstrated that the narcotic antagonist, naloxone, reduced by
approximately 30% the antinociceptive state produced by SPA applied
to the PAG region in the rat brain.

Other investigators demonstrated

only a minor antagonistic effect of naloxone 3 to 5 minutes post
stimulation (Pert and Walter, 1976) while still others report no
effect of naloxone at all (Yaksh et al., 1976b).

On the other hand,

naloxone completely reversed the analgesia produced by PAG stimulation in 6 out of 7 patients studied (Adams, 1976; Hosobuchi et al.,
1977).

Finally, analgesia arising from electrical stimulation of the
PAG region was associated with increased amounts of enkephalin-likematerial (Akil et al., 1978) and immunoreactive-S-endorphin (Hosobuchi et al., 1979) in the ventricular cerebrospinal fluid (CSF);
leucine-enkephalin levels were not altered (Hosobuchi et al., 1979).

Patients diagnosed as having organic pain exhibited significantly
lower levels of methionine-enkephalin-like-material when compared with
normal non painful volunteers or patients diagnosed as having psychogenic pain (Almay et al., 1978).

In addition, patients with high

levels (>0.9 pmol/ml) of methionine-enkephalin-like-material exhibit
higher pain thresholds and pain tolerance levelz than did patients
with low levels (<0.9 pmol/ml) of methionine-enkephalin-like-material
(Von Knorring et al., 1978) .
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In summary, although the exact role of the endogenous opioid
system in antinociception and analgesia remains to be established,
the combined data reported above suggest that these naturally
occurring peptides may be involved in the control of pain.

2.

RESEARCH OBJECTIVES

All the known potent naturally occurring and various synthetic
narcotic analgesics produce tolerance and physical dependence (Isbell,
1977) .

In spite of the fact that no nonaddicting potent analgesic

exists, the research devoted to this particular problem has led to
the development of other useful drugs such as methadone which is used
for withdrawal procedures and to maintain persons addicted to the
opioids (Isbell, 1977).

Another benefit has been the stimulation of

the basic sciences to pursue research programs directly and indirectly
related to the management of the chronic pain state.

These research

efforts have led to a more complete understanding of the anatomical,
neurochemical, neurophysiological, and psychological mechanisms involved in the perception of pain.
Compounds which produce antinociception when administered to
laboratory animals do not necessarily produce analgesia when administered to humans; however, a correlation between the antinociceptive
and analgesic properties of a drug does exist for many narcotics
(Isbell, 1977), certain compounds which affect the cholinergic system
(Herz, 1961; Harris et al., 1968; Sitaram et al., 1977; Sitaram, 1979,
personal communication),

~d

various derivatives of delta-9-tetra-

hydrocannabinol (Bhargava, 1978a; Jochimsen et al., 1978).

Thus,

investigating drug-induced antinociception as an index of effectiveness of that drug to produce analgesia, while not applicable for all
69
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drugs which produce antinociception is a valid procedure for specific
drugs and/or classes of drugs.
Previous studies indicate that ACh (Pedigo et al., 1975),
various cholinomimetics (Chen, 1958; Herz, 1961; Harris et al., 1967,
1968), and/or

~~ticholinesterases

(Harris et al., 1968; Bhargava and

Way, 1972; Koehn and Karczmar, 1978) produce antinociception as well
as potentiate narcotic-induced antinociception when administered to
rodents.

In addition, anticholinesterases, long known to potentiate

narcotic-induced analgesia in humans (Floodmark and Wrammer, 1945)
have recently been shown to produce analgesia when employed alone
(Sitaram et al., 1977).

Thus, present evidence suggests that com-

pounds which affect the cholinergic system may be useful agents to
investigate concerning the management of pain.

The purpose of this

dissertation research is to examine the antinociceptive property of the
anticholinesterase agent, diisopropyl phosphofluoridate, DFP, and
its various aspects.
The first objective of this research is to determine

whether

similarly to other anticholinesterases DFP will produce antinociception when administered to rats.
Anticholinesterase agents produce a state of immobilization
(Adams, 1973) and hypothermia (Meeter and Wolthius, 1968) when administered to rats.

Since the methods employed to assess antinoci-

ception, the hot plate and tail flick tests, involve motor and temp-
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erature dependent behavioral responses it will be important to
separate the antinociceptive effects from the attenuated mobility
and hypothermia produced by DFP; exploratory and motor activity
levels and rectal temperatures will be measured for this purpose.
The second objective of this research is to determine whether
the antinociceptive action of DFP in the rat is related to the involvement of· either the serotonergic or endogenous opioid systems
in the CNS.

Since increased activity of 5-HT neurons in the CNS

is associated with the production of antinociception (see section
1.3) and DFP markedly increases 5-HT levels and turnover rates
(Barnes et al., 1975, 1978), it may be speculated that DFP-induced
antinociception results from actions involving the serotonergic
system (see section 1.2.2).
On the other hand, an endogenous opioid system may mediate DFPinduced antinociception (see section 1.4).

Several endogenous opioid

peptides such as leucine- and methionine-enkephalin (Blasig and Herz,
1976) and 8-endorphin (Szekely et al., 1977) produce antinociception
when administered exogenously.

Since antinociception produced by

stress (Chesher and Chan, 1977 ; Bodnar et al., 1978), brain stimulation

(Ad~ms,

1976), acupuncture (Mayer et al., 1976), as well as a

number of drugs (Elliot et al., 1976; Stewart et al., 1976; Harris
et al., 1976; Berkowitz et al., 1977) is antagonized by naloxone, a
narcotic antagonist, these various procedures may release endogenous
opioids which then serve as endogenous antinociceptive agents.

Nal-

72

axone also antagonizes the antinociceptive state produced by physostigmine and oxotremorine (Harris, 1970) and ACh (Pedigo et al.,
1975).

Thus, if the enkephalins or endorphins indeed function as

endogenous antinociceptive agents, then the antinociceptive state
produced by DFP may result from DFP-induced release of the endogenous
opioids.
It is hoped that the study of the mechanisms involved in OFFinduced antinociception may provide an explanation for certain conflicting findings and may also shed some light upon the mechanisms of
antinociception in general.

Finally, this investigation may, pos-

sibly, contribute to the management of pain by providing the rationale
for implementing novel forms of drug therapy.

3•

MATERIALS AND METHODS

3.1

Animals

Male Sprague-Dawley rats, 160-350 gm obtained from LockeErickson and King Animal Distributors were used for behavioral
studies as well as for brain serotonin (5-HT) and enkephalin level
determinations.

Male CFl mice, 25-40 gm obtained from Charles River

Animal Distributors were used for vasa deferentia bioassay preparations.

Animals were housed in a temperature-controlled (22 ± 2°C)

room with lights on and off at 0700 and 1900 hours daily.

In all

cases, food and water were provided ad libitum.
3.2

Drugs and Chemicals
3.2.1

Source

Diisopropyl phosphofluoridate (DFP) obtained from K & K Laboratories, Plainview, New York in propylene glycol vehicle was diluted
as appropriate in peanut oil (Mallinckrodt Chemical Company) .
Morphine sulfate (Merck Chemical Division); atropine sulfate
(City Chemical Company); atropine methyl nitrate, para-chlorophenylalanine methyl ester (PCPA) and pilocarpine HCl (Sigma Chemical
Company); naloxone HCl (Endo Laboratories) ; MR 2266 and MR 2267
(- and+ stereoisomers of 5,9 a-diethyl-2-(furylmethyl)-2'-hdyroxy73
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6,7-benzomorphan, Boehringer Ingelheim); GPA 1843 and GPA 1847
(- and+ stereoisomers of 2-allyl-2'-hydroxy-9 B-methyl-5-phenyl6,7 benzomorphan, CIBA-Geigy Corporation); and d- and 1-cyclazocine
(Sterling-Winthrop Research Institute) were dissolved in normal
saline.
Serotonin creatinine sulfate complex (Sigma Chemical Company)
was dissolved in 0.1 N HCl (stock solution) and redissolved freshly
each day in 0.1 N HCl for use in the fluorometric assay.

Leucine-

and methionine-enkephalin (Beckman Biochemicals) were dissolved in
distilled water (stock solution) and redissolved in Krebs solution
for use in the bioassay.
Distilled water, taken from the central storage tap, was deionized (Barnstead Ultrapure Mixed Bead) and redistilled (Corning
Water Distillation Apparatus) for use thro?ghout these experiments.

3.2.2

Dosage and Schedules

DFP (1.5, 1.0, 0.5, and 0.1 mg/kg) and morphine (3.0 mg/kg)
were administered subcutaneously (s.c.) one hour prior to initiation
of experiments.

Atropine sulfate (4.0 mg/kg), atropine methyl

nitrate (4.0 mg/kg), naloxone (5.0, 0.5 and 0.05 mg/kg) MR 2266
and MR 2267 (1.0 rng/kg) ,GPA 1843 and GPA 1847 (5.0 rng/kg), and dand 1-cyclazocine (0.64 rng/kg) were administered intraperitoneally
(i.p.) 30 minutes prior to experimentation.

Pilocarpine (2.5 rng/kg)

was administered subcutaneously 30 minutes prior to experimentation.
PCPA was administered in doses of 100 (PCPA 1 ) or 300 (PCPA 2 )
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mg/kg i.p. on each of the two days preceeding testing; a third dose
of 100 mg/kg i.p. was given two hours before the initiation of experiments.
In all cases, control animals were administered the drug vehicle,
peanut oil or saline, in an identical manner.

3.2.3

Development of Tolerance

For the production of tolerance, animals were injected with morphine 3 times per day (at 0800, 1600, and 2400 hours) at a total daily
dose as follows: 30, 60, 90, 120, 150, 180, 300, 450, and 600 mg/kg
i.p. on days 1 through 9, respectively.
istered the vehicle.

Control animals were admin-

Hot plate responses (see section 3.3.2) were

measured on day 6 (Tolerance level A) and on day 9 (Tolerance level
B) •

3.3

3.3.1

Behavioral Studies

Pretest Care of Animals

Rats.were housed 3 or 4 per cage.

Since handling produces stress

in rats (Ader, 1968) and the handling involved in testing may affect
the performance of rats not previously handled (Joffe and Levine,
1973) , rats were handled for at least 5 minutes on each of the three
days preceeding any testing situation to minimize stress effects.
Preinjection (baseline) measurements of all responses except
exploratory and motor activity level determinations (see sections
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4.2.1, 4.2.2, 4.6.1, 4.6.2, 4.7.2, and 4.7.3) were obtained at least
one hour prior to the administration of any compound.
Mice were housed 10 per cage until their use for bioassay preparations.
3.3.2

Hot Plate Test

3.3.2.1

Apparatus

The following two apparatuses were utilized for hot plate studies.
First, inverted blocks of a Tecam Driblock DB-3 Test Tube Heater
served as the hot plate source.

The heat blocks were surrounded by

a wire cage (23 em long x 9.5 em wide x 9.5 em high) which restricted
the animals' movement to the heat block surface.

The

temperature

was maintained at 55 ± 0.5°C by a variable heat control.

Rats weigh-

ing 160-220 gm were employed in experiments concerning (a) effect
of atropine sulfate and atropine methyl nitrate on DFP-induced antinociception (see section 4.1.3), (b) effect of PCPA on DFP-induced
antinociception (see section 4.5.1), and (c) pharmacological comparison of DFP- and morphine-induced antinociceptive states (see section
4. 7 .1).

Second, a standard hot plate (32 em square surface, property of
the University of Iowa) was utilized.
eter

A plastic cylinder

(22 em diam-

x 30 em high) restricted the animals' movements to the hot plate

surface.

The temperature was monitored and maintained at 55 ± 0.5°C

by a series of built-in thermistors which provided the entire hot
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plate surface with a constant temperature.

Rats weighing 200-350 gm

were employed in experiments concerning: (a) DFP- and pilocarpineinduced antinociception (see section 4.1.1), (b) Effect of naloxone
on DFP-induced antinociception (see section 4.8.1), (c) Effect of
stereoisomers of narcotic antagonists on DFP-induced antinociception
(see section 4.9), and (d) Effect of tolerance to morphine on DFPand pilocarpine-induced antinociception (see section 4.10).
·3.3.2.2

Testing Procedure

The hot plate test was carried out as follows.

The rats were

placed on the hot plate surface; the latency of onset of the following
responses were recorded: ·(a) licking of the front paws, (b) licking
or lifting/spinning movement of the hind paw, and (c) jumping off of
the hot plate surface.

All response times reported represent the

latency of onset of the first response observed.

A 30 second time

limit was set to be the maximum nociceptive response time in all tests
except those involving (a) DFP- and pilocarpine-induced antinociception (see section 4.1.1) and (b) Effect of naloxone on DFP-induced
antinociception (see section 4.8.1) where a EO second time limit was
used.
3.3.3

Tail Flick Test

In the tail flick test, animals were placed in a plastic restraining cage which allowed the tail to extend outwards and to relax for
3 minutes.

The tail was then placed in a grooved slot of an asbestos
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board; the beam of the light source, Blue M Infra Oven (375 watts),
was focused one inch from the tip of the rats' tail.

A 60 second time

limit was set and the characteristic flicking movement of the tail was
used as the endpoint.
3.3.4

Activity Level Determinations
3.3.4.1

Apparatus

Exploratory and motor activity levels were assessed in a covered
circular activity cage (Lehigh Valley Instruments Corporation) with a
46 em high cylindrical wall.

Six photoelectric cells, with opposing

lights, were placed every 8.7 em along the cylindrical wall 2.5 em
above the floor.

Two counters, each responsive to 3 photoelectric

cells, recorded the number of times each beam of light was broken.
3.3.4.2

Exploratory and Motor Activity

The number of photoelectric interruptions were recorded 15 and
75 minutes after placing the rats individually in the activity cages.
Activity levels reported represent the average of the two counters.
Activity levels measured during the first 15 minutes and subsequent
60 minutes of "the test are commonly referred to as the exploratory
and motor activity periods, respectively

(Karczmar and Scudder,

1967) .
Exploratory activity levels were also measured by placing the
animals individually in the activity cages for 10 minute periods at
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at various times post drug administrations.

Counters recorded the

number of photoelectric interruptions during each 10 minute test
session.
3.4

Rectal Temperature

Rectal temperatures in rats were measured by means of a thermister
probe (Yellow Springs Instrument Company) inserted into the rectum
to a depth of 50 mm and retained in situ until a constant temperature
reading was obtained (usually 30 seconds) .
3.5

Brain Serotonin (5-HT) Assay

Brain (5-HT) levels were determined according to modifications of
methods originally described by Atack and Magnusson (1970) and Atack
(1973) .

This experimental procedure utilizes the processes of cation-

exchange chromatography to separate and spectrophotofluorometry to
quantify 5-HT; it was employed with respect to 3 different brain regions, and can be outlined as follows:
3.5.1

Tissue Samples

(a) Rats were sacrificed by decapitation (1000 to 1200 hours);
brains were quickly removed from the cranial vault.
(b) Meninges and cerebellum were discarded.
(c) Brains were rapidly divided into three regions:
(1)

Medullary (medulla)

(2)

Meso-diencephalon (thalamus, hypothalamus, pons, and
midbrain)
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(3)

Telencephalon (cortex and caudate)

(d) Brain regions

~ere

frozen in liquid nitrogen and stored at

-2ooc until analyzed.
3. 5. 2

Reagents

(a) Water (see section 3.2.1)
(b) 2N NaOH + l% EDTA (Dissolve 40 gm NaOH and 5 gm EDTA in
500 ml water)
(c) lON, 2N, and lN HCl (Made appropriately from concentrated
12 N HCl)
(d) ETOH/HCl (Combine equivalent volumes of redistilled 95%
ETOH and 2N HCl)
(e) O.lN Sodium Phosphate Buffer (Dissolve 8.83 gm

NaH Po ,
2 4

12.88 gm Na HP0 '12H o, and 1 gm EDTA in 1,000 ml water)
2
2
4
(f) Homogenizing Solution (Dissolve 0.125 gm Na
EDTA in water.

Add 8.55 ml 70% HCl0

4

s o and 0.5 gm
2 2 5

and bring to a final volume of

250 ml with water)
(g) 5N K co (Dissolve 69.0 gm K co in 200 ml water)
2 3
2 3
(h) BromPhenol Blue Solution (B.P.B.; dissolve 1-6 -mg 3'3"5'5"tetrabromophenolsulphonephthalein Na in 100 ml of redistilled 95%
ETOH)
(i) Ortho-phthaldehyde (OPT, stock solution; dissolve 29.65 mg
of OPT in 50 ml of lON HCl)
OPT (experimental solution; take 8.72 ml of OPT stock sol uti on up to 100 ml final volume with lON HCl) .
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(j) Serotonin (5-HT, stock solution; dissolve 42.95 mg of
serotonin creatinine sulfate complex in 250 ml of O.lN HCl)
5-HT (Experimental solution; take 1.0 ml of 5-HT stock
solution up to 50 ml final volume with O.lN HCl)
3.5.3

3.5.3.1

Column Preparation

Cycling and Regeneration of Resin

Ion-exchange chromatography resin should be given at least one
complete change of form to remove other ions and impurities (Mikes,
1970).

Utilizing a magnetic stirring apparatus, 250 gm of DOWEX AG

SOW X4 200-400 mesh H+ from ion-echange resin was cycled and regenerated ten times with the following solutions:
(a) 300 ml 2N NaOH + l% EDTA
(b) 300 ml ETOH/HCl
(c) 300 ml 2N HCl
(d) 300 ml water
The regenerated resin was stored in water at S°C.
3.5.3.2

Packing of Columns

The columns to be packed with ion-exchange resin have been
adapted from 1.0 ml disposable syringes (4.2 mm internal diameter x
7.0 em high; Fig. 1).

A piece of tygon tubing, which serves to attach

the column assembly to the glass syringe apparatus was affixed to the
upper end of the syringe barrel (Fig. 1).
the uniform packing of

t~e

Since air bubbles disrupt

resin, the actual packing was performed
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FIGURE 1
Diagram of column assembly and glass syringe apparatus

83
Fig. l

'

'
'
'

: ''
:'

---------------------- Wooden Board

---------------------------- Reservoir

- - - - - - - - - - - - 3-way Stopcocks

Tyqon Tube
----------------- Glass Wool

----------------- Resin Bed
----------------- Glass Wool

Column
Assembly

84

with the columns submerged in water.

First, a small piece of glass

wool which serves to trap the resin in the column, was inserted into
the column and forced to the tip with a stirring rod (Fig. 1).

A 2 ml

pipet filled with resin was inserted into the top of the column and
the resin was allowed to flow into the column.

When the resin bed

had reached a height of 50 mm, another piece of glass wool was inserted

into the top of the column, thus trapping the resin between the

two pieces of glass wool (Fig. 1).

The freshly packed column was

mounted onto one of the glass syringes in the glass syringe apparatus
(Fig. 1).

The glass syringe apparatus consisted of the following.

Two 20 ml glass syringe barrels were connected to each other through
a series of three-way stopcocks (Fig. 1).

One syringe barrel served

as a reservoir through which the extract and other reagents could be
added to the column (Fig. 1).

The other glass syringe barrel served

as the site of attachment for the column (Fig. 1).

The glass syringe

apparatus was suspended vertically through holes in a wooden board
(Fig. 1).
3.5.3.3

Preparing Columns for Samples

It is oftennecessary to ion exchange resin for elution ionexchange chromatography to adjust the pH to optimal for separation
(Mikes, 1970). Here, the resin was prepared for the addition of tissue
extracts by cycling the resin into the form of the buffer cation (Na+)
and then washing with buffer (Atack, 1973).

This was accomplished by

passing the following solutions through the column:
NaOH + 1% EDTA,

(a) 20 ml 2N

(b) 50 ml water, (c) 20 ml 2N HCl, (d) 50 ml water,
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(e)

20 ml O.lN sodium phosphate buffer (pH=6.5), and (f) 5 ml

water.

The pH of the effluent is taken as a control measurement to

check that the inflowing solution and effluent have the same composition;

thus, a pH of 6.5 indicated that the column was ready for

the addition of the tissue extracts.
3.5.4

Extraction Process

(a) Weighed brain regions were chilled and homogenized in 8.0 ml
of homogenizing solution (see section 3.5.2).
(b) Homogenate was centrifuged at 4000 RPM for 15 minutes.
(c) Supernatant was poured into 15 ml graduated tubes.
(d) Pellet was reextracted with 3.0 ml of homogenizing solution;
centrifuged at 4500 RPM for 10 minutes; supernatants were combined.
(e) pH was adjusted to 6.5 with 5N K co (using 2 drops of B.P.B.
2 3
as pH indicator) .
(f) Supernatant was set for 10 minutes on ice.
(g) Centrifuged at 5000 RPM for 15 minutes.
(h) Tissue extracts filtered (Watman No.1) onto ion-exchange
column; passed through column (flow rate <0.5 ml/min) mol.
(i) Columns rinsed by passing the following solutions:
(1) 15 ml water
(2) 15 ml O.lN sodium phosphate buffer
(3) 15 ml water
(j) 5-HT was eluted with the following sulutions:

(1) 10.5 ml lN HCl (discard)
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(2) 4.7 ml ETOH/HCl (discard)
(3) 6.0 ml ETOH/HCl (collect

=

5-HT fraction)

Internal standards were prepared by substituting 1400, 700, and
350 ng of 5-HT as well as 0.5 ml of ETOH and H o in place of a brain
2
sample.

Per cent recovery of 5-HT and column reagent blanks fluores-

cent values were determined from these five internal standards.
3.5.5

Conversion of Serotonin (5-HT) to Fluorophore

Serotonin (5-HT) content in biological tissues can be determined
by fluorescent methods directly (Maicker and Miller, 1966).

However,

reacting 5-HT with o-phthaldehyde (OPT) yields a substituted indole
compound which is 20 times more fluorescent than 5-HT itself (sensitive to 1.0 ng 5-HT; Maicker and Miller, 1966).

Therefore, 5-HT was

reacted with OPT according to the methods described by Maicker and
Miller (1966).

The process is outlined as follows:

(a) Add 2 drops

of OPT and 0.5 ml of sample eluate to 1.0 ml lON HCl (b) Boil for
15 minutes (c) Allow to cool to room temperature.
External standards and reagent blanks were prepared as follows.
To 1.0 ml of lON HCl the following amounts of standard 5-HT and reagents were added:
(a) 700 ng 5-HT [0.500 ml 5-HT (Experimental solution) + 0.000 ml
O.lN HCl]
(b) 350 ng 5-HT [0.250 ml 5-HT (Experimental solution) + 0.250 ml
O.lN HCl]
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(c) 175 ng 5-HT [0.125 ml 5-HT (Experimental solution) +
0.375 ml O.lN HCL]
(d) ETOH Blank (0.500 ml ETOH)

All samples and standards were read in an Aminco-Bowman Spectraphotofluorometer at uncorrected wavelengths of 360
m~

and 470

(emission).

m~

(activation)

The water reagent blank was set at 0.05

fluorescent units and the samples were read accordingly.
3.5.6

Calculations

The formula for calculating ng 5-HT/gm brain tissue is as
follows:
A X

(B -

C)

(D - E) X F X G

ng 5-HT/gm brain tissue

where,
A= 12 (6.0 ml/0.5 ml; total volume of 5-HT eluate fraction collected,
see section 3.5.4
Volume of 5-HT eluate fraction converted to fluorophore, see
section 3.5.5)
B

=

C

= Fluorescent

Fluorescent units of sample (tissue extract)
units of column reagent blank (determined from intern-

al standards passed through the column, see section 3.5.4).
D

Fluorescent units of external standard

E

Fluorescent units of external reagent blanks

F = Per cent recovery (determined from internal standards passed
through the column, see section 3.5.4)
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G = Brain region weight
Average recoveries for 5-HT were found to vary between 65 and
80 per cent.

Brain sample concentrations (ng/gm) were always correct-

ed for 100 per cent recovery based on the internal standard recovery
percentage for each experiment.
3.6

Brain Enkephalin-like-material Level Assay

Brain enkephalin-like-material levels were determined according
to methods originally described by Hughes et al. (1975b; 1977) and
modified at present.

Experimental procedures involved are (1) mole-

cular seive chromatography to separate and {2) vas deferens bioassay
preparation to quantify enkephalin-like-material; procedures are outlined as follows.
3.6.1

Tissue Samples

(a) Rats were sacrificed by decapitation (0800 to 1000 hours);
brains were quickly removed on ice.
(b) Meninges and cerebellum were discarded.
(c) Weighed brains were placed in 10 ml of 0.1 N HCl for the
extraction of enkephalin-like-material (see section 3.6.4).
3.6.2

Reagents

(a) Water (see section 3.2.1)
(b) O.lN HCl (Made appropriately from concentrated 12N HCl)
(c) Dichloromethane (As obtained commercially)
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(d) Methanol (MeOH) (Degassed under vacuum

in heavy walled

filtering flask)
(e) Kreb's Solution (Dissolve 13.72 gm NaCl, 0.70 gm KCl,
0.734 gm cac1 ·2H 0, 0.332 gm NaH Po ·H o, 3.96 gm d-glucose, and
2
2
2 4 2
4.20 gm NaHC0

3

in 2000 ml water)

(f) Leucine/Methionine-Enkephalin (Stock solution; dissolve
1.0 mg leucine/methionine-enkephalin in 1.0 ml water)
(g) Leucine/Methionine-Enkephalin (Experimental solution;
take 10

~1

of leucine/methionine-enkephalin stock solution up to a

final volume of 10 rnl in Kreb's solution)
3.6.3
3.6.3.1

Column Preparation
Resin Cleaning Procedure

Chromatography resin was cleaned prior to its use to remove
any impurities.

Utilizing a magnetic stirring apparatus, 250 gm of

Arnberlite XAD2, neutral polystyrene bead resin was washed with

t~e

following solutions ten times:
(a) 300 rnl Dichloromethane
(b) 300 rnl Isopropyl alcohol
(c) 300 rnl water
The cleaned resin was stored in water at room temperature.
3.6.3.2

Packing of Columns

Cylindrical columns (25 ern high, Kontes Martin Company) were
used in this procedure.

The lower portion of the column (14 ern, 8.0
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8.0 mm internal diameter) held the chromatography resin; the upper
portion (11 em, 32 mm internal diameter; 125 ml capacity) served as
a reservoir for the application of brain extracts and various solutions. A rotating plastic stopcock located at the base of the column
adjusted the flow rate.

The columns were suspended vertically through

holes in a wooden board.

A small piece of glass wool was inserted

into the column to trap the resin at the lower end.
filled with resin to a height of 80 mm.

The column was

To remove air bubbles which

interfere with the uniform packing of the resin and flow of solutions
through the columns, a small glass stirring rod was used periodically
during the times at which the columns were filled with resin as well
as during the subsequent extraction process.
3.6.4

Extraction Process

(a) Chilled homogenization of weighed brains in 10.0 ml of
O.lN HCl
(b) Centrifugation of homogenate in a total volume of 20-30 ml
of O.lN HCl at 19,000 RPM for 30 minutes
(c) Pouring of supernatant onto prewashed(300 ml H20) column
and pass through resin (flow rate < 1 ml/minute)
(d) Rinsing of columns by passing the following solutions:
(1) 40 ml QlN HCl
(2) 50-200 ml H o
2
(e) Eluting enkephalin-like-material with 40 ml MeOH
(f) Vaporizing and withdrawing

~eOH

(~egassed)

down to approximately 2 ml

under vacuum at 40°C (Buchi Rotorvapor-R Apparatus)
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(g)

Transfer of remaining eluate to 25 ml round bottom flask

and desication to complete dryness under vaccum at 50°C (Buchi Rotovapor-R-apparatus)
(h)

Freezing (-20°C) dried sample until used in bioassay

Internal standards were prepared by substituting 400 mg of leucine-enkephalin in place of two brain samples; per cent recovery of
enkephalin for each experiment was determined from these two internal
standards.
3.6.5
3.6.5.1

Bioassay

Preparation of Vasa Deferentia

(a)

Mice were sacrificed by cervical dislocation.

(b)

Vasa deferentia were quickly removed and placed in Kreb's

solution.
(c)

Cotton threads were attached to one end of each vas defer-

(d)

Tissues were mounted vertically in a 1.7 ml organ bath

ens.

(Kontes Martin Corporation, as by design) containing oxygenated (95%

o2 ;

5%

co 2 );

(e)

Krebs solution at 37°C.

The upper end of each tissue was attached by a thread to an

isometric or isotonic transducer (Harvard Apparatus).
(f)

The tissue was placed initially under 200-500 mg tension.
3.6.5.2

Electrical Stimulation

(a) Two platinum wires (10

mm long) located at each vertical
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extremity served as stimulating electrodes.
(b)

Tissues were submaximally stimulated with square pulses of

0.5 to 0.8 msec duration from a Grass 548 Stimulator.
(c)

Frequencies of 0.07 to 0.10 Hz were used.

3.6.5.3

Measurement of Enkephalin-like-material

Enkephalins inhibit the electrically evoked contractions of the
longitudinal muscle of the mouse vas deferens by depressing evoked
norepinephrine output; this effect is mediated through the opiate receptor (Hughes et al., 1975b).

The depression of evoked contraction

is represented as a depression of the twitch height and is related to
the amount of enkephalin added to the bath in a dose dependent manner
(Fig. 2).

Utilizing a bracket assay, the amount of enkephalin-like-

material in a sample may be determined as follows.

First, constant

responses (±5%) to repeated applications of known amounts of standard
leucine-enkephalin were obtained to insure reliability of tissue responses (Fig.2). Second, various amounts of unknown sample are applied
until an amount which depresses the twitch height by approximately
50% is determined. ·Third, the unknown sample is bracketed between
predetermined low and high doses of standard leucine-enkephalin; the
low dose of standard should depress the twitch height less than the
brain sample; the high dose of standard should depress the twitch
height more than the brain sample.

Finally, complete antagonism, that

is 100% reversibility, by the narcotic antagonist, naloxone (900 nM)
of the twitch height depression due to the administration of the brain
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FIGURE 2
Inhibition of electrically evoked contractions of
the longitudinal muscle of the mouse vas deferens
by leucine-enkephalin (Leu-Enk).

W =washout time.

Application of naloxone (Nal. 900 nM, bath concentration) prior to washout is used to demonstrate
that the depressant action of Leu-Enk is mediated
through the opiate receptor.
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sample identified the depressant action of the brain sample as being
mediated through the opiate receptor.

A 6 minute dose cycle was used

throughout.

3.6.6

Calculations

The amount of enkephalin-like material expressed as ng leucineenkephalin-equivalents/gm brain tissue was calculated using the following formula:

A x B

= ng

leucine-enkephalin-equivalents/gm brain tissue

C X D X E

where,
A

= ng

leucine-enkephalin equivalent in organ bath (determined

from the standard curve drawn from the low and high doses of standard leucine-enkephalin used in the bracket assay)
B

= Total

volume of Krebs solution used to redissolve sample

C

Volume of sample injected into the organ bath

D

Per cent recovery (determined from internal standards, see

section 3. 6 .4)
E

= Brain

weight

Average per cent recovery for internal standards of leucineenkephalin (400 ng) varied between 20 and 90%.

Calculations were

always corrected for 100% recovery based on the internal standard
recovery percentage for each experiment (see section 3.6.4).
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3.7

Statistical Analysis

Hot plate responses (see sections 4.1.1, 4.1.3, 4.5.1, 4.7.1,
4.8.1, 4.9, and 4.10), tail flick responses (see sections 4.1.2, and
4.5.2), and rectal temperature measurements (see section 4.3 and
4.8.3) were compared to preinjection, baseline, values for each animal
(paired student t test, two tailed).
Exploratory activity levels (see sections 4.2.2, 4.6.1, 4.7.2,
and 4.8.2), motor activity levels (see sections 4.2.1, 4.6.2, and
4.7.3), brain region 5-HT levels (see section 4.4.1, 4.4.2, and 4.4.3)
and whole brain enkephalin-like-material levels (see section 4.11)
were compared to responses and values obtained from animals administered the appropriate vehicle/s (analysis of variance, Newman-Keuls
test) .

Other tests for statistical significance are as stated in

Chapters 4 and 5.
3.8

Definitions

The statistical analysis employed in this dissertation require
more restrictive definitions of some commonly· used terms as follows.
"Antinociception" is defined as statistically significant (p<0.05)
increase in hot plate or tail flick response times (latencies) in rats
administered a compound when compared to preinjection, baseline responses (paired student t test) .
When

the preinjection, baseline, and postinjection hot plate or

tail flick response latencies (times) in rats administered known anti-
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nociceptive doses of DFP or morphine did not differ (p>O.OS; paired
student t test) due to the administration/s of an additional compound, this effect was referred to as "antagonism of the antinociceptive state".

Rarely, the administration of a compound reversed the effect of
known antinociceptive doses of DFP or morphine; that is, DFP or morphine in the presence of an additional compound produced a statistically significant (p<O.OS) decrease in the latency of the hot plate or
tail flick responses in rats when compared to preinjection, baseline
responses (paired student t test) .

This effect is referred to as

"reversal of the antinociceptive state".
Some compounds, administered alone, significantly decrease
(p<0.05) the animals' hot plate or tail flick response latencies when
compared to preinjection, baseline responses (paired student t test).
This effect is referred to as the production of a "hypernociceptive
state".

All other comparative terms such as increased, decreased, attenuated, etc. reflect statistically significant (p<0.05) differences as
described by the appropriate statistical analysis.

4.
4.1

RESULTS

DFP- and Pilocarpine-Induced Antinociception in Rats

4.1.1

Hot Plate Test

The effect of a single s.c. administration of DFP (0.1, 0.5,
1.0, and 1.5 mg/kg) or pilocarpine (2.5 mg/kg) on the hot plate response times of rats was measured 1, 2, 4, 6, 8, 24, and 48 hours
after the DFP and 30 minutes after the pilocarpine injection, respectively.

DFP produced antinociception 1 hour post injection at all

doses tested; pilocarpine (2.5 mg/kg) also produced a significant
antinociceptive state 30 minutes after its administration; the vehicle was ineffective (Table 1).

Response times of animals administered

the vehicle were not significantly different when compared to response
times of control, non-injected, animals in the hot plate test or in
any other test or measurement described in this dissertation (analysis
of variance, Newman-Keuls test; Table 1).
The antinociceptive state produced by DFP followed a dose dependent relationship in terms of potency and duration of effect.

Thus,

the response latency was increased by 77 to 94% by doses of 1.0 and
1.5 mg/kg of DFP, and by some 28% by the dose of 0.1 mg/kg.

Antinoci-

ception produced by DFP (1.0 and 1.5 mg/kg) was maintained for 6 hours
with maximum effects at 2 and 4 hours, respectively; DFP (0.1 and 0.5
mgjkg) produced antinociception that lasted for l hour after administration (Fig. 3).

Finally, it should be noted that animals admin98
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TABLE 1
Hot plate response times (seconds ± S.E.M.) of rats
subsequent to the single s.c. administration of the
vehicle, DFP (0.1, 0.5, 1.0 and 1.5 mgjkg), or pilocarpine (2.5 mg/kg).
in each group.

n

=

number of animals employed

Postinjection responses were compared

to preinjection responses for each animal (paired
Student's t Test).

*p<0.05 and **p<O.Ol.
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TABLE l
EFFECT OF DFP AND PILOCARPINE ON HOT PLATE RESPONSE
TIMES OF RATS
Hot Plate
Res,Eonse Times (Sec) ± S.E.M.
Group

(n)

Preinjection

Postinjection

Control (non-injected)

3

9.6 ± 0.7

9.5 ± 0.8

Peanut oil

8

8.9 ± 0.6

9.2 ± 0.6

DFP (0 .1 mg/kg)

8

9.9 ± 0.9

12.8 ± 1.6*

DFP (0.5 mg/kg)

8

11.0 ± 0.9

15.2 ± 1.3*

DFP (1.0 mg/kg)

8

9.7 ± 0.9

18.8 ± 3.2**

DFP (1.5 mg/kg)

8

9.4 ± 0.8

16.6 ± 2.0**

Pilocarpine (2. 5 mg/kg)

8

9.2 ± 1.3

16.0 ± 1.4**

*p<0.05 and **p<O.Ol
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FIGURE 3
Hot plate response times (seconds ± S.E.M.) of rats
subsequent to the administration of vehicles (closed
circles) or DFP (0.1 mg/kg, closed squares; 0.5 mg/kg,
closed triangles; 1.0 mg/kg,
open squares).

op~n

circles; and 1.5 mg/kg,

Each point represents the mean± S.E.M.

of eight animals.

Hot plate response times were comp-

ared to preinjection (P on abscissa) response values
(paired Student's t Test).

Statistical analysis for

significance is as stated in the text (see section 4.1.1).
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istered the vehicle or DFP (0.1 mg/kg) exhibited attenuated hot plate
responses 6 and 8 hours
4.1.2

postinjection (Fig. 3).
Tail Flick Test

The effect of DFP (0.1, 0.5, 1.0, and 1.5 mg/kg) on the tail
flick response times of rats was measured 1 hour after the DFP administration.

DFP in doses of 1.5 and 1.0 mg/kg produced antinocicep-

tion; at doses of 0.1 and 0.5 mg/kg, DFP was ineffective; animals administered the vehicle did not exhibit antinociception (Table 2) .
4.1.3

Effect of Atropine Sulfate and Atropine Methyl Nitrate
To determine whether DFP-induced antinociception arises from

stimulation of central cholinergic receptors (see section 1.2.2),
the effect of atropine sulfate and atropine methyl nitrate on DFPi~duced

antinociception was studied utilizing the hot plate test.

Ad-

ministered 30 minutes after the administration of DFP (1.5 mg/kg),
atropine sulfate (4.0 mg/kg) antagonized whereas atropine methyl nitrate (4.0 mg/kg) did not affect the antinociceptive state produced by
DFP (Table 3).

Atropine sulfate (4.0 mg/kg) or the vehicles did not

affect the hot plate response when administered alone (Table 3) .
Altogether, it is obvious that, similarly to other drugs which
affect the central cholinergic system, DFP and pilocarpine produce
antinociception.
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TABLE 2
Tail flick response times (seconds ± S.E.M.) of rats
subsequent to the single s.c. administration of the
vehicle or DFP in doses of 0.1, 0.5, 1.0 and 1.5 mgjkg.
n

= number

of animals employed in each group.

Post-

injection responses were compared to preinjection
responses for each animal (paired Student's t Test).
*p<.O .05.
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TABLE 2

EFFECT OF DFP ON TAIL FLICK RESPONSE TIMES OF RATS

Tail Flick
ResEonse Times (sec) ± S.E.M.
(n)

Preinjection

Postinjection

Control (non-injected)

8

17.9 ± 2.0

16.9 ± 1.5

Peanut oil

9

18.1 ± 1.9

18.1 ± 1.7

DFP (0 .1 mg/kg)

8

17.7 ± 1.6

18.9 ± 2.4

DFP (0.5 mg/kg)

6

18.1 ± 2.1

18.3 ± 2.7

DFP (1.0 mg/kg)

6

18.0 ± 1.8

22.8 ± 2.6*

DFP (1.5 mg/kg)

8

17.2 ± 1.9

23.6 ± 1.8*

Group

*p <0.05
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TABLE 3

Hot plate response times (seconds ± S.E.M.) of rats
subsequent to the administrations of vehicles, DFP
(1.5 mg/kg)-saline, DFP (1.5 mg/kg)-atropine sulfate
(4.0 mg/kg), DFP (1.5 mg/kg)-atropine methyl nitrate
(4.0 mg/kg), and peanut oil-atropine sulfate (4.0 mg/kg).
n

= number

of animals employed in each group.

Post-

injection responses were compared to preinjection
responses for each animal
**p < 0.01 and ***p<O.OOl.

(paired Student's t Test).
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TABLE 3
EFFECT OF DFP ON HOT PLATE RESPONSE TIMES OF RATS
Hot Plate
Res;eonse Times (Sec) ± S.E.M.
(n)

Pre injection

Postinjection

Control (non-injected)

12

8.2 ± 0.3

7.8 ± 0.7

Peanut oil-saline

10

8.7 ± 0.5

9.1 ± 0.8

DFP (1.5 mg/kg)-saline

10

8.2 ± 0.3

DFP (1.5 mg/k~-atropine
sulfate (4 .0 mg/kg)

8

8.4 ± 0.4

9.0 ± 0.5

DFP (1. 5 mg/kg)-atropine
methyl nitrate (4 .0 mg/kg)

8

8.6 ± 0.4

14.9 ± 0.5**

Peanut oil-atropine
sulfate (4 .0 mg/kg)

6

7.9 ± 0.4

9.5 ± 0.4

Group

**p<O.Ol and ***p<O.OOl

16.9 ± 0.8***
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4.2

OFF-induced Immobilization in Rats

An established effect of DFP is reduction of the animal's motor
activity (Karczmar, 1977).

Since the effects of DFP on rat motor

activity and environmental response may interfere with the hot plate
assessment of antinociception, motor and exploratory activity levels
were studied.
4.2.1

Exploratory Activity

The animal's exploratory activity, that is, its response to a
novel environment may be a particularly pertinent correlate of antinociception as measured by the hot plate test.
The effect of DFP administered in doses of 0.1, 0.5 and 1.5 mg/kg
on exploratory activity was studied one hour after the administration
of DFP.

DFP (1.5 mg/kg) decreased by 45% exploratory activity; in

doses of 0.1 and 0.5 mg/kg, DFP was ineffective; administration of the
vehicle did not affect exploration (Table 4) .
To further investigate the effect of DFP on exploration, exploratory activity levels were measured 1 to 48 hours after the administration of DFP (0.1, 0.5, 1.0, and 1.5 mg/kg) at the same time intervals at which hot plate responses were measured (see section 4.1.1).
DFP (1.5 mg/kg)

reduced exploratory activity in rats 1, 2, and 48

hours after the DFP administration.

DFP in doses of 0.1, 0.5, and 1.0

mg/kg reduced exploratory activity 2 hours after the DFP injection;
the diminution in exploration at 2 hours followed a dose dependent
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TABLE 4

Exploratory and motor activity levels (activity cage
counts± S.E.M.) of rats subsequent to the administration
of vehicle or DFP in doses of 0.1, 0.5 and 1.5 mg/kg.
n

= number

of animals employed in each group.

Exploratory

and motor activity levels were compared to levels obtained
from animals administered the vehicle (analysis of variance,
Newman-Keuls test).

*p<0.05 and **p<O.Ol.

llO

TABLE

4

EFFECT OF DFP ON EXPLORATORY AND MOTOR ACTIVITY LEVELS
OF RATS
Activit;[ Cage Counts± S.E.M.
(n)

Explorato;y

12

462 ± 27

511 ± 19

Peanut oil

9

448 ± 12

512 ± 12

DFP (0 .1 rng/kg)

7

410 ± 33

404 ± 29**

DFP (0 .5 rng/kg)

8

336 ± 28

239 ± 24**

DFP (1.5 rng/kg)

7

252 ± 19**

164 ± 13**

Group
Control (non-injected)

*p<0.05 and **p<O.Ol

Motor Activit;[
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relationship for all doses of DFP tested (Fig. 4).

Exploratory activ-

ity levels were compared to levels obtained from animals administered
the vehicle (analysis of variance, Newman-Keuls test; Fig. 4).
4.2.2

Motor Activity

The effect of DFP administered in doses of 0.1, 0.5 and 1.5 mg/kg
reduced motor activity levels (Table 4).

The diminution in motor

ac~

tivity produced by DFP(O.l to 1.5 mg/kg) followed a dose dependent relationship.

Administration of the vehicle did not affect motor activ-

ity (Table 4) .
4.3

Effect of DFP on Rectal Temperature of Rats

Mild hypothermia (a 2 to 3°C decrease in rectal temperature below
normal) produced hypernociception in the cat (Liu and Fang, 1972).
Since the systemic adrninist=ation of DFP produces hypothermia in the
rat (Meeter and Wolthius, 1968), this effect of DFP may interfere with
the correct evaluation of antinociception as measured by temperature
sensitive tests such as the hot plate and tail flick tests.

The ef-

fect of DFP on rectal temperatures of rats was measured l to 48 hours
after the administration of DFP at the same time intervals at which
hot plate responses were measured (see section 4.1.1).

DFP (1.0 mg/

kg) produced hypothermia (a 2.4oc decrease in rectal temperature) 2
hours postinjection

at 4 hrs the effect was not significant any more.

The vehicle was ineffective (Fig. 5).
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FIGURE 4

Exploratory activity levels of rats expressed as the
percent of preinjection activity cage counts ± S.E.M.
subsequent to the administration of vehicle (closed
circles) and DFP (0.1 mg/kg, closed squares; 0.5 mg/kg,
closed triangles; 1.0 mg/kg, open squares; and 1.5 mg/kg,
open circles).
animals.

Each point represents the mean of five

Exploratory activity levels were compared to

levels obtained from animals administered the vehicle
(analysis of variance, Newman-Keuls test).

Statistical

analysis for significance is as stated in the text (see
section 4.2.2).
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FIGURE 5

Rectal temperature measurements (Oc) of rats subsequent
to the administration of vehicle (closed circles) and
DFP (1.0 mg/kg; open circles).

Each point represents

the mean± S.E.M. of eight animals.

Rectal temperature

measurements were compared to preinjection

(P

on abscissa)

values for each animal (paired Student's t Test) .
.. p<O.Ol.

Fig. 5
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4.4

Brain Region Serotonin (5-HT) Levels of Rats

4.4.1

Effect of DFP

Increased levels and turnover of acetylcholine (ACh; see section
1.2.3) and/or serotonin (5-HT; see section 1.3.2) in the central
nervous system (CNS) have been associated with antinociception and
analgesia.

Since DFP markedly increased brain 5-HT levels when admin-

istered to rabbits (Barnes et al., 1975), it was important to ascertain whether-DFP exerted a similar effect in the rat.

The effect of DFP on 5-HT levels in three rat brain regions was
investigated one hour after the administration of DFP.

As shown in

Table 5, DFP (1.·5 mg/kg) increased 5-HT levels in the medulla, mesodiencephalon, and telencephalon when compared to 5-HT levels of
animals administered

t~e

vehicle, peanut oil (analysis of variance,

Newman-Keuls test; Table 5).

These increases amounted to 217, 132,

and 131 per cent in the medullary, meso-diencephalic, and telencephalic brain regions respectively, with respect to animals administered
the vehicle (Table 5).

5-HT levels of animals administered peanut

oil, saline, or saline and peanut oil did not differ from values obtained in control, non-injected animals in any case (analysis of variance, Newman-Keuls test; Table 5).
4.4.2

Effect of PCPA

To ascertain the significance of the rise in 5-HT with respect to
the antinociception produced by DFP, PCPA, a tryptophan hydroxylase
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TABLE 5

Serotonin (5-HT)levels expressed as ng 5-HT/gm tissue
± S.D. in three rat brain regions (medulla, meso-

diencephalon and telencephalon) subsequent to the
1
administration of DFP (1.5 mg/kg), PCPA , or PCPA 2 (see
1
2
section 3.2.2), PCPA -DFP (1.5 mg/kg), PCPA -DFP
(1.5 mg/kg) as well as vehicles.
regions measured.

n =number of brain

In all cases, 5-HT levels in animals

administered the various drug/s were compared to 5-HT
levels obtained in animals administered the appropriate
vehicle/s (analysis of variance, Newman-Keuls test).
**p<O .01.

TABLE 5

EFFECT OF DFP, PCPA, AND PC?A-DFP ON RAT BRAIN REGION SEROTONIN (5-HT) LEVELS
BRAIN REGION 5-HT LEVELS (ng 5-HT/gm TISSUE) ± S.D.

Group
Control (non-injected)

(n)
12

t-tedulla
270 ± 21

(n)
ll

Meso~iencephalon

548 ± 26

(n)
ll

Telencephalon
339 ± 26

DFP (1.5 mg/kg)

7

589 ± 26**

7

724 ± 43**

8

444 ± 30**

Peanut oil

6

272 ± ll

8

518 ± 24

8

350 ± 21

PCPAl

6

202 ± 20**

5

196 ± 17**

6

237 ± 13**

8

143 ± ll**

8

159 ± 25**

8

196 ± 13**

Saline

6

259 ± 23

8

517 ± 44

8

379 ± 19

1
PCPA -DFP (1.5 mg/kg)

6

213 ± 19**

7

234 ± 26**

9

282 ± 29

2
PCPA -DFP (l. 5 mg/kg)

6

173 ± 10**

6

187 ± 16**

6

227 ± 18**

Saline-peanut oil

7

279 ± 19

8

526 ± 30

8

348 ± 33

PCPA

2

**p<O.Ol

.....

.....
00
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inhibitor, was employed and its action on the DFP mediated changes in
5-HT levels, antinociception, and exploration and locomotion were
evaluated.

First~

the effect of PCPA on brain region 5-HT levels was stud-

ied; two dose regimens, PCPA

1

2
and PCPA , were employed (see section

3.2.2); in either case, PCPA reduced 5-HT levels in all three brain
regions; particularly PCPA

2

reduced 5-HT levels by 52, 70, and 48 per

cent in the medullary, meso-diencephalic, and telencephalic brain
regions, respectively, when compared to saline injected animals
(analysis of variance, Newrnan-Keuls test; Table 5).
4.4.3

Effect of PCPA-DFP

The effect of PCPA pretreatment regimens, PCPA
DFP-induced increase in 5-HT levels was studied.
PCPA

1

and PCPA

2

1

2
and PCPA , on the

Administered to

pretreated animals, DFP (1.5 mg/kg) did not affect the

dimunition in 5-HT levels produced by either PCPA

1

or PCPA

2

in any

brain region studied (analysis of variance, Newrnan-Keuls test; Table
5).

2
1
Brain 5-HT levels in PCPA -DFP (1.5 mg/kg) and PCPA -DFP (1.5

mg/kg) treated animals were still significantly reduced when compared
to animals administered saline and peanut oil except for the effect of
PCPA 1 -DFP (1.5 mg/kg) on the telencephalic 5-HT levels (analysis of
variance, Newrnan-Keuls test; Table 5).
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4.5

Effect of PCPA on OFF-induced Antinociception in Rats

4.5.1

Hot Plate Test

Since pretreatment with PCPA antagonized the OFF-induced increase in brain region 5-HT levels in rats, it was important to determine whether PCPA pretreatments would affect the antinociceptive state
produced by OFP; the hot plate and tail flick tests were employed for
this purpose.

Table 6 demonstrates the effect of two PCPA pretreatment regi2
mens (PCPA1 and PCPA ; see section 3.2.2) on the OFF-induced antinociceptive state of rats as measured by the hot plate test.

Employed

1 and PCPA 2 , produced hypernociception (Table 6).

However,

alone, PCPA

PCPA pretreatments did not antagonize the antinociceptive state produced by OFP (1.5 mg/kg; Table 6).

Administration of the vehicles was

ineffective (Table 6) .

4.5.2

PCPA

2

Tail Flick Test

(see section 3.2.2) produced a bypernociceptive state when

administered alone to rats as measured by the tail flick test (Table
7).

However, PCPA

2

pretreatment did not affect the antinociceptive

state produced by OFP (1.5 mg/kg; Table 7).
in the tail flick test (Table 7) .

Vehicles were ineffective
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TABLE 6
Hot plate response times (seconds ± S.E.M.) of rats
subsequent to the administration of vehicles, DFP
(1.5 mg/kg), PCPA

l

or PCPA

2

(see section 3.2.2), as

2
well as the combination PCPA~or PCPA -DFP (1.5 mg/kg).
n

= number

of animals employed in each group.

Post-

injection responses were compared to preinjection
responses for each animal (paired Student's t Test).
*p<0.05, **p<O.Ol, and ***p<O.OOl.
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TABLE 6
EFFECT OF PCPA ON DFP-INDUCED ANTINOCICEPTION:
HOT PLATE TEST
Hot Plate
Res:eonse Times (Sec) ± S.E.M.
Grou:e

(n)

Preinjection

Postinjection

Control (non-injected)

10

8.1 ± 0.4

8.3 ± 0.4

Saline-peanut oil

10

6.9 ± 0.6

7.3 ± 0.4

7

8.6 ± 0.9

15.3 ± 1.0**

12

7.1 ± 0.4

5.3 ± 0.4*

8

9.2 ± 1.1

5.4 ± 0.4**

PCPA 1 -DFP (1.5 mg/kg)

7

7.2 ± 0.7

21.2 ± 1.3***

2
PCPA -DFP (1. 5 mg/kg)

7

7.5 ± 0.5

21.4 ± 2.1***

DFP (1.5 mg/kg)
PCPAl
PCPA

2

*p<0.05, **p<0.01 and ***p<O.OOl
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TABLE 7

Tail flick response times (seconds ± S.E.M.) of rats
subsequent to the administration of vehicles, DFP
(1.5 mg/kg), PCPA

2

DFP (1.5 mg/kg).
in each group.

(see section 3.2.2), and PCPA 2 n

= number

of animals employed

Postinjection responses were compared

to preinjection responses for each animal (paired
Student's t Test).

***p<O.OOl.
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TABLE 7

EFFECT OF PCPA ON DFP-INDUCED ANTINOCICEPTION:
. TAIL FLICK TEST

Tail Flick
Res12onse Times (Sec) ± S.E.M.
(n)

Group

Preinjection

Postinjection

Control (non-injected)

8

17.5 ± 0.5

18.1 ± 0.6

Saline-peanut oil

9

17.3 ± 0.5

16.9 ± 0.5

8

17.2 ± 0.5

23.6 ± 0.6***

9

17.0 ± 0.5

10.7 ± 0.5***

8

17.6 ± 0.7

25.8 ± 0.5***

DFP
PCPA

(1.

5 mg/kg)

2

PCPA 2 -DFP

***p<O.OOl

(1. 5

mg/kg)
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4.6

Effect of PCPA on DFP-induced Immobilization in Rats

4.6.1

Exploratory Activity

The effects of PCPA and PCPA-DFP combinations on exploratory
and motor activity were evaluated to test whether or not the lack of
effect of PCPA on DFP-induced antinociception was related to a PCPA
action on the mobility of the rats.

As shown previously (see section

4.2.1), DFP (1.5 mg/kg) decreased exploratory activity (Table 8).
2
Administered alone, PCPA , did not affect exploratory activity (Table
8).

In addition, pretreatment with PCPA

2

did not affect the diminu-

tion in exploration produced by DFP(l.5 mg/kg; Table 8).

Administra-

tion of the vehicles was ineffective (Table 8).

4.6.2

Motor Activity

As demonstrated earlier (see section 4.2.2), DFP (1.5 mg/kg) decreased motor activity; the diminution amounted to 61% when compared
to animals administered the vehicle (Table 8).

PCPA, administered by

itself, si9nificantly increased motor activity; yet, pretreatment with
PCPA 2 did not affect the diminution in locomotion produced by DFP
(1.5 mg/kg; Table 8).
(Table 8) .

The vehicles did not affect motor activity
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'!'ABLE 8

Exploratory and motor activity levels (activity
cage counts ± S.E.M.) of rats subsequent to the
administration of vehicles, DFP (1.5 mg/kg), PCPA

2

2
(see section 3.2.2), and PCPA -DFP (1.5 mg/kg).
n

=

number of animals employed in each group.

Exploratory and motor activity levels were compared
to levels obtained from animals administered the
vehicles (analysis of variance, Newman-Keuls test).
**p<O .01.
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TABLE 8

EFFECT OF PCPA ON THE ATTENUATED EXPLORATORY AND
MOTOR ACTIVITY LEVELS OF RATS PRODUCED BY DFP
Activity Cage Counts ± S.E.M.
(n)

Exploratory

Control (non-injected)

8

473 ± 18

521 ± 28

Saline-peanut oil

9

493 ± 24

543 ± 30

DFP (1.5 mg/kg)

8

257 ± 13**

211 ± 12**

9

372 ± 40

820 ± 21**

8

177 ± 17**

183 ± 10**

Group

PCPA

2

2
PCPA -DFP (1.5 mg/kg)

**p<O.Ol

Motor
---

128
4.7

Pharmacological Comparison of DFP- and Morphine-induced
Behavioral Effects in Rats
4.7.1

Antinociception

In an attempt to ascertain whether DFP-induced antinociception
is related to a narcotic sensitive and/or endogenous opioid system,
the following experiments were performed.

The antinociceptive actions of DFP and morphine were evaluated
pharmacologically; the hot plate test was employed for this analysis
(Table 9).

DFP (1.5 mg/kg) and morphine (3.0 mg/kg)produced equiva-

lent levels of antinociception(Table 9).

Atropine sulfate (4.0 mg/kg)

antagonized the antinociceptive action of DFP but did not affect morphine-induced antinociception (Table 9).

However, naloxone (5.0 mg/

kg) antagonized both morphine- and DFP-induced antinociceptive states
(Table 9).

Atropine sulfate (4.0 mg/kg)

were ineffective when administered alone.

and naloxone (5.0 mg/kg)
The vehicles were ineffec-

tive (Table 9) .

4.7.2

Exploratory Activity

The effect of DFP and morphine on exploration and locomotion was
investigated pharmacologically to determine whether the antinociceptive state produced by these two compounds could be attributed to a
drug effect on animal mobilization.
DFP (1.5 mg/kg) and morphine (3.0 mg/kg) reduced exploratory
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TABLE 9

Hot plate response times (seconds ± S.E.M.) of rats
subsequent to the administrations of vehicles, DFP
(1.5 mgjkg) and morphine (3.0 mgjkg) as well as DFP
(1.5 mgjkg) or morphine (3.0 mg/kg) in combination
with either atropine sulfate (4.0 mg/kg) or naloxone
(5.0 mgjkg).
each group.
to

n =the number of animals employed in
Postinjection responses were compared

preinjection responses for each animal (paired

Student's t Test). *p<0.05 and ***p<O.OOl.

TABLE 9

PHARMACOLOGICAL COMPARISON OF DFP- AND MORPHINE-INDUCED ANTINOCICEPTIVE STATES: HOT PLATE TEST

Hot Plate
Res;eonse Times (Sec) ± S.E.M.
Group

(n)

Preinjection

Postinjection

Control (non-injected)

12

8.2 ± 0.3

8.3 ± 0.4

Peanut oil-saline

10

8.6 ± 0.4

8.8 ± 0.4

DFP (1.5 mg/kg)

10

8.2 ± 0.3

DFP (1.5 mg/kg)-atropine sulfate (4.0 mg/kg)

8

8.4 ± 0.4

8.9 ± 0.5

DFP (1.5 mg/kg)-naloxone (5.0 mg/kg)

8

7.8 ± 0.4

8.5 ± 0.5

10

9.1 ± 0.3

17.3 ± 0.5***

Morphine (3.0 mg/kg)-atropine sulfate (4. 0 mg/kg)

9

8.6 ± 0.5

•19.4 ±

Morphine (3.0 mg/kg)-naloxone (5 .0 mg/kg)

8

8.9 ± 0.6

Morphine (3.0 mg/kg)

16.9 ± 0.8***

o. 7***

7.0 ± 0.4*

*p<0.05 and ***p<O.OOl
~

w

0

131
The reduction in exploration by morphine

activity levels (Table 10).

or DFP was not affected by atropine sulfate (4.0 mg/kg) or naloxone
(5.0 mg/kg), nor was the affect of DFP (1.5 mg/kg) affected by atro-

pine methyl nitrate(4.0 mg/kg; Table 10).

Administered alone, atro-

pine sulfate(4.0 mg/kg) decreased exploratory activity; the vehicles
were ineffective (Table 10) .

Exploratory activity levels were comp-

ared to levels obtained from animals administered the vehicles (analysis of variance, Newman-Keuls test; Table 10).
4.7.3

Motor Activity

Employed at equi-antinociceptive doses, DFP (1.5 mg/kg) decreased, whereas morphine (3.0 mg/kg) increased motor activity (Table 10).
Atropine sulfate (4.0 mg/kg) ,atropine methyl nitrate (4.0 mg/kg) ,and
naloxone (5.0 mg/kg) did not affect the attenuated motor activity
produced by DFP (1.5 mgjkg; Table 10).

However, atropine sulfate

(4.0 mg/kg) did antagonize the increase in motor activity produced by
morphine (3.0 mg/kg); naloxone (5.0 mg/kg) not only antagonized but
reversed the motor response induced by morphine (3.0 mg/kg; analysis
of variance, Newman-Keuls test; Table 10).

Administered alone, atro-

pine sulfate (4.0 mg/kg) reduced motor activity; the vehicles were ineffective (Table 10) .

Motor activity levels were compared to levels

-obtained from animals which received the vehicles (analysis of variance, Newman-Keuls test; Table 10).
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TABLE 10

Exploratory and motor activity levels (activity cage
counts± S.E.M.) of rats subsequent to the administration
of vehicles, atropine sulfate (4.0 mg/kg), DFP (1.5 mg/kg),
and morphine (3.0 mg/kg) as well as DFP (1.5 mg/kg),
or

morphine (3.0 mg/kg) in combination with either

atropine sulfate (4.0 mg/kg) or naloxone (5.0 mg/kg).
n

= number

of animals employed in each group.

Explor-

atory and motor activity levels were compared to levels
obtained from animals administered the vehicle (analysis
of variance, Newman-Keuls test).

**p<O.Ol.

TABLE 10
PHARMACOLOGICAL COMPARISON OF THE EFFECTS OF DFP AND MORPHINE ON EXPLORATORY AND MOTOR ACTIVITY
LEVELS OF RATS

Activity Cage Counts

± S.E.M.

Group

(n)

Control (non-injected)

12

483

± 17

524

± 12

Peanut oil-saline

10

501

± 21

511

± 15

DFP (1.5 mgjkg)

10

248

± 18**

236

± 10**

DFP (1.5 mg/kg)-atropine sulfate (4.0 mg/kg)

8

311

± 13**

249

± 15**

DFP (1.5 mg/kg)-atropine methyl nitrate (4. 0 mg/kg)

8

232

± 19**

248

± 18**

DFP (1.5 mg/kg)-naloxone (5 .0 mgjkg)

8

198

± 10**

196

± 11**

10

324

± 10**

791

± 21**

Horphine (3.0 mg/kg)-atropine sulfate (4.0 mg/kg)

9

297

± 15**

557

± 32

Morphine (3.0 mg/kg)-naloxone (5.0 mg/kg)

8

293

± 12**

158

± 23**

Atropine sulfate (4 .0 mg/kg)

6

325

± 27**

390

± 19**

Morphine (3.0 mg/kg)

**p<O.Ol

Exp1orat()!"Y

Motor Act:.i_vity

I-'

w
w
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4.8

Effect of Naloxone on DFP-induced Responses in Rats

4.8.1

Antinociception

It was particularly noteworthy that naloxone, a pure narcotic
antagonist, antagonized DFP-induced antinociception (see section
4.7.1).

To further study this effect, the effect of naloxone (0.05,

0.5, and 5.0 mg/kg) on DFP-induced antinociception in rats was studied 1 to 48 hours after the single administration of DFP (1.0 mg/kg)
utilizing the hot plate test.

At the dose of 0.05 mg/kg, naloxone

did not affect DFP-induced antinociception; it was effective 1 hour
after the administration of DFP in antagonizing the DFP-induced antinociceptive state at doses of 0.5 and 5.0 mg/kg (Fig. 6).
administered in a dose of 5.0 mg/kg, naloxone
nocicpetion

1 hour

after

cles were ineffective

4.8.2

In fact,

produced hyper-

the DFP administration

(Fig. 6).

Vehi-

(Fig. 6).

Exploratory Activity

As demonstrated earlier (see section 4.7.2), DFP (1.5 mg/kg) decreased exploration 1, 2, and 48 hours after the administration of
DFP (Fig. 4).

Naloxone in doses of 0.05, 0.5,and 5.0 mg/kg did not

affect the attenuated exploratory activity produced by DFP (1.5 mg/kg).
Figure 7A demonstrates exploratory activity levels 1, 2, and 4 hours
after the DFP injection for animals administered the vehicles, DFP
(1.5 mg/kg), and the combination DFP (1.5 mg/kg) with naloxone (5.0
mg/kg).
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FIGURE 6
Hot plate response times (seconds ± S.E.M.) of rats
subsequent to the administrations of vehicles (closed
circles) ;DFP (1.0 mg/kg) with naloxone (0.05 mg/kgclosed triangles; 0.5 mg/kg-open circles; 5.0 mg/kgclosed squares); and DFP (1.0 mg/kg with saline-closed
hexagons).

Each point represents the mean ± S.E.M.

of eight animals.

Hot plate responses were compared

to preinjection (P on abscissa) responses for each
animal (paired Student's t Test) . . p<0.05, •. p<O.Ol,
and .•• p<O.OOl.
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Fig. 6
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FIGURE 7A

Exploratory activity levels of rats expressed as percent
prein,jection a_cti vi ty cage counts ± S .E .M. subsequent to
the administration of vehicles (circles), DFP (1.5 mg/kg)
with saline (squares), and DFP (1.5 mg/kg)-naloxone
(5.0 mg/kg) combination (triangles).
the mean± S.E.M. of five animals.

Each point represents
Exploratory activity

levels were compared to activity levels obtained from
animals administered the vehicles (analysis of variance,
Newman-Keuls test) . • • p<O.Ol.
7B
Rectal temperature measurements (°C) of rats subsequent to
the administration of vehicles (circles), DFP (1.0 mg(kg)
with saline (squares), and DFP (1.0 mg(kg)-naloxone (5.0
mg/kg) combination (triangles) .

Each point represents

the mean± S.E.M. of eight animals.

Rectal temperature

measurements were compared to preinjection (P on abscissa)
measurements for each animal (paired Student's t Test) .
. . p<O .01.
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Fig. 7
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4.8.3

Hypothermia

As demonstrated earlier (see section 4.3), DFP (1.0 mg/kg)
produced hypothermia 2 hours after its administration (Fig. 7B).
Naloxone (5.0 mg/kg) did not affect the hypothermic state produced
by DFP (1.0 mg/kg) 2 hours after DFP (Fig. 7B).

Administered alone,

naloxone (5.0 mg/kg) did not affect rectal temperatures; the vehicles were ineffective (Fig. 7B).

Thus, naloxone reduced the antinociceptive state produced by DFP
(see section 4.8.1) but did not affect the attenuated exploration
(see section 4.8.2) or hypothermia (see section 4.8.3) produced by
DFP.

4.9

Effect of Stereoisomers of Narcotic Antagonists on
DFP-induced Antinociception in Rats

Since non-specific actions of naloxone could contribute to its
inhibition of DFP-induced antinociception, it was important to determine if the antagonism was stereospecific.

MR 2266, MR 2267, GPA 1843, GPA 1847, d-cyclazocine, and 1-cyclazocine

were administered individually 30 minutes after the adminis-

tration of DFP (1.0 mg/kg) or morphine (3.0 mg/kg).

MR 2266 (1.0 mg/

kg) and GPA 1843 (5.0 mg/kg), the (-) isomers and active narcotic antagonists, reduced both morphine and DFP-induced antinociceptive states
(Table 11).

MR 2267 (1.0 mg/kg) and GPA 1847 (5.0 mg/kg), the corre-

spending (+) isomers, did not affect the antinociceptive

s~ates

pro~uced
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~ABLE

11

Hot plate response times (seconds± S.E.M.) of rats
subsequent to the administrations of DFP (1.0 mg/kg)
or morphine (3.0 mg/kg) followed 30 minutes later by
either the vehicle, MR 2266 {1.0 mg/kg), MR 2267
(1.0 mg/kg), GPA 1843 (5.0 mg/kg), GPA 1847 (5.0 mg/kg),
d-cyclazocine (0.64 mg/kg), or 1-cyclazocine (0,64 mg/kg).
n

= number

of animals employed in each group.

Post-

injection responses were compared to preinjection
responses for each animal (paired
*p<0.05 and **p<O.Ol.

Student's

t

Test).
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TABLE 11
EFFECT OF STEREOISOMERS OF NARCOTIC ANTAGONISTS ON
MORPHINE AND DFP-INDUCED ANTINOCICEPTIVE STATES: HOT PLATE TEST
Hot Plate
Res12onse Times (Sec) ± S.E.M.
Group

(n)

Morphine-saline

17

9.3 ± 1.2

18.6 ± 2.4**

Morphine-MR 2266 (-)

12

9.1 ± 0.9

9.8 ± 1.6

Morphine-MR 2267

12

9.0 ± 0.9

18.3 ± 2.9**

(+)

Preinjection

Postinjection

Morphine-GPA 1843

(-)

12

9.7 ± 0.7

12.2 ± 1.1

Morphine-GPA 1847

( +)

12

9.4 ± 0.8

16.5 ± 2.2**

Morphine-l,cyclazocine (-)

5

11.4 ± 1.0

13.6 ± 0.7

Morphine-d,cyclazocine

5

11.1 ± 3.2

18.2 ± 3.2*

13

8.8 ± 1.2

18.3 ± 2.7**

DFP-MR 2266 (-)

8

6.7 ± 0.7

7.4 ± 1.2

DFP-MR 2267

8

8.7 ± 1.4

12.2 ± 2.8*

DFP-GPA 1843 (-)

8

10.8 ± 1.9

12.2 ± 1.5

DFP-GPA 1847

8

8.8 ± 1.9

15.4 ± 3.1*

DFP-l,cyclazocine (-)

5

9.7 ± 0.7

16.7 ± 1. 7*

DFP-d,cyclazocine (+)

5

11.2 ± 1.3

10.6 ± 1.4

uFP-saline

( +)

(+)

(+)
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duced by either morphine

or DFP (Table 11).

The vehicle was inef-

fective (Table 11).
On the other hand, the relationship between the antagonist action
against DFP- and morphine-induced antinociception and the stereoisomers

of cyclazocine, a partial narcotic agonist, was reversed; d-

cylcazocine (0.64 mg/kg) antagonized the antinociceptive action of
DFP but did not affect morphine-induced antinociception; l-cyclazocine(0.64 mg/kg) reduced morphine-induced antinociception but was ineffective against DFP-induced antinociception (Table 11) .
4.10

Effect of Tolerance to Morphine on DFP- and
Pilocarpine-induced Antinociception in Rats

Cross tolerance studies were performed to discern a possible
common neural mechanism

mediating antinociception produced by mor-

phine, pilocarpine, and DFP.

As demonstrated earlier (see sections

4.1.1 and 4.7.1) DFP (1.0 mg/kg), pilocarpine (2.5 mg/kg), and morphine (3.0 mg/kg) produced antinociception as measured by the hot
plate test in rats (Pretolerance; Table 12).

Morphine-induced anti-

nociception was completely attenuated in animals rendered tolerant to
morphine as measured on day 6 (tolerance level A; Table 12).

However,

DFP-and pilocarpine-induced antinociception was maintained in animals
rendered tolerant to morphine on day 6 (tolerance level A) ; in addition,

DFP-induced antinociception was maintained on day 9 (tolerance

level B; Table 12).

Thus, the antinociceptive actions of DFP and

pilocarpine did not exhibit cross tolerance to the antinociceptive
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TABLE 12
Hot plate response times (seconds± S.E.M.) of rats
subsequent to administrations of DFP (1.0 mg(kg)) pilocarpine ( 2 . 5 mg/kg ), or morphine ( 3. 0 mg(kg) .

Hot

plate measurements were made both prior to the development of tolerance (Pretolerance) as well as after the
development of tolerance to morphine at different
levels (TOlerance levels A and B; see section 3.2.3).
n

= number

of animals employed in each group.

All

responses were compared to Preinjection, baseline,
responses for each animal (paired Student's t Test).
*p<O.OS and **p<O.Ol.
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TABLE 12
EFFECT OF TOLERANCE TO MORPHINE ON DFP- AND PILOCARPINE-INDUCED
ANTINOCICEPTION: HOT PLATE TEST
Hot Plate
Res12onse Times (sec) ± S.E.M.
DFP
(n=8)

Administration

Morphine
(n-8)

Preinjection

11.0 ± 0.6

11.0 ± 1.1

Pretolerance

22.7 ± 1.1**

21.2 ± 1.4**

12.3 ± 2.2*

Tolerance Level A

11.4 ± 1.0

17.6 ± 1. 7*

13.3 ± 2.6*

Tolerance Level

B

17.3 ± 2.0*

Pilocarpine
(n=8)
7.0 ± 0.7

M5

actions of morphine.

Tolerant animals exhibited no altered responses

when administered the vehicle alone.

Non-tolerant animals demonstrated

antinociceptive responses to morphine (3.0 mg/kg) and DFP (1.0 mg/kg)
on days 1,6, and 9; responses to pilocarpine (2.5 mg/kg) were not
measured on these days.
4.11

Effect of DFP on Rat Brain Enkephalin-like Material Levels

The stereospecificity of the narcotic antagonist action on the
antinociceptive state produced by DFP (see section 4.9) suggests that
DFP-induced antinociception is mediated via opiate receptors, possibly
by the release of endogenous opioids.

Therefore, the effects of DFP

on whole brain enkephalin-like-material levels in the rat were studied l hour after the administration of DFP.
Sixty-eight rat brains were assayed for enkephalin-like-material
content utilizing the mouse vas deferens bioassay technique as described in section 3.6.

Unfortunately, only 7 rat brain samples were found

to be acceptable according to the criteria of the bioassay procedure
(see section 3.6.5.3).

Enkephalin-like-material content of whole rat

brains, expressed as ng leucine-enkephalin equivalents/gm brain tissue,
was determined to be 229 ng leucine-enkephalin equivalents/gm brain
tissue in animals which received DFP (1.0 mg/kg; n=2), and 252 ng
leucine-enkephalin equivalents/gm brain tissue in animals which received peanut oil (n=5). These levels were not significantly different (analysis of variance, Newman-Keuls test).

146
The following reasons explain why, for the most part, the remaining brain samples (n=61) failed to meet acceptable bioassay criteria and therefore could not be included in the results:(i) per cent
recovery of the internal standards (see section 3.6.4) often was less
than 90% and occasionally even as low as 20% in some experiments, (ii)
the rat brain sample increased

t~1e

resting tone of the longitudinal

muscle of the mouse vas deferens making it impossible to accurately
measure the depression of the electrically-evoked twitch

height (Fig.

SA), (iii) the rat brain sample inconsistently depressed the electrically-evoked twitch height of the longitudinal muscle of the mouse vas
deferens, that is, the depressed twitch height returned to normal
prior to washout time; this suggests that substances other than en.kephalin-like-material were responsible for the twitch height depression (Fig.SB), and (iv) the depression of the electrically-evoked
twitch height of the longitudinal muscle of the mouse vas deferens
produced by the rat brain sample could not be completely (that is by
100%) reversed by the addition of naloxone (900 nM bath concentration);
this indicates that additional not enkephalin-like-materials may be
responsible for the twitch height depression (Fig. 8C).
Overall, the experiments designed to determine the effect of DFP
on rat brain enkephalin-like-material levels were incomplete and inconclusive due to the lack of reliable, extraction and bioassay techniques.
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FIGURE SA
Inhibition of the electrically-evoked contraction of the longitudinal muscle of the mouse vas deferens by a rat brain sample extract
{S) .

Notice the increased resting tone of the vas deferens produced

by S when compared to the normal resting tone following the administration of standard leucine-enkephalin (see Figure 2).

W =washout

time.
8B

Inhibition of the electrically-evoked contractions of the longitudinal
muscle of the mouse vas deferens by a rat brain sample extract {S) .
Notice the non-constant depression of twitch height produced by S
when compared to the constant twitch height depression produced by
standard leucine enkephalin (see Figure 2).

W =washout time.

sc
Inhibition of the electrically-evoked contractions of the longitudinal
muscle of the mouse vas deferens by a rat brain sample extract (S)
and subsequent reversal by the addition of naloxone (N; 900 nM bath
concentration) prior to washout (W).

Notice the incomplete, less

than 100%, reversibility by N of the depressed twitch height produced
by S when compared to the complete reversal of the twitch height
depression produced by standard leucine-enkephalin (see Figure 2).

148

Fig. 8

T

(A)

500 mg

j_
w

s

(B)

(C)

S

N

W

5.
5.1
5.1.1

DISCUSSION
General

DFP, Mechanism of Action

Anticholinesterase (anti-ChE) agents constitute one of the few
classes of drugs for which a mechanism of action has been defined in
terms of inhibition of a specific enzyme.

Until World War II, the

enzyme cholinesterase (ChE) was of pure academic interest; however,
during the war, intense research programs arose in the field of
organophosphorus anti-ChE's because their toxicities suggested their
use as potential chemical warfare agents.

Investigations in England

produced a series of organophosphorus anti-ChE's, one of which was
diisopropyl phosphofluoridate (DFP; Holmstedt, 1959; Karczmar, 1970).
Cholinesterases (ChE's) contain at least one anionic and one
esteratic site in their active centers; the most likely carrier of
the negative charge in the anionic site is glutamic acid while serine
and histidine are the basic groups of the esteratic site (Karczmar,
1970).
True cholinesterase (AChE) which hydrolyzes acetylcholine at a
higher rate than butyrylcholine is the enzyme present in the brain,
spinal cord, striated muscles, smooth muscles of the bronc:':-.ioles,
urinary bladder, salivary glands, and erythrocytes of several but not
all vertebrates (Koelle, 1951).

Pseudocholinesterase (BuChE) which

hydrolyzes butyrylcholine at a higher rate than acetylcholine is found
149
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in the serum of most vertebrates, carotid body, hepatic cells, and
muscularis mucosa of intestinal cells (Koelle, 1951).

DFP produces

8
a 50% inhibition of BuChE at low concentrations (10- M) while AChE
is 50% inhibited by higher concentrations of DFP (10
preferentially inhibits BuChE (Aldridge, 1953).

-6

M); thus, DFP

The doses of DFP

used in this dissertation, 0.1 to 1.5 mg(kg may be extrapolated in
terms of equidistribution in the tissues as corresponding to 5.4 x
10-

7

to 8.2 x 10- 6 M.

Thus, it would be expected that DFP in doses of

0.5, 1.0, and 1.5 mg/kg inhibit at least 50% of AChE; less than 50%
inhibition of AChE would be expected from the administration of 0.1
mg/kg DFP.

Actually, as an extremely lipid soluble compound (Usdin,

1970) , DFP may be expected to be distributed preferentially in the
nerve tissue.

Anti-ChE's may be classified as reversible or irreversible based
upon the ease with which the inhibitory action can be reversed.

Re-

versible inhibition has been divided into three groups: (i) competitive
(ii) noncompetitive and (iii) uncompetitive.

Competitive inhibition

occurs with anti-ChE's which are structurally similar to the normal
substrate; with these compounds, Km increases and Vmax is unaltered.
Noncompetitive inhibitors bind with some site on the ChE molecule
distinct from the active site; in this case, Vmax decreases and Km
remains unaltered.

Uncompetitive inhibition occurs when the inhibi-

tion binds to the enzyme substance complex; in this case, Km and vmax
both decrease.

Oximes, inorganic compounds, and bis and mono quater-

nary compounds are examples of reversible inhibitors (Karczmar, 1970).
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The inhibitory action of irreversible inhibitors is not easily
reversed and the amount of inhibition increases as the amount of inhibitor present increases.

Irreversible inhibition occurs in a two

step process (i) a reversible formation of enzyme-inhibitor complex
and (ii) an irreversible phosphorylation (carbamylation) of the
enzyme; the degree of inhibition depends upon the rate constant of
inhibition and is directly proportional to the amount of inhibitor
present.

Organophosphorus compounds such as DFP, carbamates, and

organosulfonates are irreversible inhibitors (Usdin, 1970).
DFP contains an electron deficient phosphorus atom by virtue of

the attached highly electronegative fluorine atom.

This phosphorus

atom makes an electrophilic attack on the electron rich oxygen atom
of the serine residue yielding diisopropylphosphoserine, a fluorine
atom, and a proton.

Thus, DFP enters the active site of serine con-

taining enzymes including ChE's, phosphorylates the serine residue,
and inactivates the enzyme (Jansz et al., 1959; Koshland, 1963).
The major mechanism of action of DFP, as well as the other ChE
inhibitors, is actually due to the accumulation of ACh within the body
as a result o= continued release from nerve terminals and failure to
be subsequently hydrolyzed by active ChE (Usdin, 1970).

Thus, the

pharmacological effects of DFP are for the most part predictable based
upon a knowledge of thosP sites where ACh is released by and the corresponding effector organs of the

c~emical

~ediator.

Single incremental subcutaneous (s.c.) administrations of DFP
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in rats produced (i) skeletal muscle twitches; (ii) increased saliva-

tion,

retching, diarrhea, and micturition; and (iii) general flacid-

ity; death when it occurred was attributed to respiratory failure,
caused in part by the neuromuscular paralysis, central depression,
and increased bronchiole secretions. Lethal dose-SO (LD-50) established
in our laboratories and elsewhere amounted 3.0 mg/kg (Horton et al.,
1946); it depends on the source and the batch of DFP.
In humans, the systemic administration of DFP produced the following: (i) twitching and generalized weakness of skeletal muscles;
(ii) bronchoconstriction and increased secretions; (iii) increased
sweating, salivation, lacrimation, and micturition; (iv) gastrointestinal disorders; and(v) slight bradycardia (Grab, 1963).

Central nerv-

ous system (CNS) manifestations included giddiness, tension excessive
dreaming, insomnia, nightmares, headache, electroencephalographic
(EEG) alterations, drowsiness, confusion, and generalized depression
of respiratory and circulatory centers (Grab, 1963).
Finally, a delayed, demyelinating neuropathy characterized by an
onset of sensory symptoms and motor weakness has been reported 8 to
14 days after exposure to DFP and other organophosphorus compounds;
the mechanism responsible for this effect remains to be determined
(Grab, 1963).
5.1.2

DFP, Investigational Compound

DFP was chosen as the investigational compound for these studies
for several reasons.

Fi=st, cholinergic-induced antinociception
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arises from stimulation of central cholinergic receptors (see section
1.2.3).

Drugs administered systemically must therefore be able to

cross the blood brain barrier (BBB) to produce antinociception.

DFP,

being highly lipophilic readily penetrates the BBB.
Second, the irreversible inhibition of ChE produced by DFP allows
the various biochemical and behavioral experimental procedures to be
performed at times distant from injection or one another, reducing the
injection frequency and handling stress effects (see section 3.3.1).
Third, both the serotonergic (see section 1.3) and cholinergic
(see section 1.2) systems have been implicated in antinociception.
That the serotonergic system is coupled with the cholinergic system
is suggested by the fact that pilocarpine, arecoline, oxotremorine,
DFP, and physostigmine increase serotonin (5-HT) and 5-hydroxyindoleacetic acid (5-HIAA) levels in rats indicating an increased 5-HT turnover (Reid, 1970; Haubrich and Reid, 1972; Barnes et al., 1978).

In

addition, DFP increased 5-HT levels to a greater extent than did the
other compounds.

This research was initiated to separate the cholin-

ergic from the serotonergic effects with respect to cholinergic·-induced antinociception. DFP, which produced the greatest effect on
5-HT levels, appeared to be best suited for this purpose.
Finally, the ability to produce antinociception when administered
to laboratory animals had not yet been demonstrated for DFP.

In fact,

DFP failed to produce antinociception in previous studies; however,
experimental procedures involved differed from those employed pres-
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ently (Saxena, 1958; Cox and Tha, 1972).

Saxena (1958) utilized

noxious pressure applied to the rats tail; the hot plate and tail
flick tests were used here.

Cox and Tha (1972) used mice; rats were

studied in this laboratory.
5.1.3

Methods of

Evalu~ting

Antinociception

Antinociception can be measured by a variety of laboratory testing procedures in several laboratory animals.
al

st~rnulation

For instance, electric-

of the tooth pulp in the dog, cat, and rabbit has been

useful in determining antinociceptive activity since the tooth pulp
contains nociceptors (see section 1.1.4.1).
Pressure or noxious mechanical stimulation applied to the tail
of the rat or mouse has been used as a means of evaluating antinociceptive activity .. This method, originally described by Haffner (1929),
utilized an artery clip applied to the base of the tail; the latency
of biting at the clip was quantitated.
The intraperitoneal (i.p.) administration of a number of cornpounds such as ACh, acetic acid, and phenylquinone produce a characteristic response in mice called writhing.

The ability of compounds to

inhibit this response has also been used to assess antinociceptive
activity.
The classical method of experimentation employs noxious heat
stimuli to evaluate the antinociceptive activity of drugs.

The orig-

inal method of D'Amour and Smith (1941) involved focusing a beam of
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of light through a prism onto a rats tail; the latency of the
characteristic tail flick was quantitated.
The reaction of a mouse or rat placed on a hot plate, noxious
heat source, has also been used extensively to evaluate antinociceptive activity. The original paper of Woolfe and MacDonald (1944)
described the responses observed when mice were placed on a hot plate;
included here were sitting up, blowing on the front paws so as to
cool them, licking of the hind paws, and eventually jumping off of the
hot plate surface.
Overall, the simplest and yet effective method is the use of the
hot plate.

By placing the animal, which has received the test drugs,

on the hot plate surface and recording the time to response it is
possible to determine the relative potency, onset, intensity, and
duration of antinociceptive activity.

Thus, the hot plate test was

used in these experiments.
The application of heat to the rats tail is another method which
may prove useful in the evaluation of antinociception since the characteristic tail flick response represents a spinally mediated reflex
which appears to be independent of motor behavior; thus, this test
also was used here.
The choice of animals and procedures was dependent also on the
following considerations; (i) the hot plate and tail flick tests are
easily performed requiring no additional surgical procedures as in the
tooth pulp stimulation experiments and no additional injections as in
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the writhing tests, (ii) the choice of antinociception testing procedures

limited the choice of laboratory animals to be used to the rat

or mouse.

The decisive factor was the ability to extract sufficient

quantities of 5-HT and enkephalin-like-material for quantitative
analysis of the brain.
5.2

DFP-Induced Antinociception

DFP produced antinociception when administered to rats whether
measured by the hot plate or tail flick test (Tables 1 and 2) .
antinociceptive state produced

The

by DFP followed a dose dependent re-

lationship as determined by the hot plate procedure (Table 1) .
Antinociception produced by DFP was long lasting, up to 6 hours duration in the hot plate test, which is consistent with the irreversible
effect of DFP on ChE (Fig. 3).
When one considers that besides being bound to ChE's, DFP is also
bound irreversibly to non-ChE proteins and proteolipids and as it is
readily hydrolyzed enzymatically (Mazur, 1946), DFP is a particularly
potent antinociceptive agent, as at the dose of 1.5 mg/kg it increased
by 214 and 132% the animals response times in the hot plate and tail
flick tests, respectively (Tables 1 and 2).
It is noteworthy that even at low doses (0.1 mg/kg), DFP produced
a significant antinociceptive response (Table 1).

While DFP is con-

sidered as acting primarily via the inhibition of ChE with resultant
ACh accumulation, it appears that anti-ChE's may have actions independent of ChE inhibition (Van Meter et al., 1978).

Therefore, DFP may
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produce antinociception by actions independent of ChE inhibition such
as affecting ionic conductances or rendering the cholinergic receptor
more reactive to ACh (Van Meter et al., 1978).
Cholinergic-induced antinociception and analgesia result from
actions involving central cholinoceptive sites of the muscarinic type
(see section 1.2.3).

Similarly, DFP-induced antinociception appears

to result from central actions involving muscarinic receptors since
atropine sulfate antagonized while atropine methyl nitrate was ineffective in blocking this response (Table 2).
Specific central sites involved in mediating the antinociceptive
effects of DFP cannot be determined from these studies.

However,

additional experiments which would provide evidence for specific sites
of action could be performed as follows.
First, spinal and supraspinal structures may be associated with
DFP-induced antinociception.

Assessment of tail flick response in

animals in which the spinal cord has been transected (T6-T8) may provide evidence for a principal spinal or supraspinal site of action.
Second, previous investigations suggest that certain structures such
as the septum, mesencephalic reticular formation, and medial thalamic
nuclei may be involved in mediating cholinergic-induced antinociception(see section 1.2.3).

Localized injections of DFP with the concom-

itant assessment of nociceptive responses may therefore provide additional evidence for an anatomical substrate for the particular DFP
effect.
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Third, cholinergic-induced antinociception may be indirectly mediated through the involvement of other neurotransmitter systems in the
CNS as suggested earlier (see section 1.2.4).

Various pharmacological

manipulations can be used to ascertain which neurotransmitter system
or systems as well as which tracts or areas are involved.

In fact,

this principle was utilized to determine the involvement of the serotonergic system in DFP-induced antinociception (see section 5.5).
Similar studies could be designed to determine the involvement of
other neurotransmitter systems such as the noradrenergic and dopaminergic systems.
Another problem is concerned with the clinical application of
the data.

Although DFP is too toxic to be employed in clinical stud-

ies, other anti-ChE's such as physostigmine can be utilized to gain
information concerning a possible site of action and mechanism of
cholinergic-induced antinociception.

The assessment of pain in a clin-

ical setting may provide evidence to suggest which component of the
pain experience, sensory-discriminative,

~otivational-affective,

cognitive-evaluative, is affected by the drug.

or

Since specific brain

mechanisms are thought to be related to specific anatomical structures
data obtained in the clinics may provide evidence for not only which
brain process but also which anatomical loci are involved in cholinergic-induced antinociception (Melzack and Casey, 1968; Melzack,l975).
Recently, Sitaram et al. (1977) have demonstrated that physostigmine produced analgesia in normal human volunteers as measured by
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(i) the subjects verbal response and (ii) specific cortical average
evoked electroencephalographiG responses (AER).

Sitaram et al. (1977)

suggest that physostigmine affects the motivational-affective and cognitive-evaluative psychological components of the pain experience via
its cortical arousal effect. This dissertation provides the basis for continued clinical investigations concerned with the involvement of the
cholinergic system in the pain phenomenon.

In particular, the effect

of physostigmine on narcotic-induced analgesia will be studied (appendix 1).

See section 5.6.3 and appendix 1 for a complete discussion of

the appended clinical investigation protocol.
Finally, one problem concerning the present data should be emphasized.

Hot plate responses of animals administered either 0.1 mg/kg

or 0.5 mg/kg of DFP or the drug vehicle were attenuated 6 to 8 hours
post injection (Fig. 3).

Two explanations concerning this effect may

be presented as follows.

The attenuation of hot plate responses could

be attributed to a learning/conditioning effect; repeated exposure to
a task involving a negative consequence
creases the time associated in the task.

(hot plate surface)

de-

Alternatively, the animals

were exhibiting a diurnal variation in responsiveness to noxious input.
Significant diurnal variations have been demonstrated for hot plate
response times in mice (Frederickson et al., 1977).

Thus, the animals

administered the vehicle or DFP in low doses (0.1 and 0.5 mg/kg) may
have been exhibiting a normal diurnal variation in responsiveness;
employed in doses of 1.0 and 1.5 mg/kg DFP was so potent as not to
allow this expression of a diurnal rhythm (Fig. 3).
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5.3

DFP-Induced Immobilization

The first question which arises is whether the antinociceptive
state produced by DFP is due to or dependent on, the attenuation of
spontaneous locomotor activity; tnis is particularly pertinent in the
case of the hot plate test since the behavioral responses which are
measured in this test involve locomotor movements (see section 3.3.2).
The animals exploratory activity level, that is its response to
a novel environment, may be a pertinent correlate of antinociception
as measured by the hot plate test since both measurements were made
immediately after placing the animal in this novel environment.
DFP reduced exploratory activity levels; neither atropine sulfate
nor atropine methyl nitrate affected the attenuation of exploration
produced by DFP (Tables 4 and 10).

In fact, atropine sulfate also

reduced exploration when administered alone; this may account for its
inability to restore exploratory activity attenuated by DFP (Table
10).

Yet, DFP-induced antinociception was antagonized by atropine

sulfate; atropine sulfate, alone, failed to alter hot plate responses
(Table 3).

Thus, the antinociceptive state produced by DFP is not

related to the attenuated exploration produced by DFP.

An

apparent discrepancy arises concerning the effect of anti-

cholinergic agents on exploration (see section 1.2.4), as many inves-tigators reported that atropine augments exploratory and/or motor
activity.

However, this discrepancy can be explained by examining
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the operational definitions employed in each case.

Kornisaruk (1970)

defined exploratory activity in terms of sniffing behaviors; Abeelen
et al. (1972) regarded rearing, leaning, and sniffing as exploratory
acts; presently, exploration was defined in terms of gross locomotor
movements during early phase of exposure to novel surroundings (see
section 3.3.4.2).

Clearly, while all studies measured behaviors in

a novel environment, exploration, these studies do not measure identical behaviors.
Additional evidence that the antinociception and attenuation of
exploration produced by DFP are independent phenomena is as follows:
(i) peak attenuation of exploration did not coincide with peak antinociceptive responses at any time tested 1 to 48 hours after the administration of any dose of DFP, (ii) at 0.1 mg/kg, DFP produced antinociception but did not affect exploratory activity, and (iii) naloxone antagonized DFP-induced antinociception but did not affect DFPinduced attenuation of exploration (Tables 9 and 10) .
cussion

A complete dis-

of the effect of naloxone on DFP-induced behavioral responses

is provided in section 5.6.
Motor activity levels which represent the animals ability to make
spontaneous locomotor movements also were studied as a potential
correlate to antinociception.

It should be pointed out that motor

activity was measured 15 minutes after the animals had been placed in
the activity cages while hot plate responses were measured immediately
after placing the animal on the hot plate surface(see section 3.3.4.2).
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DFP reduced in a dose dependent manner motor activity in rats;
the diminution in motor activity produced by DFP was not affected by
atropine sulfate, atropine methyl nitrate, or naloxone (Tables 4 and
10).

However, employed by itself, atropine sulfate reduced motor

activity; this may account for its inability to restore motor activity attenuated by DFP (Table 10).

On the other hand, DFP-induced

antinociception was antagonized by atropine sulfate and naloxone;
atropine methyl nitrate was ineffective (Table 9).

Thus, DFP-induced

antinociception was sensitive to the actions of both atropine sulfate
and naloxone whilst DFP-induced attenuation of motor activity was not
affected by either atropine sulfate or naloxone.

Therefore, the anti-

nociception and attenuation of motor activity produced by DFP do not
appear to be related.
Finally, it must be emphasized that DFP produced antinociception
in the tail flick test as well; this test appears to be less dependent
on changes in motor behavior than the hot plate test.

Since antinoci-

ception and the attenuation of locomotion appear to be independent,
further experiments to separate these two phenomena need not be proposed.

5.4

DFP-Induced Hypothermia

Since the hot plate and tail flick tests involve temperature
sensitive measurements and as the systemic administration of DFP is
known to produce hypothermia (Meeter and Wolthius, 1968), the hypothermic state produced by DFP may interfere with the evaluation of
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DFP-induced antinociception.

In agreement with the earlier data of Meeter and Wolthius (1968) ,
DFP produced a pronounced hypothermia (Fig. 5).

Here, DFP-induced

antinociception and hypothermia were seemingly independent effects:
(i) DFP (1.0 mg/kg) produced antinociception which lasted up to 6
hours post administration (Fig. 3) while hypothermia was obtained only
at 2 hours post injection (Fig. 5) and, (ii) naloxone antagonized the
DFP-induced antinociceptive state (Table 8) but did not affect hypothermia produced by DFP (Fig. 7).

A complete description of the

effect of naloxone on DFP-induced behavioral responses is given in
section 5.6.
Liu and Fong (1972) demonstrated that hypothermia produced an
alteration in the antinociceptive response to intra-arterial injections of ACh in cats; mild hypothermia, a 2 to 3° decrease in rectal
temperature below normal, produced a hypernociceptive state; a further
reduction in rectal temperature, 5 to 6° below normal rectal temperature, produced antinociception.

Based upon the study of Liu and

Fong (1972) , the hypothermia produced by DFP in the present experiments, a 2.4° decrease in rectal temperature, would be expected to
produce hypernociception and thus antagonize the antinociceptive state
produced by DFP.

In fact, DFP produced both a pronounced level of

antinociception and hypothermia in the rat and thus it appears that
DFP-induced antinociception and hypothermia are unrelated.
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5.5

DFP-Induced antinociception and the Serotonergic System
5.5.1

Neurochemistry

The next question which arises concerns the neurochemical mechanisms involved in DFP-induced antinociception.

The antinociceptive

state and ACh levels and/or turnover rates may be correlated for some
but not all centrally acting cholinomimetics, anticholinesterases,
narcotic agonists and antagonists, and various CNS depressants (see
section 1.2.3).

Thus, the antinociceptive state produced by those

compounds may not be directly attributable to actions via the central
cholinergic system.

The multitransmitter character of the CNS as well

as the effects which cholinergic agents produce on systems other than
the cholinergic system suggest the possibility that DFP-induced antinociception may be attributed to a DFP action mediated by non-cholinergic systems (Karczmar, 1975).
First, the interplay between the
systems may be involved.

~holinergic

and serotonergic

For a long time now the serotonergic system

has been implicated in antinociception; increased activity of brain
and spinal cord serotonin neurons such as that produced by electrical
stimulation, precursor loading, uptake inhibitors, and receptor agonists is associated with antinociception and enhanced antinociceptive
potency of drugs such as morphine; decreased activity in those neurons
induced by electrical and chemical lesioning as well as precursor
restricted diets is associated with hypernociception and diminished
antinociceptive drug potency (see section 1.3).
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That the serotonergic system may be coupled with the cholinergic
system is suggested by the fact that oxotremorine and physostigmine
(Reid, 1970) , pilocarpine and arecoline (Haubrich and Reid, 1972),
and DFP (Barnes et al., 1974, 1975) increase 5-HT and 5-HIAA levels;
these data indicate that DFP increased 5-HT turnover, and indeed
appropriate measurements showed that this is so (Barnes et al., unpublished) .
It was therefore important to determine if DFP had a similar
effect in rats.

As shown in Table 5, 5-HT levels were markedly in-

creased in the rat medulla, meso-diencephalon, and telencephalon following a single administration of DFP.

DFP increase in 5-HT levels

and turnover as well as the antinociceptive state produced by DFP are
mediated through activation of central muscarinic receptors since
atropine sulfate antagonized whereas atropine methyl nitrate did not
affect these two effects of DFP (Barnes et al., 1978; Koehn and
Karczmar, 1978).
It may be speculated that the resultant accumulation of ACh due
to DFP inhibition of ChE depolarizes serotonergic neurons thus increasing 5-HT levels and turnover.

On the other hand, the increase in

5-HT levels and turnover elicited by DFP might be due to a direct
stimulatory action of DFP upon 5-HT release.

The present experiments

do not demonstrate which explanation is correct.

Finally, DFP may

increase 5-HIAA brain levels by affecting transport systems responsible
for 5-HIAA elimination.
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Since the rise in 5-HT levels and turnover produced by DFP could
underlie DFP-induced antinociception, it was important to separate
these two phenomena produced by DFP.

One method by which this could

be accomplished is by manipulating the serotonergic system followed by
DFP administration,measurements of nociception and of 5-HT levels.
Para-chlorophenylalanine (PCPA) which inhibits the synthesis of 5-HT
by inhibiting tryptophan hydroxylation was employed for this purpose.
The use of PCPA as an inhibitor of 5-HT biosynthesis was first
reported by Koe and Weissman (1966).

The mechanism of action of PCPA

on the 5-HT biosynthetic process appears to involve three separate
parts.

These various mechanisms must be considered in experiments in

which PCPA is used to evaluate biochemical mechanism underlying behavioral and pharmacological phenomenon.
First, a reversible inhibition of tryptophan hydroxylase (TH)
activity lasting 4 hours with peak effect at 1 to 2 hours post injection was observed following the systemic administration of PCPA; this
inhibition of enzyme activity was attributed to 1) competition of PCPA
with substrate for entry into the nerve ending as well as 2) the

co~

petitive inhibition of the enzyme for the substrate (Knapp and Mandell,
1972).

A second, irreversible inhibition of TH was observed 2 days

after the PCPA injection; this inhibition has been attributed to incorporation of PCPA into TH during new protein synthesis in the nerve
cell body (Gal et al., 1970).

Thus, pretreatment of the animal two

days as well as 2 hours prior to experimentation

yields a model

M7

system in which the three mechanisms involved in the inhibition of
5-HT synthesis by TH are maximally inhibited.

In fact, this was the

basis of the injection schedules employed presently (PCPA

1

2
and PCPA ;

see section 3.2.2).
Finally, the doses of PCPA utilized in these experiments were
selected because these doses specifically inhibited TH activity without affecting the activity of other enzymes such as tyrosine hydroxylase, aromatic amino acid decarboxylase, or monoamine oxidase all
of which affect dopaminergic or noradrenergic neurotransmitter systems
(Koe and Weissman,l966).
Serotonin (5-HT) levels were measured in rat medulla,

meso~dien-

cephalon, and telencephalon subsequent to the administration of PCPA 1
or PCPA2 (see section 3.2.2) to monitor the inhibitory action of PCPA
on 5-HT biosynthesis.

As shown in Table 5, PCPA decreased 5-HT levels

in all three rat brain regions, particularly following the two daily
2
300 mg/kg doses followed on the third day by a 100 mg/kg dose (PCPA ).
It should be pointed out that the depletion of rat brain 5-HT was not
as great as that originally described by Koe and Weissman (1966).
However, the experimental procedures in these two studies differed in
the following ways.

First, Koe and Weissman (1966) sacrificed the

rats by an intravenous (i.v.) administration of pentobarbital; decapitation was used in the present studies (see section 3.5.1).

Second,

spectrophotofluorometric methods for quantitation of 5-HT differed;
Koe and Weissman (1966) measured 5-HT directly whereas, here, 5-HT
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was converted to a substituted indole compound which is more fluorescent than 5-HT itself (see section 3.5.5).

Subsequently, the effect of DFP on rat brain region 5-HT levels
in animals pretreated with either PCPA
section 3.2.2).

1

or PCPA

2

was determined (see

DFP did not affect attenuation of 5-HT levels by

PCPA pretreatment dosage regimens in any of the three rat brain regions studied; that is, PCPA pretreatment prevented the DFP-induced
augmentation of 5-HT levels (Table 5).

Thus, DFP-induced increase in

rat brain 5-HT levels depends upon a functionally intact 5-HT biosynthetic system.
5.5.2

Antinociception

Since the DFP augmentation of 5-HT levels in rat brain depends
upon a functionally intact 5-HT biosynthetic system, it was important
to determine whether the antinociceptive state produced by DFP also
depends upon this system.
PCPA produced hypernociceptive responses in rats as measured by
the hot plate test (Table 6).

This effect of PCPA is consistent with

earlier findings of Tenen (1967) and Messing et al.

(1975) who demon-

strated an increased sensitivity to electric footshock in rats as
measured by the flinch-jump test.
The tail flick test was also employed to assess the nociceptive
responses of rats following PCPA treatment.

Here, the tail flick

apparatus was adjusted so that the response latency of control animals
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was long enough (15 seconds; see section 4.5.2) to allow monitoring
of possible hypernociceptive responses.

As a result, it would be

shown that PCPA produced hypernociception in rats also as measured by
the tail flick test (Table 7).

Thus, just as in the case of previous

reports (see section 1.3), decreased serotonergic neurotransmission
such as that produced by PCPA correlates with the hypernociceptive
state in rats.
As demonstrated earlier (see sections 4.1.1 and 4.1.2), DFP produced antinociception in rats as measured by the hot plate (Table 6)
and tail flick tests (Table 7).

If DFP-induced antinociception were

dependent upon a functionally intact 5-HT system, the pretreatment
with PCPA would be expected to antagonize the antinociceptive action
of DFP.

Alternatively, if DFP-induced antinociception were independ-

ent of the 5-HT system, PCPA pretreatment would not be expected to
affect the DFP-induced antinociceptive state.

Tables 6 and 7 demon-

strate the effect of PCPA pretreatment on the DFP-induced antinociceptive state as measured by the hot plate and tail flick tests, respectively.

The interesting finding was that PCPA pretreatment

did not antagonize DFP-induced antinociception as evaluated by either
test (Tables 6 and 7).

Thus, DFP-induced antinociception and the

increase in brain 5-HT levels produced by DFP appear to be independent
effects.

The augmentation of rat brain 5-HT levels is dependent

whereas antinociception produced by DFP is independent of a functionally intact 5-HT biosynthetic system.
Generally, the antinociceptive effects of physostigmine were
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affected by manipulation of the serotonergic system
2.3.3).

(see section 1.

This discrepancy concerning the effect of PCPA pretreatment

on cholinergic-induced antinociception (see section 1.2.3.3) may be
due to differences in the mechanism of the cholinergic effects of oxotremorine, DFP and physostigmine.

Thus, it should not be surprising

that the antinociceptive states produced by these compounds may arise
through different mechanisms.

In fact, in the case of oxotremorine·

and physostigmine this was found to be so; oxotremorine-induced antinociception is potentiated by procedures which decrease brain catecholamine systems but is unaffected by procedures which change the brain
5-HT system; physostigmine-induced antinociception is affected by procedures which alter catecholamine and 5-HT systems (Pleuvry and Tobias,
1971).

It should also be noted that with the exception of the present

study, none of the other investigations measured 5-HT levels and/or
turnover and thus were unable to correlate behavioral and neurochemical data.

Finally, differences in technique and dosages must also be

considered in this context.
5.5.3

Immobilization

It has long been known that PCPA affects spontaneous locomotor
activity in the rat (Tenen, 1967).

Since the hot plate test involves

locomotor sensitive measurements, the effects of PCPA and PCPA-DFP
combinations were evaluated to determine whether the lack of effect of
PCPA on DFP-induced antinociception was related to a PCPA action on
the mobility of the rat.
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Previous investigations have demonstrated that PCPA decreased
exploration in rats (Marsden and Curzon, 1976), contrary to the present findings.

However, it should be noted that Marsden and Curzon

(1976) defined exploration in terms of open field activities such as
the number of squares entered, number of rearings, number of 1800
turns, grooming time, and number of fecal pellets; thus, their operational definition of exploration was different from the locomotor
activity levels measured as exploration in the present experiments
(see section 3.3.4.2).

As demonstrated earlier (see section 4.2.1), DFP reduced exploratory activity levels of rats(Table 8).

PCPA, administered by itself,

did not affect exploration nor was it capable of affecting the diminution of exploratory activity produced by DFP (Table 8).

It would

be expected that via reducing exploratory activity in rats PCPA could
interfere with the assessment of the nociceptive response.

However,

since PCPA did not affect exploration nor did pretreatment with PCPA
affect the diminution of exploration produced by DFP, the lack of
effect of PCPA on DFP-induced antinociception was not related to an
alteration of exploration produced by PCPA.
As demonstrated earlier (see section 4.2.2), DFP reduced motor
activity levels of rats (Table 8).

PCPA, administered by itself, in-

creased motor activity (Table 8); this effect of PCPA on motor activity is consistent with the original findings of Tenen (1967).

How-

ever, PCPA was unable to affect the DFP-induced decrease in motor activity(Table 8).

If PCPA affected the antinociceptive state produced
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by OFF by altering the animals motor activity levels, it would be expected that the PCPA-induced increase in motor activity would antagonize OFF-induced antinociception.

However, PCPA pretreatment did not

antagonize the antinociception produced by OFF (Table 8).

Thus, the

PCPA affect on motor activity was not related to the PCPA lack of
effect on OFF-induced antinociception.

5.6

OFP-induced Antinociception and the Endogenous Opioid System

5.6.1

Antinociception, Pharmacological Analysis

It has long been known that anti-ChE's such as prostigmine
(Slaughter and Munsell, 1940), physostigmine (Floodmark and Wrammer,
1940), and OFP (Bhargava and Way, 1972); cholinomimetic compounds such
as pilocarpine (Saxena and Gupta, 1957); as well as ACh (Pedigo et
al., 1975) itself, potentiate narcotic-induced antinociception and/or
analgesia.

Recent discoveries of the stereospecific opiate receptor

(Goldstein et al., 1971) and several endogenous opioid-like peptides,
enkephalins (Hughes et al., l975a) and endorphins (Li and Chung, 1976;
Guillemin et al., 1976) have advanced our working knowledge of pain
mechanisms.

Therefore, any hypothesized role for a neurotransmitter

such as ACh in pain modulation must take into account possible interactions with endogenous opioid system.

A pharmacological analysis of

the antinociceptive actions of OFP and morphine was performed to investigate possible relationships between the cholinergic and endogenous

opioid systems in the pain phenomenon.
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As described earlier (see section 4.1.1), DFP produced antinociception in the rat as measured by the hot plate test (Table 9).
As expected, morphine also produced antinociception in rats as measured by the hot plate test; this effect was antagonized by the narcotic
antagonist, naloxone; atropine sulfate was ineffective (Table 9).

The

interesting finding of this study was the fact that naloxone antagcnized DFP-induced antinociception (Table 9) .
Naloxone has been reported to block the antinociceptive effects
of other compounds which affect the cholinergic system such as physostigmine and oxotremorine (Harris et al., 1969) and ACh (Pedigo et
al., 1975) as well as other pharmacologically- and physiologicallyinduced antinociceptive states such as those produced by acupuncture
(Mayer et al., 1976), stimulation produced analgesia (SPA; Akil et
al., 1976), and stress (Bodnar et al., 1977; Chesher and Chan, 1977).
The fact that naloxone antagonized the antinociception arising from
these various procedures suggests that antinociception may result from
actions mediated through the opiate receptor, possibly via the release
of endogenous opioids.
However, it must be pointed out that naloxone antagonism of antinociception is necessary but not sufficient evidence to implicate the
involvement of the endogenous opioid system.

Nonspecific actions of

naloxone could interfere with the assessment of nociceptive responses.
First, naloxone may act as a gamma amino butyric acid (GABA) antagonist.

The iontophoretic application of naloxone antagonized GABA-
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induced inhibition of firing in 21 out of 27 spontaneously active,
olfactory tubercle neurons in the rat (Dingledine et al., 1978).
Furthermore, applied iontophoretically, naloxone antagonized ACh,
nicotine and morphine-induced excitation but did not affect morphineinduced inhibition of Renshaw cells in cats (Duggan et al., 1975).
Thus, naloxone also may act as a cholinergic-nicotinic receptor antagonist.

Alternative explanations describing the naloxone effect

are also plausible.

Finally, naloxone itself, has been shown in some

cases to produce analgesia.

Lasagna (1965) demonstrated a bidirec-

tional effect of naloxone; low doses of naloxone, 1 to 2 mg, produced
analgesia whereas higher doses, 5 to 8 mg, produced

~yperalgesia

measured by verbal reports in patients with postoperative pain.

as
Re-

cently, naloxone has been shown to produce analgesia measured as changes in cortical evoked potentials following electrical stimulation, in
pain-sensitive individuals; the same dose of naloxone produced hyperalgesia in pain-sensitive individuals (Buschsbaum et al., 1977).
Experiments which would help define the role of the endogenous
opioids include the following.

First, stereoisomers of narcotic an-

tagonists other than naloxone may be used to determine the stereospecificity of the narcotic antagonism.
MR 2266/7,

the~

methyl

and~

Experiments with MR 1452/3 and

ethyl N furylmethyl analogues of

~-5,9-

dialkyl-2'-hydroxy-6,7-benzomorphan, respectively and GPA 1843/7, the
N-allyl analogue of S-9-methyl-5-phenyl-2'-hydroxy-6,7-benzomorphan,
have confirmed the stereospecific effects of naloxone on the electrically evoked release of ACh from guinea pig ileum (Waterfield and

Kosterlitz, 1975).

Jacob and Ramabadran (1978) also have confirmed

stereospecific effects of MR 2266/7 on the morphine-induced antinociceptive state in mice utilizing the hot plate test.

The effect of

stereoisomers of narcotic antagonists on DFP-induced antinociception
is discussed in section 5.6.2 below.
Next, the existence of cross tolerance with the antinociceptive
action of morphine may be used to demonstrate the involvement of a
common neural substrate.

Both exogenous S-endorphin (Szekely et al.,

1977) and methionine-enkephalin (Blasig and Herz, 1976)
duce cross tolerance

with

morphine.

pro-

In addition, tolerance to mer-

phine reduced the effective level of antinociception produced by electrical stimulation (SPA) of periaqueductal gray areas (PAG; Mayer and
Hayes, 1975) and stress in rats (Spiaggia et al., 1979); reciprocal
tolerance was incomplete in each case (Mayer and Hayes, 1975; Spiaggia
et al., 1979).

Cross tolerance studies between DFP- and morphine-

induced antinociception are described in section 5.6.3).
Direct release of endogenous opioid peptides by an appropriate
stimulus constitutes further evidence for the involvement of the endogenous

opioid system.

Electrical stimulation (SPA) of the periaque-

ductal gray region (PAG) , which produced analgesia in patients suffering from chronic intractable pain, was associated with increased cerebrospinal fluid (CSF) levels of enkephalin-like-material (Akil et al.,
1978) and immunoreactive-S-endorphin

(Hosobuchi et al., 1979).

Elec-

tro-acupuncture increased endorphin activity CSF levels in chronic
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pain patients (Sjolund et al., 1977).
enous

The effect of DFP on the endog-

opioid system is discussed below in section 5.6.4.
Additional experiments that would clarify the mechanisms involv-

ed

in DFP-induced antinociception may be suggested.

Pomeranz et al.

(1977) demonstrated that electro-acupuncture-induced antinociception
could be blocked by hypophysectomy in mice.

Li and Chung (1976) and

Guillemin et al. (1976) have reported that morphine-like-pituitarypeptides, endorphins, are concentrated in the pituitary.

If OFF-

induced antinociception was mediated via the release of endorphins
from pituitary sites, then hypophysectomy would be expected to block
the antinociceptive action of DFP.

Carboxypeptidase A and leucine

aminopeptidase are known to enzymatically degrade enkephalins (Hughes
et al., 1975a).

In addition, the enkephalins are rapidly degraded by

enzymes found in rat cerebral tissues (Dupont et al., 1977).

If OFF-

induced antinociception were mediated by the release of enkephalins,
agents which inhibit the degradative enzymes should potentiate this
response.

For example, bacitracin is known to inhibit the enzymatic

breakdown of enkephalins in rat brain tissue extracts (Simantov et
al., 1976c).

However, the specificity and potential side effects as-

sociated with any enzyme inhibitor which would otherwise interfere with
nociception measurements, must be considered.
5.6.2

Stereospecificity

Since non-specific actions of naloxone could contribute to its
inhibition of DFP-induced antinociception (see section 5.6.1), it was
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important to determine whether the antagonism was stereospecific;
synthetic antagonists of the benzomorphan series were employed for
this purpose.
agonists

MR 2266, MR 2267 and GPA 1847 possess relatively low

activity while GPA 1843 possesses no agonist activity as

measured by their abilities to depress the electrically evoked
contraction of the guinea-pig ileum (Waterfield and Kosterlitz, 19751.
The (-) isomers of two narcotic antagonists, MR 2266 and GPA 1843,
antagonized both morphine and DFP-induced antinociceptive responses
whereas the corresponding (+) isomers, MR 2267 and GPA 1847, did not
reduce either morphine or DFP-induced antinociceptive responses
(Table 11).

This stereospecificity of narcotic antagonist action

suggests that DFP-induced antinociception is indeed mediated via
opiate receptors.

Jacob and Ramabadran (1978) have demonstrated

similar effects of MR 2266 and MR 2267 on antinociception

p~oduced

by arecoline and physostigmine.
Although Pert and Snyder (1973) could not find affinity of ACh,
atropine, or carbamylcholine for stereospecific opiate receptors,
the possibility remains that DFP may itself act directly on the
opiate receptor; appropriate binding studies are required.
Stereoisomers of cyclazocine, a partial narcotic agonist, had a
differential effect on the antinociceptive states produced by OFP
and morphine; (-) cyclazocine antagonized whereas (+) cyclazocine
did not affect morphine-induced antinociception; alternatively (+)
cyclazocine antagonized DFP-induced antinociception while (-) cycla-
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zocine was ineffective (Table 11).

This effect has been reported

previously employing stereoisomers of cyclazocine and pentazocine
(Pedigo et al., 1975).

The discrepancy between the action of narcotic

antagonists and partial narcotic.agonists on cholinergic-induced
antinociception is particularly puzzling.

The type of test employed

or drug specificity does not explain this effect as different tests
for measuring nociceptive responses and different compounds which
affect the cholinergic system have produced similar results (Pedigo
et al., 1975; Table 11).

No plausible interpretation of this ef-

fect can be presented at present.
Finally, inconsistencies in the actions of the (+) isomers (MR
2267, GPA 1847, and d-cyclazocine, Table 11) suggest that different
opiate receptors may mediate the antinociceptive actions of DFP and
morphine.

Additional investigations such as pA

2

studies are required

to clarify these effects.
5.6.3

Cross Tolerance Studies

Cross tolerance exists.between the antinociceptive responses to
morphine and exogenous opioid peptides (Blasig and Herz, 1976;
Szekely et al., 1977).

It would be expected that if DFP- and mor-

phine-induced antinociception were mediated via a common neuronal
substrate, cross tolerance to morphine and DFP would be observed
(see section 5.6.1).

However, cross tolerance did not develop

between morphine-induced antinociception and the antinocieptive

17~

state produced by DFP (Table 12) .

Cross tolerance studies between

morphine and pilocarpine were performed to determine whether
the lack of cross tolerance between morphine and DFP was specific
for DFP or representative of cholinergic-induced antinociception.
Pilocarpine was selected since it enhances cholinergic neurotransmission by different mechanisms than does DFP {see section
5.1.1); pilocarpine mimicks directly the action of ACh on cholinergic-muscarinic receptors.

Again, cross tolerance failed to

develop between the antinociceptive actions of morphine and pilocarpine (Table 12).

A similar lack of cross tolerance between

morphine and oxotremorine (Howes et al., 1969) and physostigmine
(Pleuvry and Tobias, 1971) has been reported.

Thus, it appears

that morphine- and cholinergic-induced antinociception is not
cross tolerant.

The possibility that the level of morphine tolerance was inadequate to demonstrate cross tolerance with DFP appears unlikely
since DFP maintained an antinociceptive action even at increased
levels of morphine tolerance (tolerance level B, Table 12).

Alternatively, the lack of cross tolerance suggests that
multiple neural substrates may act via opiate receptors to produce
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antinociception.

The chronic administration of morphine while

producing tolerance to exogenous opioid peptides (Blasig and Herz,
1976; Szekely et al., 1977) may not induce tolerance at those
site? in the CNS at which a DFP- and pilocarpine-endogenous
opioid interactions occur.

Distinct opiate receptor populations which exhibit selective
high affinity binding for (D-ala, D-leu)-enkephalin and morphine
have been identified in the rat CNS (Chang and Cuatrecasas, 1979).
It has not been established whether morphine, exogenous opioid
peptides, or endogenous opioid peptides normally interact with
one or both opiate receptors.

However, it may be that cholinergic

compounds release endogenous enkephalins which then interact with
one type of opiate receptor while morphine interacts with another
opiate receptor.

Whether cross tolerance occurs between these

two opiate receptor populations remains to be established.

The basis for implementing the appended clinical investigation
protocol (see appendix 1) may be reviewed in light of these present
findings as to the lack of cross

toler~nce

between morphine and DFP.
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Anti-ChE's administered by themselves, are known to produce antinociception (Harris et al., 1968; Koehn and Karczmar, 1978) and analgesia
(Sitaram et al., 1977); in addition, anti-ChE's potentiate narcoticinduced antinociception (Bhargava and Way, 1972; Ireson, 1970) and
analgesia (Floodmark and Wrammer, 1940).

The antinociceptive actions

of anti-ChE's do not exhibit cross tolerance with the antinociceptive
action of morphine (Pleuvry and Tobias, 1971; Koehn et al., 1979).
The appended clinical investigation protocol (see appendix 1) was designed to determine whether the anti-ChE's agent, physostigmine, would
produce analgesia in narcotic tolerant patients.

It is hoped that

this study will provide evidence for the existence of a cholinergic
sensitive system which may be manipulated pharmacologically for the
treatment of pain.
5.6.4

Effect of DFP on the Endogenous Opioid System

The release of endogenous opioid peptides by an appropriate stimulus is required to establish the involvement of the endogenous opioid
system in antinociception.

If OFF-induced antinociception arises via

actions involving the endogenous opioid system, DFP should release
endogenous opioids.

Potassium~induced

depolarizations have been shown

to release methionine- and leucine-enkephalin from isolated

stria~al

slices (Henderson et al., 1978) as well asS-endorphin from pituitary
and hypothalamic sites (Przewlocki et al., 1978; Osborne et al., 1978).
The present experiments were designed to study the effect of DFP on
enkephalin-like material release from rat brain.

Experimental proce-

dures for extraction (Hughes et al., 1977) and quantitation (Hughes et
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al.,l975b) of enkephalin-like-material were chosen for this purpose
(see section 3.6).

In fact, the studies of the effects of DFP on

enkephalin-like-material did not yield adequate data due to the lack
of reliable extraction and bioassay techniques (see section 4.11).
Methodological requirements for release studies include the
following.

First, the extraction process should eliminate any cont-

aminants which would otherwise interfere with the quantitation procedure.

This, in fact, was the primary failure in the present experi-

ments(see section 4.11).

Second, the assay technique must be appro-

priately sensitive to measure experimentally-induced changes; here,
sensitivities of 0.5 ng leucine-enkephalin equivalents are required,
and this sensitivity did not obtain in our experiments.

Enkephalin-

like-material levels in rats were studied with and without a DFP injection in an attempt to establish proper methodology required for release studies as well as to demonstrate an effect of DFP on enkephalin-like-material content (see section 4.11).

While only 7 out of

68 rat brain samples studied fulfilled acceptable criteria for bioassay (see section 3.6.5.3), no significant differences in enkephalinlike-material levels were observed between animals administered DFP
or the drug vehicle.

The failure of the remaining brain samples to

meet acceptable criteria was due to the presence of a non-enkephalinlike-material contaminant (see section 4.11).
Several changes implemented to eliminate any impurities or contaminants can be outlined as follows: (i) the chromatography resin
was recycled an additional 10 times with isopropyl alcohol and water
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(see section 3.6.3.1), (ii) brain homogenates were centrifuged at
between 5 and 120,000 G for between 10 to 60 minutes (see section
3.6.4), (iii) height of the resin bed was changed to 40, 80 and 120 mm
(see section 3.6.3.2), (iv) eluate was put through columns to reelute
enkephalin-like-material (see section 3.6.4), (v) eluate was taken to
complete dryness by freeze evaporation techniques under vaccurn with
phosphorus

pentoxide as drying agent whenever samples would not go

to complete dryness in Rotorvapor Apparatus (see section 3.6.4), (vi)
freeze dried samples were heated (see section 3.6.4), and (vii) brain
samples were passed through Arnberlite IRA-400 anion exchange resin
prior to introduction onto Arnberlite XAD-2 columns (see section 3.6.4).
Invariably, these changes failed to improve the extraction process.
Although the experimental procedures utilized in these experiments failed to produce results, alternative methods are available.
Radioimmunoassay techniques have been used to determine the enkephalin
content of several rat brain regions (Yang et al., 1977; Kobayashi et
al., 1978b).

The sensitivity and specificity of the antisera employed

in the radioimmunoassay must be taken into account for quantitative
analysis of this type.
5.6.5

Exploratory and Motor Activity

An established effect of DFP treatment is reduction of the animal's locomotion (see section 1.2.4).

Since the effects of DFP and

morphine on rat mobility and environmental response may interfere with
the hot plate assessment of antinociception, exploratory and motor
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activity effects of these drugs with and without their antagonists
were studied.
As described earlier (see section 5.3), DFP reduced exploratory
activity levels in rats; neither atropine sulfate, atropine methyl
nitrate, nor naloxone affected the DFP reduction of exploration (Table
10).

Morphine also reduced exploration in rats; naloxone and atropine

sulfate did not alter this morphine effect (Table 10). However, the
antinociceptive states produced by DFP and morphine do not depend upon
the reduction of exploration produced by either compound since naloxone antagonized the antinociceptive state but failed to alter the
attenuated exploration produced by these two compounds.
It must be pointed out that atropine sulfate, alone, reduced
exploration; this may account for its lack of effect in reversing
DFP-induced reduction in exploratory activity.

A similar effect of

naloxone, alone, could account for its failure to reverse the
tion in exploration produced by morphine.

th~

reduc~

Since the effect of naloxone

on exploration was not studied in the present experiments, further investigations are required to clarify this point.
As described earlier (see section 5.3), DFP reduced motor activity levels of rats; atropine sulfate, atropine methyl nitrate, and
naloxone did not affect the diminution in locomotion produced by DFP
(Table 10).

On the other hand, morphine increased locomotion; atro-

pine sulfate prevented while naloxone reversed the morphine-induced
increase in motor activity (Table 10).
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Section 5.3 describes the effect of DFP on locomotion, indicating that DFP-induced antinociception and DFP-induced attenuation of
locomotion are not related.

In addition, the endogenous opioid system

does not appear to participate in the DFP-induced depression of locomotion since naloxone failed to alter this DFP effect.
It is well recognized that morphine affects spontaneous locomotor
activity in rats.

Low doses of morphine (1.0 to 5.0 mg/kg) increase

locomotion while higher doses of morphine (10 to 40 mg/kg) produced
biphasic changes, initial depression followed by stimulation of locomotion (Domino et al., 1976).

In the present experiments, morphine

(3.0 mg/kg) increased locomotion (Table 10).

The locomotor effect of

morphine appears to be mediated via opiate receptors since naloxone
antagonized this effect (Table 10) .

Naloxone not only antagonized but

actually reversed the effect of morphine on locomotion (Table 10).
However, since the effect of naloxone, alone, was not studied it is
impossible to determine whether the action of naloxone on morphine depression of locomotion was due to the effect of the former on motor
behavior

or involved the endogenous opioid system.

Other investiga-

tors failed to demonstrate an effect of naloxone on motor activity
(Bhargava, 1978b; Amir et al., 1979).
It is interesting to note that atropine sulfate antagonized the
increased locomotion produced by morphine thus implicating the cholinergic system in this particular morphine effect (Table 10) .
studies have

s~own

Recent

that the effect of morphine on locomotion and ACh

synthesis in rats correlates for some but not all doses of morphine;
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thus, the depressant and/or stimulant action of morphine on locomotion may involve neurotransmitter systems other than the cholinergic system (Vasko and Domino, 1978).

Finally, the antinociceptive effects of morphine and DFP do not
appear to be related to the effect of these drugs on motor activity
since (i) employed at equiactive antinociceptive doses, morphine
increased while DFP decreased locomotion, (ii) atropine sulfate and
naloxone antagonized DFP-induced antinociception but failed to alter
the attenuation of locomotion produced by DFP, (iii) atropine sulfate
antagonized the augmented motor activity produced by morphine but
failed to alter morphine-induced antinociception (Table 10).

5.6.6

Effect of Naloxone on DFP-induced Responses

The effect of naloxone on antinociception, attenuated mobility,
and hypothermia produced by DFP was studied 1 to 48 hours after the
DFP injection to determine if the naloxone antagonism of DFP-induced
antinociception was related to a naloxone effect on animal mobility
or temperature.
As discussed earlier (see section 4.7.1), naloxone antagonized
DFP-induced antinociception in a dose dependent manner (Fig. 6).
Naloxone (5.0 mg/kg) not only antagonized DFP-induced antinociception
but also produced hypernociception following the DFP administration
(Fig. 6).

Naloxone has been shown to produce hypernociception

only under certain circumstances such as stress (Madden et al.,
1977;

Rossier et al., 1977a).

Thus, the reversal of DFP-
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induced antinociception may be attributed in part to a naloxone effect
in a stressed animal.

It should also be pointed out that naloxone

(5.0 mg/kg) produced different effects on DFP-induced antinociception
in

different studies;

naloxone (5.0 mg/kg) antagonized DFP-induced

antinociception in earlier studies (see section 5.6.1).
That the duration of action of DFP was greater than that of naloxone correlates well with the irreversible nature of this anti-ChE
agent (Fig. 6).

In adnition, the antinociceptive response induced

by morphine similarity outlasts the antagonistic action of naloxone
(Smits, 1976).
As described earlier (see section 4.8.2),

naloxone failed to

alter DFP-induced decrease in exploration 1 to 48 hours post DFP injection (Fig. 7A).

Naloxone also failed to affect DFP-induced atten-

uation of motor activity (Table 10).

Thus, the naloxone antagonism

of DFP-induced antinociception is not related to a naloxone effect
on DFP-induced immobilization.
As discussed earlier (see section 4.3), DFP produced hypothermia
in rats.

Naloxone did not affect the hypothermia produced by DFP nor

did it alter rectal temperatures in naive animals (Fig. 7B).

Since

naloxone antagonized DFP-induced antinociception (Table 9) but failed
to affect the hypothermia produced by DFP (Fig. 7B), the naloxone antagonism of DFP-induced antinociception is independent of a naloxone
temperature effect.
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5.7

Concluding Comments

Pain, by itself, is an extremely complex, ill-defined phenomenon (see section 1) .

All research investigations concerning

the various aspects of the pain phenomenon entail experimental
procedures which may produce complicating factors, thus, the
scientific study of pain can be additionally complex.
The basic scientist attempts to correlate the antinociceptive
and analgesic properties of a drug so that preliminary research
on pain can be conducted in the laboratory.

Here, behavioral

responses to a variety of noxious stimuli in several laboratory
animals are measured (see section 5.1.3).

While this procedure

does not appear to be valid for all drugs which produce antinociception, a correlation does exist between the antinociceptive and
analgesic properties of a particular drug or group of drugs such
as drugs which affect the cholinergic system (see section 2) .

The

antinociceptive action of the anticholinesterase agent, diisopropyl
phosphofluoridate (DFP), was studied in this dissertation.

Certain factors, which can interfere with the correct assessment
of antinocicpetion, are inherent in every testing procedure.
instance, here, DFP is

kn~Nn

to depress locomotor activity and

For
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produce hypothermia (see section 2) .

While these two effects of

DFP were controlled during the present studies, either effect
could have interfered with the correct evaluation of antinociception (see sections 5;3 and 5.4).
It also should be pointed out that DFP may produce antinociception by stimulating Renshaw Cells.

Here, the apparent anti-

nociception would be attributable to a decreased alpha motor neuron
excitability, thus, a decreased ability to respond.

This mechanism,

however, seems unlikely since cholinergic-induced antinociception
is known to arise from stimulation of supraspinal cholinergic
receptors (see section 1.2.3.2).
The ultimate test, however, is to determine whether the drug
in question produces a clinically significant level of analgesia
when administered to humans.

The clinical value must take into

account potential deleterious side effects as well as the effective
level of analgesia produced by the drug.

Thus, pain studies can

be conducted only in the clinical setting.

While DFP is too toxic for use in clinical studies, another
anticholinesterase agent, physostigmine, is available and approved
for clinical use.

A study to determine the effect of physostigmine

on the pain state in narcotic-tolerant individuals is described in
the appendix (see appendix 1) .

6.

SUMMARY

Oiisopropyl phosphofluoridate (DFP; 0.1 to 1.5 mg/kg s.c.) produced antinociception in rats as measured by the hot plate test.
duration and intensity of the antinociceptive response
the dose of OFP was increased.

incr~ased

The
as

Administered 30 minutes after the ad-

ministration of DFP (1.5 mg/kg s.c.), atropine sulfate (4.0 mg/kg i.p.)
antagonized while atropine methyl nitrate (4.0 mg/kg i.p.) did not
affect the OFF-induced antinociceptive response.

Administered in.

doses of 1.0 and 1.5 mg/kg s.c., OFF produced antinociception in rats
as measured by the tail flick test.

OFF (0.1 to 1.5 mg/kg s.c.) de-

creased exploratory and motor activity levels in rats.

Administered

in a dose of 1.0 mg/kg s.c., DFF decreased rectal temperatures in
rats.

Atropine sulfate (4.0 mg/kg i.p.) failed to alter the diminu-

tion in exploration or motor activity produced by OFP.

These results

indicate that OFF-induced antinociception in rats arises via actions
involving central cholinergic system; antinociception produced by OFF
was independent of the locomotor depression and hypothermia produced
by DFF.
OFF (1.5 mg/kg s.c.) increased serotonin (5-HT) levels in rat
medulla, meso-diencephalon, and telencephalon.

As the serotonergic

and cholinergic systems have been implicated in antinociception, OFFinduced antinociception could be attributed to either system; parachlorophenylalanine (FCFA) was employed to clarify this point.

Ad-

ministered alone, FCPA (i) decreased 5-HT levels in all three rat
190
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brain regions studied, (ii) produced hypernociception as measured by
the hot plate and tail flick tests, and (iii) increased motor activity
levels; PCPA, alone, did not affect exploratory activity.

Pretreat-

ment with PCPA prevented the augmentation of 5-HT levels produced by
OFF (1.5 mg/kg s.c.) but did not affect the antinociceptive state or
attenuation of exploratory or motor activity levels produced by OFF.
Thus, OFF-induced antinociception is independent of the serotonergic
system.
Administered 30 minutes after the administration of OFF (1.0 mg/
kg s.c.), naloxone (0.5 to 5.0 mg/kg i.p.) antagonized OFF-induced
antinociception.

MR 2266 (-5,9 a-diethyl-2-(3-furylmethyl)-2'-hy-

droxy-6,7-benzomorphan, 1.0 mg/kg i.p.) and GPA 1843 (-2-allyl-2'hydroxy-9 S-methyl-5-phenyl-6,7-benzomorphan, 5.0 mg/kg i.p.), the
active (-) isomers of narcotic antagonists, reduced morphine- and
OFF-induced antinociception; MR 2267 and GPA 1847, the inactive (+)
isomers of the corresponding narcotic antagonists, did not affect
morphine- or OFF-induced antinociception.

MR 2266, MR 2267, GPA 1843,

and GPA 1847 did not produce antinociception in naive animals.

An-

imals rendered tolerant t9 the antinociceptive action of morphine
(3.0 mg/kg s.c.) by repeated daily injections of morphine failed to
exhibit cross tolerance to an equiactive antinociceptive dose of DFP
(1.0 mg/kg s.c.) or pilocarpine (2.5 mg/kg s.c.).

These results sug-

gest that OFF-induced antinociception is mediated via stereospecific
opiate receptors, possibly by the release of endogenous opioid peptides.

This latter phenomenon could not be demonstrated at this time.

7.
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CLINICAL INVESTIGATION PROTOCOL

1.

Introduction

Acetylcholine, various cholinomimetics, and several anticholinesterase agents exhibit an antinociceptive action and the ability to
potentiate narcotic-induced antinociception in experimental animals
(Chen, 1958; Harris et al., 1968; Pedigo et al., 1975). Several investigations have demonstrated that the anticholinesterase agent,
physostigmine has similar actions in humans (Slaughter, 1950; Karczmar,
1977) . Recent animal studies in these laboratories are particularly
pertinent (Koehn and Karczmar, 1978). First, we confirmed the antinociceptive potency of anticholinesterase compounds described by
others; in fact, some of those compounds appeared, in animals, to be
several times more potent than morphine. Second, we have showed that
this antinociceptive effect can be obtained in full in animals rendered tolerant to morphine. Presently, intractable pain is treated by
the chronic administrations of narcotic analgesic compounds. Side
effects associated with this treatment include nausea, drowsiness,
constipation, hypotension, and increased intracranial pressure, as
well as addiction liability. What is most important, there is development of tolerance to the analgetic action of the narcotic compound;
thus, to achieve pain control larger and larger doses of narcotic is
needed. Ultimately, the patients become refractory, as there is no
dose of the narcotic that will produce analgesia short of causing respiratory depression and death.
This study is designed to test the analgetic property of physostigmine, when used in combination with narcotic analgesics. It is
hoped that the results will demonstrate that it is possible to increase the pain threshold beyond that obtained with any dose of the
narcotic used alone, thus, allowing the dose of narcotic analgesic to
be reduced; smaller dose of the narcotic may be sufficient to produce
pain control in the presence of physostigmine. Altogether, it is hoped
to establish new therapeutic regimen for treating intractable as well
as other associated pain states.
The feasibility and safety of the proposed study can be readily
substantiated. In the past, neostigmine was used in man to produce
analgesia and to potentiate analgesia produced by codeine (for references cf. Karczmar, 1977); as is well known, neostigmine is used safely fo~many years in myasthenic patients. Physostigmine was tested
as an analgesic in normal volunteers (Sitaram et al., 1977); furthermore, it was employed in man in a number of other conditions. For
instance, it is used to antagonize toxicity due to scopolamine and
atropine, phenothiazines and tricyclic antidepressants; in fact, it is
the treatment of choice in this latter condition (Snyder et al., 1974).
It was used also in facilitating recovery from general anesthesia
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(Bidwai et al., 1976; Brebner and Hadley, 1976). Furthermore, it is
used currently in man to control mania, Huntington's chorea, and tardive dyskinesia, and to improve memory (for references, cf. Karczmar,
1976; 1977; Karczmar and Dun, 1978). In these various conditions,
physostigmine was used in intravenous (IV) , intramuscular (IM) , and
oral (PO) doses of up to 2-4 mg total dose; there is no report of serious side actions and none of toxicities. In some patients, nausea
and abdominal cramps were noticed. More rarely, sweating and salivation were observed. However, pretreatment with a synthetic anticholinergic agent Robinul (0.15 mg IM) 30 minutes prior to the administration of physostigmine (0.5 mg IV) prevents these peripheral side
effects. No further side actions or toxicities will be expected from
the dose used. There are special considerations pertinent in the context of the safety of study in question. First, physostigmine is a
so-called reversible inhibitor of cholinesterase, the inhibition being
short-lived and not extending, in both animal and human studies, beyond l to 2 hours. Second, physostigmine acts via temporary accumulation of acetylcholine;as the latter is hydrolyzed upon the termination (reversal) of anticholinesterase action of physostigmine, no
potentially deleterious delayed effects and no pathology result from
the action of physostigmine. Third, there are specific, fast acting
and safe antagonists of physostigmine; the quaternary anticholinergics
such as methanthaline and propanthaline can be used to control the
peripheral effects of physostigmine, such as gastrointestinal hypermotility, while atropine and scopolamine may be used to prevent both
central and peripheral actions of physostigmine. Finally, physostigmine (Antilirium) is obtainable in a preparation designed for human
use.
2.

(A)
of:

Specific Aims
This investigation is designed to establish the following:
Physostigmine potentiation of narcotic-induced analgesia in terms

(1} Latency to onset of analgesia after drug administration
(2) Duration of analgesic effect
(3) Peak analgetic action
(B) Therapeutic evaluation of combined narcotic-physostigmine drug
treatment on the subjective pain experience.
(l) Sensory qualities in terms of temporal, spatial, pressure et
al.
(2) Affective qualities in terms of tension, fear, and autonomic
properties •
(3) Evaluative qualities that describe the subjective overall
intensity of the total pain experience.

3.

Experimental Protocol
All patients and controls used in this study will be obtained by
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their consent from the service of Dr. K. Badrinath, Chief, Oncology
Section, Loyola University Medical Center. Patients who are presently
being administered narcotic analgesics on a chronic basis for relief
of intractable pain will be selected for this study. Patients shall
have no known history or evidence indicating the presence of cardiac
arrythmias, demonstrable intracranial lesions or any other physical
or psychological abnormalities which would by the discretion of the
attending physician place them at any particular risk. The age range
of the patients will vary; primarily adults (i.e. greater than 21 years
of age) will be used. No financial compensation is planned as part of
this study. No additional laboratory or diagnostic procedures will be
employed in or solely for the purpose of this study.
4.

Clinical Protocol

Patients who receive narcotic analgesics on a regular basis will
be utilized in this study. All patients participating in this study
will be required to complete an informed consent (see pp.203). Having
obtained the patients consent, the research investigator along with
the patient will complete the McGill Pain Assessment Questionnaire
which is used to gather a medical history as well as to initially
evaluate the patients' pain status (Melzack, 1975). This requires
approximately 30 minutes of the patients time.
On the test day (day 1, Table 1) a patient will receive his/her
regularly scheduled pre-determined dose of narcotic analgesic. Robinul
(0.15 mg IM) will be administered 30 minutes before the subsequent
drug administration for the relief of pain. At that time, the narcotic analgesic physostigmine or narcotic-analqesic placebo comination
will be employed in place of the regularly scheduled dose of narcotic
analgesic. The correct evaluation of any drug effect requires that a
double blind study be utilized. The choice of the combination for the
particular patients will be randomized according to the methods de~
scribed by Sakal and Rohlf (1973). Furthermore, neither the patients
nor the physician administering the drugs will know whether he/she is
given the narcotic analgesic-placebo or the narcotic analgesic-physostigmine combination. The patients will be asked to evaluate and compare his/her conditions for the time periods corresponding to the two
drug administrations mentioned previously; all evaluations will be
made by completing the McGill-Melzack Pain Questionnaire 20 minutes
after the administration of the regularly scheduled dose of the narcotic analgesic and subsequent narcotic analgesic-physostigmine/placebo
combination (Melzack, 1975). This procedure will be repeated (day 3,
Table 1). Those patients who received the narcotic-analgesic physostigmine drug combination on day 1 will now, day 3 receive the narcotic analgesic-placebo drug combination and vice versa. The McGillMelzack Pain Questionnaire will be administered as before. Double
blind study technique will be employed. In accordance with the I.R.B.
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guidelines, patient confidentiality will be secured. Patients will be
identified by a coded patient identification number on all forms.

5.

Interpretation of Data

This investigation will be evaluated by tabulating the patients
responses from the McGill-Melzack Pain Questionnaire (Melzack, 1975).
The original McGill-Melzack Pain Questionnaire was specifically designed to provide quantitative measures of clinical pain that can be
treated statistically. The 3 major measures are:
(1) the pain rating
index, based on two types of numerical values that can be assigned to
each word descriptor, (2) the number of words chosen, and (3) the
present pain intensity based on a 1 to 5 intensity scale. Modification of the original questionnaire (i.e. the addition of part 5) was
instituted to gather additional pertinent information for this study
(Melzack, 1975).
Statistical analysis to determine the effecti,~ness of this procedure can be performed by comparing the patients responses in the
various categories for the regularly scheduled dose of the narcotic
analgesic and the narcotic analgesic-physostigmine/placebo combination
testing sessions. If a patient's responses for the drug combination
are greater than for the regularly scheduled dose of narcotic, it is
rated+; if less,-; if no change, '0'. Then, a simple sign test for
significance can be carried out. Similarly, the t test can be used
in which the mean net changes are calculated and the differences from
the mean are calculated for each testing session to determine whether
a statistically significant difference has occurred. Both types of
tests will be employed in this study. It is anticipated that this
study will employ 20 to 40 patients. However, a pilot study utilizing
5 patients will be performed in an unblinded manner which will allow
the investigators to determine the degree of significance, thus allowing for a better estimate of the number of patients (n) required.
'n'
will be set on the basis of fewest patients which would be likely to
show a statistically significant difference (p<0.05).
6.

Risks and Potential Benefits

Risks to the patient include the potential side effects of Robinul
and physostigmine treatments; dry mouth, nausea, bradycardia, and hypotension. Gastric symptoms and heart signs if they appear will be
treated with clozapine and atropine respectively. Any complaints of
pain at any time during the study will be recorded and a narcotic analgesic given immediately. The only actual discomfort associated with
this experiment is due to the intramuscular (IM) and intravenous (IV)
administrations of Robinul and physostigmine/placebo respectively.
The potential benefits of this experiment are as follows: physo-

224
stigrnine is expected to potentiate narcotic-induced analgesia by producing a greater level of analgesia; thus,(l) the refractory patient
would be responsive to the analgetic effect of the combined drug
treatment and (2) the dose of the narcotic analgesic could be reduced,
thus reducing the severity of associated side effects. If the results
are positive this would lend evidence and support for establishing a
new more effective treatment plan for the control of pain. This could
also lend further evidence for the use of anticholinesterase agents
as analgesic substances (new use).
7.

Table 1

Informed consent form for each patient utilized in this study must
be completed (see pp. 203).
McGill Pain Assessment Questionairre completed before test day
(Melzack, 1975).
Test Day

Drug Administrations
Regularly scheduled, predetermined dose of narcotic analgesics administered throughout study (Narc.).
Narc.
*McGill-Melzack Pain Questionnaire 20 min. post drug
administration.
Robinul (0.15 mg IM) 30 minutes prior to Narc. + Physostigmine/Placebo

1

Narc. + Physostigmine (0.5 mg IV)/Placebo
*McGill-Melzack Pain Questionnaire 20 min. post drug
administration
Narc.
Narc.

2

Narc.
Narc.
Narc.
*McGill-Melzack Pain Questionnaire 20 min. post drug
administration
Robinul (0.15 mg IM) 30 minutes prior to Narc. + Physostigmine/Placebo
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3

Narc. + Physostigmine (0.5 mg IV)/Placebo
*McGill-Melzack Pain Questionnaire 20 min. post drug
administration
Narc.
*McGill-Melzack Pain Questionnaire (Melzack, 1975).
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8.

Informed Consent

IRB Number

--------

Loyola University Medical Center
Maywood, Illinois
Department of Medicine
Section of Oncology and Pharmacology
Patient's Name
Project

8.1
8.1.1

Date:

-------------Title:
-------------------------------------------------------------

Patient Information
Description and Explanation of Procedure

Your illness requires frequent and repeated administration of
narcotic analgesic drugs to prevent the pain which you experience. As
you become tolerant to the analgetic action of the narcotics the dose
must be increased to remain effective. Associated with the chronic
administration of narcotics are several side effects; most notably
nausea, drowsiness, constipation, and respiratory depression. Sometimes your pain cannot be controlled satisfactorily even as we increase the dose. The purpose of this investigation is to study the
usefulness of the drug physostigmine, used in a combination therapy
program with the narcotic analgesic to potentiate the effective level
of analgesia. This would allow the dose of the narcotic to be reduced lessening the severity of side effects attributable to narcotic
administration, and may improve pain control and your well-being.
The correct pharmacological analysis requires that this study
be done according to double-blind technique. To correctly evaluate
the usefulness of physostigmine each patient will receive the narcotic
analgesic-physostigmine combination and the narcotic analgesic-placebo
(inactive compound) combination on test days l and 3 or vice versa.
Neither the patient nor the physician administering the drug will know
who receives what. In addition, 30 minutes prior to the administration
of the narcotic analgesic-physostigmine/placebo combination you will
receive an intramuscular (IM) injection of Robinul to prevent the appearance of side effects attributable to the administration of physostigmine. Each patient will participate in this study on three
days. During this time, you will be asked to complete with the help
of a research investigator five questionnaires as follows. First, the
McGill Pain Assessment Questionnaire will be administered on the day
preceding the first test day. This will require approximately 30 minutes of your time. Second, the McGill-Melzack Pain Questionnaire will
be administered two times each on test days l and 3. You will be asked
to complete this form following your regularly scheduled dose of nar~otic analgesic as well as following the combination regularly scheduled dose of narcotic analgesic with physostigmine/placebo on each
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test day (total of 4 times) .
day 2.
8.1.2

No participation is required on test

Risks and Discomforts

There are essentially no life risks involved using physostigmine
at this dose (0.5 mg); potential adverse side effects are few. Some
patients report feelings of nausea which can be remedied by administration of Clozapine or Compazine. Bradycardia (slow heart) constitutes another side effect which has developed in some patients. Your
heart rate and blood pressure will be monitored and in need can be
corrected by administration of atropine" The only discomfort associated with this procedure would be due to the needle for intramuscular
(IM) injection of Robinul and the intravenous (IV) injection of physostigmine/placebo.
I understand that biomedical or behavioral research such as that
in which I have agreed to participate, by its nature, involves risk
of injury. In the event of physical injury resulting from these research procedures,emergency medical treatment will be provided at no
cost, in accordance with the policy of Loyola University Medical Center. No additional free medical treatment or compensation will be
provided except as required by Illinois law.
In the event you believe that you have suffered any physical
injury as the result of participation in the research program, please
contact Dr. H.J. Blumenthal, Chairman, Institutional Review Board for
Protection of Human Subjects at the Medical Center, telephone (312)
531-3384.
8.1.3

Potential Benefits

The benefit to you that we hope for will be a lessening of pain,
and reduction of untoward side effects due to narcotic drug administration (drowsiness and constipation) . We also hope that this particular therapeutic regimen will prove to be effective and thus establish
a new procedure for treating patients who require this type of care.
8.1.4

Alternatives

The alternative method for management of your pain is to be maintained on a narcotic analgesic treatment plan. The side effects and
risks associated with this therapy are stated previously.
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Consent
I have fully explained to
(name: patient)
the nature
and purpose of the above described procedure and the risks that are
involved in its performance. I have answered and will answer all
questions to the best of my ability.
(signature: principal investigator)
I have been fully informed of the above-described procedure with its
possible benefits and risks. I give permission for my participation
in this study. I know that Dr. Ketty Badrinath or his associates will
be available to answer any questions I may have. If, at any time,
I feel my questions have not been adequately answered, I may request
to speak with a member of the Medi~al Center Institutional Review
Board. I understand that I am free to withdraw this consent and
discontinue participation in this project at any time without prejudice to my medical care. I have received a copy of this informed
consent document.
(signature: patient)
(signature: witness to signatures)
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